Page last updated: 2024-08-17

carbostyril and Schizophrenia

carbostyril has been researched along with Schizophrenia in 581 studies

Research

Studies (581)

TimeframeStudies, this research(%)All Research%
pre-19901 (0.17)18.7374
1990's2 (0.34)18.2507
2000's273 (46.99)29.6817
2010's275 (47.33)24.3611
2020's30 (5.16)2.80

Authors

AuthorsStudies
Hibino, H; Inoue, Y; Matsumoto, H; Mikami, K; Suzuki, H; Takaya, A; Yamamoto, K2
Fernando, R; Gan, L; Xiao, J; Yun, Y1
Baymeeva, NV; Kaleda, VG; Miroshnichenko, II; Platova, AI; Tikhonov, DV1
Kamińska, K; Lech, MA; Lorenc-Koci, E; Rogóż, Z1
Schooler, NR1
Bellagamba, S; Orsolini, L; Salvi, V; Volpe, U1
Hishimoto, A; Matsukawa, M; Sekine, D; Yamada, S; Yasui-Furukori, N1
Dorozhenok, IY1
Cai, J; Gao, M; Huang, J; Huang, Y; Kang, D; Li, L; Liu, F; Long, Y; Ou, J; Peng, X; Shao, P; Shao, T; Shen, Y; Song, C; Su, Y; Sun, M; Wang, W; Wang, X; Wu, Q; Wu, R; Xiao, J; Xie, P; Yang, Y1
Harada, T; Hosokawa, T; Kishi, Y; Miyaji, C; Nomura, A; Okahisa, Y; Sakamoto, S; Takaki, M; Takao, S; Takeda, T; Washida, K; Yada, Y; Yamada, N; Yoshimura, Y1
Cahill, D; Kohegyi, E; Larsen, F; Raoufinia, A; Wang, X; Wang, Y; Ward, C; Zoubroulis, A1
Cheng, CS; Kuo, CJ; Lin, SK1
Dean, B; Gogos, A; Hopper, S; Pavey, GM1
Kumakura, J; Okada, T; Suda, S; Yasuda, M1
Futamura, T; Kikuchi, T; Maeda, K; Niidome, K; Suzuki, M; Usami, T1
Aoki, S; Shimizu, H; Takeda, T; Washida, K; Yamashita, R; Yoshimura, Y1
Crippa, A; Davis, JM; Leucht, S; Orsini, N; Patel, MX; Siafis, S1
Broder, MS; Chang, E; Greene, M; Houle, CR; Tarbox, MH; Waters, HC; Yan, T1
Ikuta, T; Iwata, N; Kishi, T; Matsuda, Y; Sakuma, K1
Antoun Reyad, A; Girgis, E; Mishriky, R1
Copolov, D; Hope, J; Keks, N; McLennan, H; Meadows, G; Schwartz, D1
Ishigooka, J; Iwashita, S; Kojima, Y; Matsuo, S; Usami, T1
Baker, RA; Cox, K; Eramo, A; Kojima, Y; Okame, T; Potkin, SG; van Erp, TG1
Markovic, M; Maroney, M; Stummer, L1
Ismail, Z; Meade, N; Meehan, SR; Shi, L; Weiss, C1
Boku, S; Fujiyama, H; Fukuhara, R; Kanno, T; Kawahara, K; Sugawara, H; Takebayashi, M; Tanaka, H1
Kikuchi, T; Otsubo, T; Watanabe, Y; Yamada, S1
Aoki, K; Inada, K; Ishigooka, J; Iwashita, S; Kojima, Y; Niidome, K; Yamada, S1
Baas, CAJ; Knegtering, H; Spoelstra, SK1
Edinoff, AN; Girma, B; Kaye, AD; Kaye, AJ; Kaye, AM; Kaye, JS; Leethy, KN; Maxey, BS; Mychaskiw, G; Odisho, A; Ren, AL; Urits, I; Viswanath, O; Wu, NW1
Bruno, CD; Chow, CR; Elmokadem, A; Greenblatt, DJ; Housand, C; Jordie, EB; Lesko, LJ1
Higashi, K; Ishigooka, J; Iwashita, S; Liew, EL; Tadori, Y1
Ekinci, A; Ekinci, O1
Castle, D; Hope, J; Keks, NA1
Forbes, A; Hakala, M; Hobart, M; Ouyang, J; Pfister, S; Shi, L1
Ishigooka, J; Iwashita, S; Tadori, Y2
Goldnik, A; Mach, A; Malek, G; Marszalek, D; Pawinski, T; Somogi, A1
Baker, RA; Duffy, RA; Gwin, KK; McQuade, RD; Weiller, E; Weiss, C; Zhang, P1
Eriksson, H; Newcomer, JW; Weiller, E; Weiss, C; Zhang, P1
Baker, RA; Correll, CU; Duffy, RA; Eramo, A; Hobart, M; Shi, L; Weiller, E; Weiss, C1
Frampton, JE1
Limandri, BJ1
Crespo-Facorro, B; Martínez-Garcia, O; Mata, I; Ortiz-Garcia de la Foz, V; Pérez-Iglesias, R; Valdizan, EM; Vazquez-Barquero, JL1
Cheung, C; Chua, SE; Collier, DA; Deng, W; Gong, Q; Huang, C; Jiang, L; Li, M; Li, T; Ma, X; McAlonan, GM; Sham, PC; Wang, Q; Wang, Y1
El-Sayeh, HG; Hunger, H; Khanna, P; Komossa, K; Leucht, S; Rummel-Kluge, C; Schwarz, S1
Furuya, M; Horiguchi, J; Ieda, M; Liaury, K; Miyaoka, T; Takechi, M; Tsuchie, K; Wake, R1
Wang, YC1
Li, W; Lv, L; Wang, S; Wang, X; Yang, G; Yang, Y; Zhang, H; Zhao, J2
Caccia, F; Caloro, M; Cuomo, I; De Filippis, S; De Persis, S; Gentile, G; Girardi, P; Janiri, D; Kotzalidis, GD; Lionetto, L; Piazzi, G; Sciarretta, A; Simmaco, M; Simonetti, A; Telesforo, CL1
Fukui, N; Ono, S; Saito, M; Someya, T; Sugai, T; Suzuki, Y; Tsuneyama, N; Watanabe, J1
Cichocki, M; Jarmuszkiewicz, Z; Kus, K; Nowakowska, E; Ratajczak, P; Woźniak, A1
Baker, RA; Carson, W; Fleischhacker, WW; Forbes, RA; Jin, N; Johnson, B; Kane, JM; McQuade, R; Sanchez, R1
Falkai, P; Schmitt, A1
Aggarwal, A; Gopalakrishna, G; Lauriello, J1
Baker, RA; Duca, AR; Eramo, A; Johnson, BR; Kane, JM; McQuade, RD; Peters-Strickland, T; Sanchez, R; Zhao, J1
An, SK; Chang, JG; Cho, HS; Jung, YC; Kim, CH; Roh, D1
Tadokoro, S1
Adams, DH; Baygani, S; Kinon, BJ; Kollack-Walker, S; Millen, BA; Velona, I; Walling, DP1
Grossman, F; Hassan, M; Meyer, K; O'Day, K; Rajagopalan, K1
Remington, G; Takeuchi, H1
Tsukarzi, EE1
Accordini, S; Barbui, C; Cipriani, A; Girlanda, F; Nosè, M; Purgato, M; Tansella, M1
Bonete Llácer, JM; García Escudero, MA; Martínez Pastor, CJ; Ziadi Trives, M1
Jalenques, I; Kernisant, M; Legrand, G; May, R; Richard, B1
Chen, CK; Chou, MC; Chou, WJ; Huang, YS; Tang, CS; Wang, LJ; Yeh, CB1
Carson, W; Correll, CU; Forbes, RA; Mankoski, R; Marcus, R; McQuade, R; Zhao, J1
Baker, RA; Bricmont, P; Eramo, A; Kasper, W; Mallikaarjun, S; McQuade, R; Peters-Strickland, T; Potkin, SG; Raoufinia, A; Sanchez, R1
Bricmont, P; Carson, W; Fleischhacker, WW; Forbes, RA; Kane, JM; Mallikaarjun, S; McQuade, R; Sanchez, R1
Hashiguchi, M; Kunitomi, T; Mochizuki, M1
Buchanan, RW; Dickerson, FB; Earl, AK; Feldman, S; Fischer, BA; Keller, WR; Kelly, DL; McMahon, RP; Shim, JC; Sullivan, KM; Warfel, D; Wehring, HJ1
Ishigooka, J; Iwata, N; Nakagome, K; Ohmori, T1
Datta, SS; Furtado, VA; Kumar, A; Russell, PS; Wright, SD1
Poncin, YB; Stubbe, DE; Webb, JE; Webb, JR1
Arnoldy, R; Curtis, J; Samaras, K1
Au, RW; Chiu, HF; Dickerson, F; Kreyenbuhl, J; Lai, KY; Man, D; Shum, D; Tang, WK; Ungvari, GS; Wang, CY; Xiang, YT; Yu, X; Zhou, FC; Zhou, JJ; Zhou, Y1
Allain-Veyrac, G; Gaboriau, L; Gérardin, M; Grall-Bronnec, M; Jolliet-Evin, P; Victorri-Vigneau, C1
Buchanan, RW; Newcomer, JW; Weiden, PJ1
Bojarski, AJ; Marciniec, K; Partyka, A; Pawlowski, M; Wesolowska, A; Zajdel, P1
El-Sayeh, HG; Khanna, P; Komossa, K; Leucht, S; Ma, H; Rummel-Kluge, C; Suo, T; Xia, J1
Aida, SA; Hatim, A; Mohamed, Z; Reynolds, GP; Roffeei, SN; Said, MA; Zainal, NZ1
Charpeaud, T; Llorca, PM; Samalin, L1
Dai, G; Zhang, Y1
Anzai, N; Furukawa, S; Hatsuse, N; Ikebuchi, E; Iwata, K; Kishimoto, T; Matsuda, Y; Sato, S; Watanabe, Y1
Chen, TT; Huang, WL; Tsai, CH1
Alva, G; Brams, M; Citrome, L; Glick, ID; Hochfeld, M; Jackson, R; Kianifard, F; Mattingly, G; Meng, X; Pestreich, L; Weiden, PJ; Winseck, A1
Awad, G; Hassan, M; Hsu, J; Loebel, A; Pikalov, A; Rajagopalan, K1
Kanno-Nozaki, K; Katsumi, A; Mashiko, H; Miura, I; Niwa, S; Shiga, T; Yabe, H1
Kagawa, S; Kondo, T; Mihara, K; Nagai, G; Nakamura, A; Nemoto, K; Suzuki, T4
Sumiyoshi, T1
Cao, B; Hou, R; Jian, J; Mi, G; Qiu, H; Tang, M; Wang, M1
Baker, RA; Bentley, TG; Citrome, L; Eramo, A; Gutierrez, B; Hansen, K; Kamat, SA; Ortendahl, J; Sapin, C1
Aguglia, E; Bianchini, O; Cannavò, D; De Ronchi, D; Nespeca, C; Porcelli, S; Serretti, A; Trappoli, A1
Danilov, DS1
Baker, RA; Carson, WH; Eramo, A; Fleischhacker, WW; Jin, N; Johnson, BR; Kane, JM; McQuade, RD; Perry, PP; Peters-Strickland, T; Sanchez, R; Walling, D1
Perry, CM; Shirley, M1
Gu, N; Kane, JM; Li, H; Luo, J; Wang, C; Wang, X; Xie, S; Xu, X; Yu, W1
Bilenberg, N; Correll, CU; Fagerlund, B; Fink-Jensen, A; Gluud, C; Jantzen, P; Jensen, KG; Jeppesen, P; Jepsen, JR; Juul, K; Klauber, DG; Lauritsen, MB; Madsen, S; Nyvang, L; Pagsberg, AK; Paludan, J; Pedersen, J; Rasmussen, S; Rudå, D; Saldeen, EA; Skoog, M; Stenstrøm, AD; Stentebjerg-Olesen, M; Thomsen, PH; Vernal, DL; Werge, TM; Wetterslev, J; Winge, K1
Pawelczyk, A; Pawelczyk, T; Rabe-Jablonska, J1
Gentile, S1
Baker, RA; Carson, WH; Eramo, A; Gara, M; Hertel, P; Jin, N; Kane, JM; McQuade, RD; Perry, PP; Peters-Strickland, T; Sanchez, R1
Goyal, P; Kumar, D; Prakash, O; Tripathi, P1
Lai, EC; Yang, YH1
Du, Y; Ehrich, EW; Hard, M; Risinger, R; Turncliff, R1
Eifler, S; Englisch, S; Esslinger, C; Kirsch, P; Meyer-Lindenberg, A; Mier, D; Rausch, F; Schirmbeck, F; Zink, M1
Baker, RA; Carson, WH; Eramo, A; Fleischhacker, WW; Johnson, BR; Kane, JM; McQuade, RD; Perry, PP; Peters-Strickland, T; Sanchez, R; Tsai, LF1
Alva, G; Citrome, L; Glick, ID; Jackson, R; Kianifard, F; Mattingly, G; Meng, X; Weiden, PJ; Winseck, A1
Argyelan, M; Gallego, JA; Ikuta, T; Kane, JM; Karlsgodt, K; Lencz, T; Malhotra, AK; Robinson, DG; Sarpal, DK; Szeszko, PR1
Stroup, TS1
Heres, S1
Chiu, HF; Dong, H; Han, X; Lu, Z; Ungvari, GS; Wang, CY; Wu, YF; Xiang, YT; Yang, FD; Yu, X; Yuan, YB; Zhao, JP1
Kobayashi, H; Tadori, Y1
Deng, C; Han, M; Hu, CH; Huang, XF; Pan, B1
Baker, RA; Eramo, A; Kostic, D; Landsberg, W; Larsen, F; Nylander, AG; Raoufinia, A1
Gupta, SK; Kamboj, A1
Fleischhacker, WW; Sanchez, R1
Brugnoli, R; De Filippis, S; Di Sciascio, G; Fagiolini, A; Maina, G1
Carson, WH; Eriksson, H; Hobart, M; Kane, JM; McQuade, RD; Nyilas, M; Ouyang, J; Pfister, S; Sanchez, R; Skuban, A1
Audo, I; Faure, C; Letessier, JB; Robert, MP; Zeitz, C1
Chang, CH; Chang, YC; Chen, YW; Cheng, YS; Chung, W; Tseng, PT; Wang, HY; Wu, CK1
Howland, RH1
Carson, WH; Correll, CU; Eriksson, H; Hobart, M; McQuade, RD; Nyilas, M; Ouyang, J; Pfister, S; Sanchez, R; Skuban, A1
Citrome, L5
Kibble, A1
Greig, SL1
Goff, DC2
Yee, A1
Citrome, L; McEvoy, J1
Stahl, SM2
Baker, RA; Citrome, L; Nagamizu, K; Ota, A; Perry, P; Weiller, E1
Garnock-Jones, KP1
Badran, IA; Correll, CU; Curran, RL; DelBello, MP; Pedapati, EV; Peppers, V1
Correll, CU; Hobart, M; Kane, JM; Ouyang, J; Skuban, A; Weiller, E; Weiss, C2
Bruijnzeel, D; Tandon, R1
Ishigooka, J; Nishiyama, K; Noda, T; Shima, T; Tadori, Y; Tamaru, N; Yamasaki, Y1
Carson, WH; Fleischhacker, WW; Forbes, A; Hobart, M; McQuade, RD; Nyilas, M; Ouyang, J; Pfister, S; Sanchez, R; Weiller, E1
Baker, RA; Malla, A; Nagamizu, K; Ota, A; Perry, P; Weiller, E1
Hakala, MJ; Hobart, M; Josiassen, MK; Marder, SR; Ouyang, J; Weiller, E; Weiss, C; Zhang, P1
Hsu, WY; Lane, HY; Lin, CH1
Gallipani, A; Markovic, M; Maroney, M; Patel, KH1
Dhamija, R; Verma, R1
Azorin, JM; Camus, V; Costentin, J; Crocq, MA; Daléry, J; Glikman, J; Krebs, MO; Limosin, F; Millet, B1
Abbasian, C; Power, P1
Sikich, L1
Karakatsanis, NA; Karapoulios, E; Kouzoupis, AV; Masdrakis, VG; Oulis, P; Soldatos, CR; Zervas, IM1
Boulton, DW; Kollia, G; Komoroski, B; Kovalick, LJ; Mallikaarjun, S; Reeves, RA; Sharma, A1
Collins, J; Mervak, B; Valenstein, M1
Labrie, V; Lipina, T; Roder, JC1
Azorin, JM; Camus, V; Costentin, J; Crocq, MA; Daléry, J; Gliskman, J; Krebs, MO; Limosin, F; Millet, B1
Berman, RM; Breder, C; Campos, JA; Carson, WH; Kerselaers, W; L'italien, GJ; Marcus, RN; McQuade, RD; Newcomer, JW; Nys, M1
Nahata, T; Saini, TR1
Boulton, DW; Carson, WH; Findling, RL; Forbes, RA; Kauffman, RE; Mallikaarjun, S; Nyilas, M; Pikalov, A; Sallee, FR; Shoaf, SE1
Bachmann, CJ; Heinzel-Gutenbrunner, M; Hiemke, C; Remschmidt, H; Rieger-Gies, A; Theisen, FM1
Bhattacharjee, J; El-Sayeh, HG2
Barbero, JD; Benito, N; Cobo Gómez, JV; Coronas, R; Domenech, C; Fuste, G; García-Parés, G; Gómez, JV1
Ayache, L; Buysschaert, M; Fagnart, O; Feys, JL; Gruson, D; Hermans, MP; Jamart, J; Luts, A; Mertens de Wilmars, S; Misson, A; Oriot, P1
Bruggeman, R; Postema, R; Schilthuis, M; Schorr, SG; Slooff, CJ; Taxis, K; Van Oven, W1
Wang, SJ; Yang, TT1
Carson, WH; Findling, RL; Forbes, RA; Ivanova, S; Iwamoto, T; Jin, N; Marcus, R; McQuade, RD; Nyilas, M; Robb, A1
Arsura, E; Sethi, NK; Torgovnick, J1
Choi, JS; Jang, IJ; Kang, DH; Kim, E; Kwon, JS; Shin, SG; Yu, KS1
Assunção-Talbott, S; Crandall, DT; Eudicone, JM; Kane, JM; Pikalov, A; Whitehead, R1
Kashima, H; Kikuchi, T; Manki, H; Nakajima, S; Nomura, K; Suzuki, T; Takeuchi, H; Uchida, H; Watanabe, K1
Langosch, JM; Schlachetzki, JC1
Azzoni, A; Raja, M1
Montero, I; Ruiz, I; Talavera, M1
Chen, CH; Lu, ML; Shen, WW1
Chen, CH; Chen, SF; Chen, SJ; Chen, YJ; Lin, CC; Luu, SU; Shen, YC1
Baardewijk, Mv; Davies, A; L'italien, GJ; Loze, JY; Sennfalt, K; Vardeva, K1
Baker, RA; Carson, WH; Crandall, DT; Eudicone, JM; L'italien, G; Marcus, RN; McQuade, RD; Meyer, JM; Newcomer, JW; Pikalov, A; Vester-Blokland, E1
Archibald, D; Carson, WH; Fleischhacker, WW; Marcus, RN; McQuade, RD; Swanink, R1
Chen, L; Kinon, BJ; Kollack-Walker, S; Sniadecki, J; Stauffer, VL1
Glick, ID; Ivanova, O; Koran, LM; Poyurovsky, M1
Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Miller, AL; Rosenheck, RA; Stroup, TS; Swartz, MS1
Baker, RA; Byerly, MJ; Eudicone, JM; Marcus, RN; Tran, QV; Whitehead, R1
Hanssens, L; Kerselaers, W; L'Italien, G; Loze, JY; Marcus, RN; Pans, M1
Hauser, D; Ladds, B; Mejia, C; Thomas, P1
Jong-Yih, L1
Cho, SJ; Jang, JH; Kang, DH; Kim, YK; Kwon, JS; Yoo, SY1
Assunção-Talbott, S; Crandall, DT; Eudicone, JM; Glick, ID; Janicak, PG; Marcus, RN; Marder, SR; McQuade, RD1
Bueno, JR; Campos, JA; Chaves, A; de Abreu, PB; de Matos E Souza, FG; de Oliveira, IR; de Sena, EP; E Silva, JA; Elkis, H; Gattaz, WF; Louzã, MR1
Costentin, J2
Barnett, AH; Knapp, M; L'Italien, GJ; Loze, JY; Millar, HL; van Baardewijk, M1
Bashir, M; Keith, S; MacRae, A; Majjiga, C; Murphy, J; Shajahan, P; Taylor, M1
Caykoylu, A; Ekinci, O; Yilmaz, E1
Chen, CH; Chen, SF; Shen, YC2
Breier, A; Kane, JM; Kryzhanovskaya, LA; Osuntokun, O; Stauffer, VL; Watson, SB; Xu, W1
Ascher-Svanum, H; Ball, T; Conley, R; Liu, L; Stauffer, V1
Coley, KC; Fabian, TJ; Lenze, EJ; Ruby, C; Scipio, TM1
Chiesa, A; De Ronchi, D; Mandelli, L; Pae, CU; Serretti, A2
Bopp, K; Petti, TA; Stern, RG; Tobia, A1
Chiesa, A; De Ronchi, D; Kim, J; Lee, C; Mandelli, L; Pae, CU; Paik, IH; Serretti, A1
Accordini, S; Artioli, P; Barale, F; Barbui, C; Beneduce, R; Berardi, D; Bertolazzi, G; Biancosino, B; Bisogno, A; Bivi, R; Bogetto, F; Boso, M; Bozzani, A; Bucolo, P; Casale, M; Cascone, L; Ciammella, L; Cicolini, A; Cipresso, G; Cipriani, A; Colombo, P; Dal Santo, B; De Francesco, M; Di Lorenzo, G; Di Munzio, W; Ducci, G; Erlicher, A; Esposito, E; Ferrannini, L; Ferrato, F; Ferro, A; Fragomeno, N; Frova, M; Gardellin, F; Garzotto, N; Giambartolomei, A; Giupponi, G; Grassi, L; Grazian, N; Grecu, L; Guerrini, G; Laddomada, F; Lazzarin, E; Lintas, C; Malchiodi, F; Malvini, L; Marchiaro, L; Marsilio, A; Mauri, MC; Mautone, A; Menchetti, M; Migliorini, G; Mollica, M; Moretti, D; Mulè, S; Nicholau, S; Nosè, F; Nosè, M; Occhionero, G; Pacilli, AM; Parise, VF; Pecchioli, S; Percudani, M; Piantato, E; Piazza, C; Pontarollo, F; Pycha, R; Quartesan, R; Rillosi, L; Risso, F; Rizzo, R; Rocca, P; Roma, S; Rossattini, M; Rossi, G; Sala, A; Santilli, C; Saraò, G; Sarnicola, A; Sartore, F; Scarone, S; Sciarma, T; Siracusano, A; Strizzolo, S; Tansella, M; Targa, G; Tasser, A; Tomasi, R; Travaglini, R; Veronese, A; Ziero, S1
Chung, S; Jeon, YW; Jeong, B; Jun, TY; Jung, HY; Kim, CE; Kim, CY; Kim, DH; Kwon, JS; Lee, JN; Lee, MS1
Kahn, JP; Kerselaers, W; Lissens, J; McQuade, RD; Modell, S; Ryckmans, V; Sanchez, R; Werner, C1
Bergmann, F; Ebrecht, M; Kungel, M; Modell, S; Nass, A; Spevakné-Göröcs, T; Urban, R; Werner, C; Zacher, A1
Chiu, NY; Hsu, WY; Kahn, DA; Lee, CI1
Dziuba, J; Keshavan, M; Lachover, L; Manji, S; Pizzuti, A; Rajarethinam, R1
Pae, CU1
Borba, CP; Boxill, R; Cather, C; Copeland, PM; Evins, AE; Fan, X; Freudenreich, O; Goff, DC; Henderson, DC; Sharma, B1
Bachmann, CJ; Lehr, D; Preiss, M; Theisen, FM1
Englisch, S; Inta, D; Weinbrenner, A; Zink, M1
Kashima, H; Suzuki, T; Takeuchi, H; Uchida, H; Watanabe, K2
Bian, QT; Chen, JX; Haile, C; Kosten, TR; Liu, YH; Su, YA; Wang, N; Wang, SL; Yang, FD; Zhang, XY1
Mace, S; Taylor, D1
Kondo, T; Mihara, K; Nagai, G; Nakamura, A; Suzuki, T1
Bates, JA; Guo, Z; Kan, HJ; Kane, JM; Kim, E; Pikalov, A; Whitehead, R1
de Haan, L; Peters, B1
Shan, JC; Tseng, MC1
Pesek, MB1
El-Sayeh, HG; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S1
Gagliano, A; Masi, G1
Assunção-Talbott, S; Carson, WH; Correll, CU; Goff, DC; Kane, JM; Kirkpatrick, B; Marder, SR; Pikalov, A; Sun, W; Vester-Blokland, E1
Fekete, S; Herold, R; Kovacs, A; Osvath, P; Simon, M; Tenyi, T; Voros, V1
Assunção-Talbott, S; Barnes, TR; Buckley, P; Correll, CU; Eudicone, J; Kane, JM; McQuade, R; Pikalov, A; Sachs, G; Tran, QV1
Rocha, FF1
Stip, E; Tourjman, V1
Chiesa, A; Gibiino, S; Mandelli, L; Pae, CU; Patkar, AA; Serretti, A1
Ali, M; Assunção-Talbott, S; Carson, WH; Forbes, RA; Iwamoto, T; Nyilas, M; Pikalov, A; Robb, AS; Whitehead, R1
Fujita, K; Fukuo, Y; Furukawa, O; Iwata, N; Kawashima, K; Kishi, T; Kitajima, T; Moriwaki, M; Naitoh, H; Okochi, T1
Albayrak, Y; Caykoylu, A; Ekinci, O; Kuloglu, M1
Roxanas, MG1
Hanatani, T; Ikejiri, Y; Kondo, M; Sumi, N1
Beck, A; Dembler, T; Dinges, M; Friedel, E; Gallinat, J; Heinz, A; Juckel, G; Sarkar, R; Schlagenhauf, F; Wrase, J; Wüstenberg, T1
Chen, HK; Shao, CH; Wu, BJ1
Ebrecht, M; Kungel, M; Messer, T; Modell, S; Schmauss, M; Spevakne-Goeroecs, T; Werner, C1
Hori, H; Ikenouchi-Sugita, A; Nakamura, J; Ueda, N; Umene-Nakano, W; Yoshimura, R1
Asenbaum, S; Barnas, C; Fischer, P; Mossaheb, N; Spindelegger, C1
Duggan, L; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S1
Radics, J1
Benedetti, AM; Frazee, LA; Leung, JG; Myers, N1
Cerovecki, A; Dehning, S; Engel, RR; Matz, J; Möller, HJ; Müller, N; Musil, R; Obermeier, M; Opgen-Rhein, M; Riedel, M; Schennach-Wolff, R; Seemüller, F; Severus, E; Spellmann, I1
Carrick, T; Feenstra, R; Kowal, DM; Kruse, CG; Lai, M; Marquis, KL; Pausch, MH; Reinders, JH; Robichaud, AJ; Rotella, DP; van der Neut, M; Yan, Y; Zhang, J; Zhou, P1
Deng, C; Huang, XF; Lian, J; Pai, N1
Hahn, SW; Ham, BJ; Kang, RH; Lee, HY; Lee, MS; Paik, JW1
Dewaele, P; Fleischhacker, WW; Heikkinen, ME; Hennicken, D; Kerselaers, W; Landsberg, W; Loze, JY; McQuade, RD; Olié, JP1
Chiesa, A; Pae, CU; Serretti, A1
Inada, K; Ishigooka, J; Oshibuchi, H1
Bae, KY; Kim, JM; Kim, SW; Shin, IS; Yang, SJ; Yoon, JS1
Arand, J; Farger, G; Hiemke, C; Lutz, UC; Wiatr, G; Wildgruber, D1
Guirguis-Blake, J1
Hamidin, A; Normala, I1
Baker, RA; Docherty, JP; Eudicone, J; Mankoski, R; Marcus, RN; Mathew, S; McQuade, RD1
Kozumplik, O; Sedić, B; Uzun, S1
Cohen, J; Gavaudan, G; Lançon, C; Léonetti, G; Magalon, D; Pélissier-Alicot, AL1
Kibbey, KJ; Nicholson, GC; Roberts, AM1
Chen, J; Deng, C; Hu, C; Huang, XF1
Ishitobi, M; Kosaka, H; Murata, T; Shukunami, K; Wada, Y2
Brunetti, L; Patel, MK1
Chang, CC; Chen, SH; Hwang, PL; Ko, JY; Wei, SY; Yeh, HH1
Davis, JM; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Lobos, CA; Rummel-Kluge, C; Schmid, F; Schwarz, S1
Fujii, A; Furukori, H; Kaneko, S; Sugawara, N; Yasui-Furukori, N1
Chiesa, A; Mandelli, L; Pae, CU; Serretti, A1
Abekawa, T; Ito, K; Koyama, T; Nakagawa, S; Nakato, Y1
Hori, H; Nakamura, J; Okamoto, T; Umene-Nakano, W; Yoshimura, R1
Janicak, PG; Rado, J1
Kirino, E2
Carson, W; Cziraky, MJ; Delorenze, G; Niemcryk, SJ; Oliveria, SA; Phillips, S; Quesenberry, CP; Skovron, ML; Tsai, AL; Ulcickas Yood, M; Wells, K; Willey, VJ1
Girgis, RR; Lieberman, JA; Merrill, DB; Pikalov, A; Vorel, SR; Whitehead, R; You, M1
Atallah, AN; Melnik, T; Puga, ME; Soares, BG1
Gen, K; Inoue, Y; Suzuki, H1
Claes, S; De Hert, M; Martens, GJ; Moons, T; Peuskens, J; Van Loo, KM; Van Schijndel, JE; van Winkel, R1
Ardizzone, I; Carratelli, TI; Ferrara, M; Marconi, A; Nardecchia, F1
Calcagno, E; Carli, M; Invernizzi, RW; Mainini, E; Mainolfi, P1
Bastiampillai, T; Lander, M1
Barlow, KB; Kapur, S; Natesan, S; Nobrega, JN; Reckless, GE1
Case, M; Conley, RR; Hoffmann, VP; Jacobson, JG; Stauffer, VL1
Ascher-Svanum, H; Faries, DE; Kane, JM; Osuntokun, OO; Peng, X; Stauffer, VL; Stensland, MD1
Correll, CU1
Lee, SY; Pae, CU; Park, MH; Patkar, AA1
Cohn, T; Faulkner, G; Mukundan, A; Remington, G1
Arakaki, H; Kagawa, S; Kondo, T; Mihara, K; Nagai, G; Nakamura, A; Nemoto, K; Ohta, I; Suzuki, T; Uno, T1
Lee, J; Ng, KW; Swapna, V1
Kan, HJ; King, D; Knapp, M; Loze, JY; Razzouk, D; Thomas, P; van Baardewijk, M1
Arends, J; Cohen, D; van Kooten, M1
Boyer, L; Christophe, L; Cohen, J; Magalon, D; Simon, N1
Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S1
Bruno, A; Di Nardo, F; Micò, U; Muscatello, MR; Pandolfo, G; Santoro, V; Scimeca, G; Spina, E; Zoccali, RA1
Chen, CY; Lin, TY; Shuai, HA; Wang, CC1
Bobo, WV; Crystal, S; Gerhard, T; Huang, C; Lieberman, JA; Olfson, M1
Bernagie, C; De Hert, M; Dockx, L; Leucht, S; Peuskens, B; Peuskens, J; Sweers, K; Tack, J; Van de Straete, S; Wampers, M1
Hashimoto, K; Iyo, M; Kanahara, N; Okamura, N; Sekine, Y; Tadokoro, S1
Hackett, LP; Ilett, K; Nguyen, T; Teoh, S1
Aleman, A; Bous, J; Hollander, K; Knegtering, H; Liemburg, E1
De Risio, A; Gentile, B; Giannarelli, D; Pancheri, A; Simonetti, G; Stefanutto, L1
Englisch, S; Esslinger, C; Meyer-Lindenberg, A; Rausch, F; Schirmbeck, F; Zink, M1
Accordini, S; Barbui, C; Cipriani, A; Esposito, E; Girlanda, F; Nosè, M; Purgato, M; Stroup, S; Tansella, M; Veronese, A1
Ahn, YM; Jung, DC; Kang, UG; Kim, EY; Kim, SH; Kim, YS; Lee, NY; Sung, KH; Yu, HY1
Breton, C; Delahaye, F; Dickes-Coopman, A; Dutriez-Casteloot, I; Guillemot, J; Laborie, C; Lesage, J; Lukaszewski, MA; Mayeur, S; Montel, V; Vieau, D1
Howes, OD; Jang, IJ; Jeong, JM; Kapur, S; Kim, E; Kwon, JS; Lee, JS; Shin, SG; Yu, KS1
Andel, R; Becker, MA; Boaz, TL; Chandler, K; Desmarais, SL; Howe, A; Van Dorn, RA1
Kasahara, M; Murashima, A; Nakajima, K; Nakamura, T; Sugibayashi, R; Watanabe, N; Watanabe, O1
Chiu, NY; Hsu, WY; Lee, BS; Liao, YC; Lin, TW1
Barbato, A; D'Avanzo, B; Parabiaghi, A; Tettamanti, M1
Eriksson, J; Kasteng, F; Lindgren, P; Sennfält, K1
Kaneda, A; Kaneko, S; Sugawara, N; Tomita, T; Yasui-Furukori, N1
Sokolski, KN1
Hou, YC; Lai, CH1
Basu, R; Brar, JS; Chang, CC; Ganguli, R; Garbut, R1
Bous, J; de Boer, MK; Hamamura, T; Knegtering, H; Sytema, S; van der Moolen, AE; Wiersma, D; Wilffert, B1
Fukui, N; Ono, S; Sawamura, K; Someya, T; Sugai, T; Suzuki, Y; Tsuneyama, N; Watanabe, J1
Hamer, RH; LaVange, LM; Lieberman, JA; McEvoy, JP; Nussbaum, AM; Perkins, DO; Ring, KD; Rosenheck, RA; Stroup, TS; Swartz, MS1
Eberhard, J; Fors, BM; Hansen, K; Lindström, E; Sapin, C1
Bowden-Jones, H; Kitchenham, N; Smith, N1
de Arce Cordón, R; Eding, E; Marques-Teixeira, J; Milanova, V; Rancans, E; Schreiner, A1
Biswas, J; Gandhi, RA; George, RJ; Nair, AG1
Belgamwar, RB; El-Sayeh, HG2
Chou, J; Chung, MT; Lin, CH; Ma, H1
Camacho, LR; Celso, F; Da Rosa, KM; Da Silva, TG; Dos Santos, Bde J; Freitas, TM; Monteiro, JD; Pereira, P; Picada, JN; Pontes, VM; Vieira, LR1
Faludi, G; Fejes, L; Inczédy-Farkas, G; Kassai-Farkas, A; Lazáry, J; Makkos, Z1
Weiden, PJ1
Cho, HY; Fang, ZH; Kim, YH; Lee, BJ; Lee, CH; Lee, JG; Park, SW; Phuong, VT; Seo, MK1
Bervoets, C; Constant, E; de Patoul, A; Delatte, B; Gillain, B; Halkin, V; Kok, F; Loze, JY; Peuskens, J; Touquet, G; Vansteelandt, K1
Diaz-Atienza, F; Gurpegui, M; Gutiérrez-Rojas, L; Jurado, D; Martínez-Ortega, JM1
Lai, CH1
Chang, KY; Wu, YF1
Bastiampillai, T; Dhillon, R; Goh, T1
Ikeda, R; Katagiri, N; Mizumura, S; Mizuno, M; Nemoto, T; Shiraga, N; Tohgi, N; Tsujino, N; Yamaguchi, T1
Fleischhacker, WW; Han, C; Lee, SJ; Masand, PS; Pae, CU; Park, MH; Patkar, AA1
Chen, CK; Lin, SK; Liu, YL1
Endo, T; Fukui, N; Ono, S; Shindo, M; Someya, T; Sugai, T; Suzuki, Y1
Kanno, K; Katsumi, A; Mashiko, H; Miura, I; Mori, A; Niwa, S; Numata, Y; Takeuchi, S; Yang, Q1
Brotzge, K; El-Mallakh, RS; Manshadi, M1
Atake, K; Hayashi, K; Hori, H; Ikenouchi-Sugita, A; Katsuki, A; Nakamura, J; Tomita, M; Umene-Nakano, W; Yoshimura, R1
Berkowitz, RL; Docherty, JP; Ni, Q; Parks, JJ; Patel, U1
Bobo, WV; Chen, Y; Jayathilake, K; Meltzer, HY; Tang, T; Watts, K1
Croxtall, JD1
Goto, S; Terao, T; Tomita, M; Uchimura, N1
Chatziioannou, S; Filippopoulou, A; Lykouras, L; Peppa, M; Rizos, E; Tsigkaropoulou, E; Xelioti, I; Zompola, C1
Jindal, KC; Munjal, V; Singh, GP1
Ahlbrand, R; Bronson, SL; Grainger, M; Horn, P; McNamara, RK; Richtand, NM; Tambyraja, R1
Hashimoto, N; Ito, K; Koyama, T; Kusumi, I; Matsuda, N1
Doey, T1
Han, C; Jeong, HG; Joe, SH; Ko, YH; Lee, HY; Lee, MS1
Johnsen, E; Kroken, RA1
Chang, LR; Huang, WL1
Hayashi, K; Hori, H; Ikenouchi-Sugita, A; Katsuki, A; Nakamura, J; Umene-Nakano, W; Yoshimura, R1
Dunn, G; French, P; Hutton, P; Morrison, AP; Taylor, PJ; Yung, AR1
Anandarajan, T; Bastiampillai, T; Dhillon, R; Tibrewal, P1
Mari, Jde J; Moreira, HC; Nunes, LV; Nunes, SO; Razzouk, D1
Kikuchi, T; Tadori, Y1
Carson, WH; Fleischhacker, WW; Forbes, RA; Jin, N; Johnson, BR; Kane, JM; McQuade, RD; Perry, PP; Sanchez, R1
Abdallah, CG; Hong, X; Huang, H; Huang, Q; Jiang, L; Liang, C; Liu, Y; Wan, X; Wang, J; Wu, R; Xu, C; Zhang, J1
Fleischhacker, WW; Uchida, H1
Chen, CK; Chou, MC; Chou, WJ; Huang, YS; Liang, HY; Tang, CS; Wang, LJ; Wu, YY; Yeh, CB1
Alvir, JM; Berger, A; Edelsberg, J; Mychaskiw, MA; Oster, G; Sanders, KN1
Moteshafi, H; Stip, E1
Azorin, JM; Gasquet, I; Gierski, F; Leguay, D; Lemogne, C; Limosin, F; Raucher-Chéné, D; Rouillon, F; Schuster, JP1
Kanno, K; Katsumi, A; Mashiko, H; Miura, I; Niwa, S; Takeuchi, S; Watanabe, K1
Borba, CP; Copeland, P; Fan, X; Freudenreich, O; Goff, DC; Hayden, D; Henderson, DC1
Chaumartin, N; Lachaux, B; Monville, M1
Bervoets, C; Constant, E; de Patoul, A; Halkin, V; Kok, F; Morrens, M; Peuskens, J; Pitsi, D; Sabbe, B; Vansteelandt, K1
Kato, M; Kinoshita, T; Nishida, K; Okugawa, G; Sakai, S; Suwa, A; Takekita, Y; Wakeno, M1
Arakaki, H; Kagawa, S; Kondo, T; Mihara, K; Nagai, G; Nakamura, A; Nemoto, K; Ohta, I; Suzuki, T1
Landowski, J; Wichowicz, H; Wilkowska, A1
Hiranyatheb, T; Ittasakul, P; Ketter, TA; Srivastava, S1
Arndt, S; Glorioso, DK; Golshan, S; Henry, R; Jeste, DV; Jin, H; Kraemer, HC; Mudaliar, S; Shih, PA1
Chang, HC; Chang, LR; Huang, WL; Liu, CM; Tsai, YF1
Bouvard, S; Ciumas, C; d'Amato, T; Daléry, J; Lerond, J; Lothe, A; Poulet, E; Ryvlin, P; Saoud, M1
Chen, L; Zhou, Z; Zhu, H1
Bienroth, M; Curtis, V; Debenham, M; George, M; Gonzalez, D; Jones, S; Pitsi, D1
Ananjit, S; Badiah, Y; Bulgiba, A; Habil, MH; Hairi, NN; Haslina, MY; Hatim, A; Mahmud, B; Ramli, MA; Said, MA; Sapini, Y; Shah, M; Zafidah, W1
Okamoto, Y; Sato, G; Yamashita, H; Yamawaki, S; Yoshimura, S1
Higuchi, Y; Kawasaki, Y; Miyanishi, T; Seo, T; Sumiyoshi, T; Suzuki, M1
Leung, JG; Nelson, S1
Ali, MW; Carson, WH; Ingenito, GG; Kane, JM; McQuade, RD; Saha, AR; Zimbroff, DL1
Goa, KL; McGavin, JK1
Goodnick, PJ; Jerry, JM1
Ali, MW; Carson, WH; Casey, DE; Ingenito, GG; Jody, D; Liebeskind, A; Saha, AR1
Bailey, KP1
Keck, PE; McElroy, SL1
Buckley, PF2
Bowles, TM; Levin, GM1
Crismon, ML; DeLeon, A; Miller, AL1
Kutscher, EC1
Ali, M; Iwamoto, T; Kaplita, S; Marcus, R; Marder, SR; McQuade, RD; Safferman, AZ; Saha, A; Stock, E1
Gasperoni, TL; Grady, MA; Kirkpatrick, P1
Woods, SW1
Ali, M; Carson, WH; Ingenito, G; Kujawa, MJ; Marder, SR; Potkin, SG; Saha, AR; Stock, E; Stringfellow, J1
Carlsson, A; Grunder, G; Wong, DF1
Kaplan, D; Koliatsos, V; Lindsey, RL; Sandson, NB; Walters, JK1
Ali, M; Archibald, D; Carson, WH; Ingenito, G; Kasper, S; Lerman, MN; Marcus, R; McQuade, RD; Pigott, T; Saha, A1
Carson, WH; Ingenito, GG; Pigott, TA; Saha, AR; Stock, EG; Torbeyns, AF1
Tamminga, CA1
Winans, E1
Carlsson, A; Carlsson, ML; Nilsson, M1
Buckley, PF; Glazer, W; Sebastian, CS1
DeQuardo, JR1
Green, B1
Lieberman, JA1
Duggal, HS1
El-Sayeh, HG; Morganti, C2
Buchanan, RW; Buckley, PF; Chiles, JA; Conley, RR; Crismon, ML; Ereshefsky, L; Essock, SM; Finnerty, M; Hall, CS; Marder, SR; McEvoy, JP; Miller, A; Miller, DD; Rush, AJ; Saeed, SA; Schooler, NR; Shon, SP; Stroup, S; Tarin-Godoy, B1
Crismon, ML; DeLeon, A; Patel, NC1
Perry, CM; Swainston Harrison, T1
Kasper, S; Winkler, D1
Fear, C1
Shayegan, DK; Stahl, SM1
Chakraborty, N; Johnston, T1
Tsai, SJ1
Bogunovic, O; Brenner, R; Gupta, S; Madhusoodanan, S; Reddy, H1
Lambert, M; Naber, D1
Archibald, D; Carson, WH; Gharbia, NA; Jody, D; Marcus, R; McQuade, RD; Stock, E; Vanveggel, S1
Bark, N; Citrome, L; Josiassen, R; Mallikaarjun, S; Salazar, DE1
Bolonna, AA; Kerwin, RW1
Cousins, DA; Young, AH1
Burns, T; Dursun, S; Fahy, T; Frangou, S; Gray, R; Haddad, PM; Hunter, R; Taylor, DM; Travis, MJ; Young, AH1
Cosi, C; Newman-Tancredi, A; Rollet, K; Tesori, V; Waget, A1
Launer, M1
Kinghorn, WA; McEvoy, JP1
Bartholomä, A; Gregor, A; Hein, J; Heinz, A; Juckel, G1
Bridler, R1
Alfers, J; Beresford, HF; Beresford, TP; Clapp, L; Martin, B; Wiberg, JL1
Baldessarini, RJ; Centorrino, F; Cimbolli, P; Cincotta, SL; Fogarty, KV; Salvatore, P; Sani, G; Thompson, TA1
Ostroff, R; Wahl, R1
Barr, BM; Coughenour, LL; Gregory, TF; Singer, JM; Walters, MA1
Been, A; de Bruijn, C; Vergouwen, AC1
Hiemke, C; Kirschbaum, KM; Malevani, J; Mobascher, A; Müller, MJ; Saria, A; Zernig, G1
Church, CO; Fugate, SE; Stevens, DL1
Fleischhacker, WW1
Annable, L; Beauclair, L; Chouinard, G; Kolivakis, TT; Margolese, HC; Miller, R1
Hirose, T; Kikuchi, T1
Folnegović-Smalc, V; Kozumplik, O; Mimica, N; Uzun, S1
Odiyoor, M; Salmoiraghi, A1
Duggal, V; Glick, ID; Hodulik, C1
Carson, WH; Citrome, L; Czobor, P; Hardy, S; Kostic, D; Marcus, R; McQuade, RD; Volavka, J1
Borba, CP; Cather, C; Daley, TB; Evins, AE; Freudenreich, O; Goff, DC; Henderson, DC; Kunkel, L; Louie, PM; Nguyen, DD1
Bork, B; Christensen, A; Christensen, AF; Christensen, M; Nielsen, CT; Poulsen, J1
Crandall, DT; Iwamoto, T; Kostic, D; Marcus, RN; McQuade, RD; Nyilas, M; Pans, M; Riera, LC; Stock, EG; Tandon, R1
Raja, M1
Baciu, D; Walther, S1
Ebrecht, M; Göröcs, T; Gründer, G; Kungel, M; Modell, S1
Harms, E; Kropp, S; Luebbe, G; Ziegenbein, M1
Kantrowitz, JT; Srihari, VH; Tek, C2
Kim, YK; Lee, BH; Park, SH1
Clarke, LA; Kaushik, S; Lindenmayer, JP1
Duggal, HS; Mendhekar, DN1
Strawn, JR1
Bahta, E; Levine, S; Manas, K; Reddymasu, S; Slay, LE1
Bourin, M1
Gaszner, P1
Almond, SL; Armstrong, EJ; Brandon, NJ; Chiu, CS; Fradley, RL; Heavens, RB; Hutson, PH; Konno, R; Newman, RJ; Rutter, AR1
Tsai, JF1
Egger, C; Geretsegger, C; Muehlbacher, M; Nickel, M; Rauscher, A; Stuppaeck, C1
Adams, CE; El-Sayeh, HG; Morganti, C1
Crossman, AM; Lindenmayer, JP1
Alla, L; Sabaratnam, M; Shastri, M1
Bies, RR; Chew, ML; Gharabawi, G; Greenspan, A; Kapur, S; Kirshner, MA; Lehman, ME; Mulsant, BH; Pollock, BG1
De Hert, M; Hanssens, L; Peuskens, J; Scheen, A; Van Eyck, D; van Winkel, R; Wampers, M3
Gründer, G; Paulzen, M1
Carson, WH; Cutler, AJ; Hardy, SA; Marcus, RN; McQuade, RD; O'Donnell, A1
Andrezina, R; Carson, WH; Iwamoto, T; Josiassen, RC; Manos, G; Marcus, RN; Oren, DA; Stock, E1
Fernald, DS; Hovens, JE; Loonen, AJ; van Dellen, RT1
Kang, SG; Kim, L; Lee, HJ; Lee, MS; Park, JS1
Harborne, GC; Karunakaran, K; Tungaraza, TE1
Chrzanowski, WK; Marcus, RN; McQuade, RD; Nyilas, M; Torbeyns, A1
Correll, CU; Frederickson, AM; Kane, JM; Manu, P1
Kovács, G; Kovács, L1
Andrezina, R; Carson, WH; Manos, G; Marcus, RN; McQuade, RD; Oren, DA; Stock, E1
Dimopoulos, NP; Kararizou, EG; Katsa, AN; Katsanou, MN; Mitropoulos, PA; Mitsonis, CI; Tsakiris, FE1
Chen, R; Johnson, JL; Jordan, S; Kambayashi, J; Kikuchi, T; Kitagawa, H; McQuade, R; Regardie, K; Tadori, Y1
Hirose, T; Kameya, T; Kikuchi, T; Mamiya, N; Taguchi, M; Yamada, S1
Padala, KP; Padala, PR; Sadiq, HJ1
Abu-Tair, F; Bergemann, N; Kopitz, J1
Chavez, B; Poveda, RA1
Kropp, S; Wittmann, G; Ziegenbein, M1
De Oliveira, IR; Juruena, MF1
Cassano, GB; Fagiolini, A; Lattanzi, L; Monteleone, P; Niolu, C; Sacchetti, E; Siracusano, A; Vita, A1
Liskow, BI; Moeller, KE; Shireman, TI1
Arlien-Soborg, P; Kondziella, D1
Oosterhuis, M; Tenback, D; Van De Kraats, G1
Engel, JA; Fejgin, K; Klamer, D; Pålsson, E; Safonov, S; Svensson, L; Wass, C1
Auby, P; Marcus, RN; McQuade, RD; Oren, DA; Sack, DA; Tran-Johnson, TK1
Pinninti, NR; Sanghadia, M1
Keller Ashton, A1
Thomas, P1
Limosin, F1
Lamberti, JS; Olsen, D; Spurling, RD; Tang, W; Tu, X1
Freeman, B; Gorman, JM; Levy, W1
Chen, YY; Hung, GC2
Boulton, DW; Citrome, L; Macher, JP; Mallikaarjun, S; Salazar, DE1
Crandall, DT; Gutierrez-Esteinou, R; Lau, GS; Marcus, RN; Marder, SR; Pikalov, A; Pultz, JA; West, B1
Chen, CH; Chen, SJ; Lin, CC; Shen, YC1
Citrome, LL; Crandall, DT; Currier, GW; Manos, G; McQuade, R; Oren, D; Pikalov, AA; Zimbroff, DL1
Allen, MH; Crandall, DT; Currier, GW; Daniel, DG; Manos, G; McQuade, R; Oren, D; Pikalov, AA; Zimbroff, DL1
Fan, XW; Luo, JW; Zeng, DZ1
Banki, CM; Beuzen, JN; Hanssens, L; Herman, E; Kerwin, R; L'Italien, G; Lublin, H; McQuade, RD; Millet, B; Pans, M1
Bienroth, M; Jones, M; Millar, H; Ratna, L; Sullivan, G; Taylor, D1
Feldman, JJ; Rosenberg, J; Salzman, C1
Cuffel, BJ; Loebel, AD; Mullins, CD; Naradzay, J; Obeidat, NA1
Carson, WH; Daniel, DG; Marcus, RN; McEvoy, JP; McQuade, RD1
Abbasi, FA; Glick, ID; Ivanova, O; Kim, SH; Lamendola, CA; Reaven, GM1
Bourgeois, JA; Kahn, D1
Carson, WH; Crandall, DT; Eudicone, J; Kane, JM; Marcus, RN; Pikalov, A; Swyzen, W1
Forbes, RA; Kikuchi, T; Kitagawa, H; McQuade, RD; Stark, A; Tadori, Y1
Adelbrecht, C; Allain, H; Bernardo, M; Janssen, F; Laughton, J; Lublin, H; Maier, W; Millar, H; Pans, M; Salokangas, RK; Smeraldi, E; Werner, C; Wolf, J1
Wooten, J1
Kessler, RM1
Conley, RR; Jung, DU; Kelly, DL; Liu, KH; Seo, YS; Shim, JC; Shin, JG; Shon, JH1
Graff, A; Kapur, S; Mamo, D; Mizrahi, R; Romeyer, F; Shammi, CM1
Chiclana, C; Gonzalez, R; Lopez-Garcia, P1
Burchardt, C; Hiemke, C; Kirschbaum, KM; Malevani, J; Mobascher, A; Müller, MJ; Piel, M1
Chen, CH; Huang, MC; Lu, ML2
Loebel, A; Siu, C; Warrington, L; Yang, R; Zimbroff, D1
Allen, MH; Nordstrom, K1
Carson, WH; Casey, DE; Kan, HJ; L'Italien, GJ; Marcus, RN1
Atkinson, J; Fischetti, C; Jones, S; Sparshatt, A; Taylor, D1
Chou, YH; Su, TP; Yang, KC1
Keating, GM; Sanford, M2
Bushe, CJ; Leonard, BE1
Rosenheck, RA1
Hettema, JM; Ross, DE1
Lee, C; Lee, CU; Lim, HK; Pae, CU1
Thone, J1
Eudicone, JM; Kim, E; Miller, DD; Pikalov, A1
Chou, SY; Chung, PC; Su, JA; Tsang, HY1
Calabrese, JR; Gajwani, P; Ganocy, SJ; Gao, K; Kemp, DE; Muzina, DJ1
Gonidakis, F; Papadimitriou, G; Ploubidis, D1
Desseilles, M; Mathot, F1
Gray, R; Jones, M1
Bashir, M; Macrae, A; Shajahan, P; Taylor, M1
Hughes, D; Morcos, M1
Hazra, M; Mamo, DC; Remington, G1
Poyurovsky, M; Weizman, A; Weizman, R1
Sanford, M; Scott, LJ1
Andersen, SE; Johansson, M; Manniche, C1
Bianchi, F; Di Lorenzo, G; Leo, R; Razzini, C; Romeo, F; Siracusano, A; Tesauro, M; Zanasi, M1
Ahn, YM; Chang, JS; Kang, UG; Kim, SH; Kim, YS; Lee, KY; Park, HJ1
Corey-Lisle, PK; Crosby, RD; Kan, HJ; Kolotkin, RL; McQuade, RD1
Boy, C; Bröcheler, A; Fellows, C; Gründer, G; Hellmann, S; Hiemke, C; Janouschek, H; Kirschbaum, KM; Rösch, F; Schaefer, WM; Spreckelmeyer, KM; Vernaleken, I; Veselinovic, T1
Abi-Dargham, A; Alvarez, B; Bae, SA; Frankle, WG; Gil, R; Gonzales, R; Hackett, E; Kegeles, LS; Kim, JH; Laruelle, M; Slifstein, M; Xu, X1
Hanssens, L; L'Italien, G; Loze, JY; Marcus, RN; Pans, M; Taylor, D1
Blonde, L; Gutterman, EM; Hanssens, L; Kan, HJ; Kim, MS; L'Italien, GJ; McQuade, RD1
Campanella, LM; Lartey, R; Shih, R1
Strange, PG1
Hwang, MY; Kim, JM; Kim, SW; Shin, IS; Yang, SJ; Yoon, JS1
Kelly, DL; Shim, JC; You, YS1
Bailey, P; Castro, JO; Crocq, MA; Duval, F; Lataste, X; Macher, JP; Mokrani, MC1
Cañive, JM; Davis, JT; Edgar, JC; Lewine, JD; Miller, GA; Torres, F; Tuason, VB1
Albert, MJ; Baldessarini, RJ; Centorrino, F; Kelleher, JP1
Fourie, J; Ozdemir, V; Ozdener, F1
Biziere, K; Bramer, S; Dannals, RF; Dogan, AS; Gründer, G; Ravert, H; Stephane, M; Suri, A; Wong, DF; Yokoi, F1
Bochnik, J; Demisch, L; Gerbaldo, H; Lehmann, CO1

Reviews

121 review(s) available for carbostyril and Schizophrenia

ArticleYear
Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
    The American journal of psychiatry, 2020, 04-01, Volume: 177, Issue:4

    Topics: Acute Disease; Administration, Oral; Antipsychotic Agents; Aripiprazole; Clozapine; Delayed-Action Preparations; Dose-Response Relationship, Drug; Haloperidol; Humans; Imidazoles; Indoles; Isoxazoles; Lurasidone Hydrochloride; Olanzapine; Paliperidone Palmitate; Piperazines; Piperidines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Thiophenes

2020
Aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysis.
    Psychopharmacology, 2020, Volume: 237, Issue:5

    Topics: Acute Disease; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Humans; Network Meta-Analysis; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Thiophenes; Weight Gain

2020
Efficacy and safety of brexpiprazole in acute management of psychiatric disorders: a meta-analysis of randomized controlled trials.
    International clinical psychopharmacology, 2020, Volume: 35, Issue:3

    Topics: Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Humans; Psychiatric Status Rating Scales; Quetiapine Fumarate; Quinolones; Schizophrenia; Thiophenes; Treatment Outcome

2020
Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia.
    CNS drugs, 2020, Volume: 34, Issue:5

    Topics: Animals; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Receptors, Dopamine D3; Schizophrenia; Thiophenes

2020
Brexpiprazole for the Treatment of Schizophrenia in Adults: An Overview of Its Clinical Efficacy and Safety and a Psychiatrist's Perspective.
    Drug design, development and therapy, 2020, Volume: 14

    Topics: Adult; Antipsychotic Agents; Dopamine Agonists; Humans; Psychiatry; Quinolones; Receptors, Dopamine D2; Schizophrenia; Thiophenes; Treatment Outcome

2020
Brexpiprazole for the Treatment of Schizophrenia and Major Depressive Disorder: A Comprehensive Review of Pharmacological Considerations in Clinical Practice.
    Psychopharmacology bulletin, 2021, 03-16, Volume: 51, Issue:2

    Topics: Antipsychotic Agents; Depressive Disorder, Major; Humans; Quinolones; Schizophrenia; Thiophenes

2021
Brexpiprazole: A Partial Dopamine Agonist for the Treatment of Schizophrenia.
    Reviews on recent clinical trials, 2018, Jan-31, Volume: 13, Issue:1

    Topics: Dopamine Agonists; Humans; Quinolones; Schizophrenia; Thiophenes; Treatment Outcome

2018
Brexpiprazole: a new leaf on the partial dopamine agonist branch.
    Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, 2018, Volume: 26, Issue:1

    Topics: Antipsychotic Agents; Aripiprazole; Depressive Disorder, Treatment-Resistant; Dopamine Agonists; Humans; Quinolones; Schizophrenia; Thiophenes

2018
Changes in metabolic parameters and body weight in brexpiprazole-treated patients with acute schizophrenia: pooled analyses of phase 3 clinical studies.
    Current medical research and opinion, 2018, Volume: 34, Issue:12

    Topics: Adult; Antipsychotic Agents; Clinical Trials, Phase III as Topic; Double-Blind Method; Glucose; Humans; Longitudinal Studies; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Thiophenes; Triglycerides; Weight Gain

2018
Brexpiprazole: A Review in Schizophrenia.
    Drugs, 2019, Volume: 79, Issue:2

    Topics: Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Approval; Humans; Japan; Quinolones; Schizophrenia; Serotonin Receptor Agonists; Thiophenes; United States

2019
Aripiprazole versus other atypical antipsychotics for schizophrenia.
    The Cochrane database of systematic reviews, 2013, Feb-28, Issue:2

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Olanzapine; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Thiazoles

2013
Long-acting injectable aripiprazole: how might it fit in our tool box?
    Clinical schizophrenia & related psychoses, 2013,Summer, Volume: 7, Issue:2

    Topics: Administration, Oral; Antipsychotic Agents; Aripiprazole; Humans; Injections; Piperazines; Quinolones; Schizophrenia; Treatment Outcome; United States

2013
[Aripiprazole as "dopamine sensitivity stabilizer"].
    Nihon rinsho. Japanese journal of clinical medicine, 2013, Volume: 71, Issue:4

    Topics: Antipsychotic Agents; Aripiprazole; Dopamine; Dopamine Agonists; Humans; Piperazines; Quinolones; Receptors, Dopamine; Schizophrenia

2013
A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder.
    Psychopharmacology, 2013, Volume: 228, Issue:2

    Topics: Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Humans; Piperazines; Practice Guidelines as Topic; Psychoses, Substance-Induced; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology

2013
[Efficacy of aripiprazole (amdoal) in the long-term treatment of schizophrenia].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2013, Volume: 113, Issue:3

    Topics: Antipsychotic Agents; Aripiprazole; Follow-Up Studies; Humans; Piperazines; Quinolones; Schizophrenia; Time Factors; Treatment Outcome

2013
Long-acting injectable aripiprazole (Abilify Maintena) for schizophrenia.
    The Medical letter on drugs and therapeutics, 2013, Apr-29, Volume: 55, Issue:1415

    Topics: Animals; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Delayed-Action Preparations; Humans; Injections; Piperazines; Quinolones; Schizophrenia; Time Factors

2013
Atypical antipsychotics for psychosis in adolescents.
    The Cochrane database of systematic reviews, 2013, Oct-15, Issue:10

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Molindone; Olanzapine; Piperazines; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia

2013
Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence-based practice.
    The Journal of clinical psychiatry, 2013, Volume: 74, Issue:11

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Drug Substitution; Dyskinesia, Drug-Induced; Evidence-Based Medicine; Humans; Lipids; Olanzapine; Patient Outcome Assessment; Piperazines; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology

2013
Quinoline- and isoquinoline-sulfonamide analogs of aripiprazole: novel antipsychotic agents?
    Future medicinal chemistry, 2014, Volume: 6, Issue:1

    Topics: Antipsychotic Agents; Aripiprazole; Humans; Isoquinolines; Piperazines; Protein Binding; Quinolines; Quinolones; Receptors, Dopamine; Receptors, Serotonin; Schizophrenia; Sulfonamides

2014
Aripiprazole versus other atypical antipsychotics for schizophrenia.
    The Cochrane database of systematic reviews, 2014, Jan-02, Issue:1

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia

2014
[Efficacy of aripiprazole for the treatment of schizophrenia: what dose is required?].
    L'Encephale, 2014, Volume: 40, Issue:1

    Topics: Aripiprazole; Dose-Response Relationship, Drug; Double-Blind Method; Evidence-Based Medicine; Hostility; Humans; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Treatment Outcome

2014
Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia.
    Drugs, 2014, Volume: 74, Issue:10

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Schizophrenia

2014
A safety evaluation of aripiprazole for treating schizophrenia during pregnancy and puerperium.
    Expert opinion on drug safety, 2014, Volume: 13, Issue:12

    Topics: Animals; Antipsychotic Agents; Aripiprazole; Female; Humans; Piperazines; Postpartum Period; Pregnancy; Psychotic Disorders; Quinolones; Schizophrenia

2014
[In vitro pharmacology of antipsychotics at human dopamine D2 and D3 receptors].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2014, Volume: 144, Issue:6

    Topics: Animals; Antipsychotic Agents; Aripiprazole; CHO Cells; Cricetulus; Depression; Dopamine; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Piperazines; Quinolones; Receptors, Dopamine D2; Receptors, Dopamine D3; Schizophrenia; Synaptic Transmission

2014
Initiation of aripiprazole once-monthly in patients with schizophrenia.
    Current medical research and opinion, 2015, Volume: 31, Issue:3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Biomedical Research; Delayed-Action Preparations; Drug Administration Schedule; Drug Monitoring; Drug Substitution; Female; Humans; Injections; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Treatment Outcome

2015
Atypical neuroleptic malignant syndrome in patients treated with aripiprazole and clozapine: a case-series study and short review.
    International journal of psychiatry in medicine, 2015, Volume: 49, Issue:1

    Topics: Adult; Aripiprazole; Clozapine; Creatine Kinase; Dose-Response Relationship, Drug; Drug Substitution; Drug Therapy, Combination; Female; Fluoxetine; Hospitalization; Humans; Injections, Intramuscular; Male; Middle Aged; Neuroleptic Malignant Syndrome; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology

2015
Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be hel
    International journal of clinical practice, 2015, Volume: 69, Issue:9

    Topics: Antidepressive Agents; Antipsychotic Agents; Chemotherapy, Adjuvant; Clinical Trials as Topic; Depressive Disorder, Major; Dopamine Agonists; Humans; Quinolones; Schizophrenia; Thiophenes

2015
Brexpiprazole: a new dopamine D₂receptor partial agonist for the treatment of schizophrenia and major depressive disorder.
    Drugs of today (Barcelona, Spain : 1998), 2015, Volume: 51, Issue:7

    Topics: Depressive Disorder, Major; Dopamine Agonists; Humans; Quinolones; Receptors, Dopamine D2; Schizophrenia; Thiophenes

2015
Brexpiprazole (Rexulti) for schizophrenia and depression.
    The Medical letter on drugs and therapeutics, 2015, Aug-17, Volume: 57, Issue:1475

    Topics: Animals; Depressive Disorder, Major; Dopamine Agonists; Humans; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Serotonin Agents; Thiophenes

2015
Brexpiprazole: First Global Approval.
    Drugs, 2015, Volume: 75, Issue:14

    Topics: Depressive Disorder; Drug Approval; Humans; Internationality; Molecular Structure; Quinolones; Schizophrenia; Thiophenes

2015
Brexpiprazole for the treatment of schizophrenia.
    Expert review of neurotherapeutics, 2016, Volume: 16, Issue:2

    Topics: Antipsychotic Agents; Dopamine Agonists; Humans; Quinolones; Schizophrenia; Serotonin Agents; Thiophenes; Treatment Outcome

2016
Brexpiprazole for the Treatment of Schizophrenia: A Review of this Novel Serotonin-Dopamine Activity Modulator.
    Clinical schizophrenia & related psychoses, 2016,Winter, Volume: 9, Issue:4

    Topics: Antipsychotic Agents; Humans; Quinolones; Schizophrenia; Thiophenes

2016
Brexpiprazole: A Review in Schizophrenia.
    CNS drugs, 2016, Volume: 30, Issue:4

    Topics: Animals; Antipsychotic Agents; Humans; Quinolones; Schizophrenia; Thiophenes

2016
Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies.
    Schizophrenia research, 2016, Volume: 174, Issue:1-3

    Topics: Acute Disease; Antipsychotic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Thiophenes

2016
Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia.
    Schizophrenia research, 2016, Volume: 174, Issue:1-3

    Topics: Antipsychotic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Thiophenes

2016
Spotlight on brexpiprazole and its potential in the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression.
    Drug design, development and therapy, 2016, Volume: 10

    Topics: Animals; Depressive Disorder, Major; Humans; Quinolones; Schizophrenia; Thiophenes

2016
Brexpiprazole for the treatment of schizophrenia.
    Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:2

    Topics: Antipsychotic Agents; Cognition; Dopamine; Humans; Psychomotor Agitation; Quinolones; Receptors, Dopamine D2; Schizophrenia; Serotonin; Thiophenes

2017
Emerging pharmacological therapies in schizophrenia: what's new, what's different, what's next?
    CNS spectrums, 2016, Volume: 21, Issue:S1

    Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Humans; Injections, Intramuscular; Paliperidone Palmitate; Piperazines; Quinolones; Schizophrenia; Tetrabenazine; Thiophenes; Valine

2016
Brexpiprazole.
    The Annals of pharmacotherapy, 2017, Volume: 51, Issue:4

    Topics: Antidepressive Agents; Antipsychotic Agents; Clinical Trials, Phase III as Topic; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Quinolones; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Schizophrenia; Thiophenes; Weight Gain

2017
[Present data and treatment schedule of aripiprazole in the treatment of schizophrenia].
    L'Encephale, 2008, Volume: 34, Issue:1

    Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Drug Administration Schedule; Follow-Up Studies; Humans; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome

2008
Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders.
    The Journal of clinical psychiatry, 2008, Volume: 69 Suppl 4

    Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain Diseases; Child; Chronic Disease; Clozapine; Comorbidity; Disease Progression; Humans; Magnetic Resonance Imaging; Olanzapine; Piperazines; Prognosis; Psychotic Disorders; Quinolones; Schizophrenia; Thiazoles; Treatment Failure

2008
[Clinical potentialities and perspectives for the use of aripiprazole in other disorders than its classical indications. A critical analysis of the recent literature].
    L'Encephale, 2008, Volume: 34, Issue:2

    Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Borderline Personality Disorder; Depressive Disorder, Major; Humans; Mental Disorders; Neurodegenerative Diseases; Parkinson Disease; Piperazines; Quinolones; Schizophrenia; Substance-Related Disorders; Tourette Syndrome

2008
Aripiprazole versus typical antipsychotic drugs for schizophrenia.
    The Cochrane database of systematic reviews, 2008, Jul-16, Issue:3

    Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia

2008
The efficacy of aripiprazole in the treatment of multiple symptom domains in patients with acute schizophrenia: a pooled analysis of data from the pivotal trials.
    Schizophrenia research, 2008, Volume: 105, Issue:1-3

    Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Female; Humans; Male; Piperazines; Placebos; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Treatment Outcome

2008
Clinical trials with a new atypical antipsychotic (Aripiprazole): gender specific information analysis.
    Women & health, 2008, Volume: 47, Issue:4

    Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Sex Distribution; Treatment Outcome; United States; United States Food and Drug Administration

2008
Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine.
    Schizophrenia research, 2008, Volume: 106, Issue:2-3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cholesterol; Cholesterol, HDL; Endpoint Determination; Female; Humans; Lipoproteins; Male; Multicenter Studies as Topic; Olanzapine; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Treatment Outcome; Triglycerides

2008
The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.
    The Journal of clinical psychiatry, 2009, Volume: 70, Issue:1

    Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Evidence-Based Medicine; Female; Haloperidol; Humans; Male; Middle Aged; Multicenter Studies as Topic; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Recurrence; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Young Adult

2009
[A new pharmacological strategy for schizophrenia: the partial agonists of D2 dopaminergic receptors. The principle characteristics of aripiprazole].
    L'Encephale, 2009, Volume: 35, Issue:1

    Topics: Antipsychotic Agents; Aripiprazole; Brain; Humans; Neurons; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia; Synaptic Transmission

2009
A review of the safety and tolerability of aripiprazole.
    Expert opinion on drug safety, 2009, Volume: 8, Issue:3

    Topics: Animals; Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Schizophrenia

2009
Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder.
    CNS drugs, 2009, Volume: 23, Issue:9

    Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Piperazines; Psychotic Disorders; Quinolones; Receptors, Dopamine D2; Schizophrenia

2009
[A new approach to antischizophrenic therapeutics: D2 dopamine receptor partial agonists].
    Annales pharmaceutiques francaises, 2009, Volume: 67, Issue:5

    Topics: Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Drug Design; Dyskinesia, Drug-Induced; History, 20th Century; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia

2009
Aripiprazole versus other atypical antipsychotics for schizophrenia.
    The Cochrane database of systematic reviews, 2009, Oct-07, Issue:4

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Olanzapine; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia

2009
Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials.
    Journal of psychopharmacology (Oxford, England), 2010, Volume: 24, Issue:7

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Haloperidol; Humans; Hypnotics and Sedatives; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Treatment Outcome

2010
Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Clinical therapeutics, 2010, Volume: 32 Suppl 1

    Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Nausea; Piperazines; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Weight Gain; Young Adult

2010
Olanzapine versus other atypical antipsychotics for schizophrenia.
    The Cochrane database of systematic reviews, 2010, Mar-17, Issue:3

    Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Sulpiride; Thiazoles

2010
[Action of amygdala dopamine and effect of antipsychotics].
    Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, 2010, Volume: 30, Issue:2

    Topics: Amygdala; Animals; Antipsychotic Agents; Aripiprazole; Catecholamines; Conditioning, Classical; Dopamine; Fear; Haloperidol; Humans; Piperazines; Quinolones; Rats; Schizophrenia; Schizophrenic Psychology; Stress, Psychological

2010
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.
    Schizophrenia research, 2010, Volume: 123, Issue:2-3

    Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Cholesterol; Clinical Trials as Topic; Clozapine; Dibenzothiazepines; Humans; Imidazoles; Indoles; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Sulpiride; Thiazoles; Weight Gain

2010
Aripiprazole for late-life schizophrenia.
    Clinical interventions in aging, 2010, Sep-07, Volume: 5

    Topics: Aged; Aging; Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Schizophrenia

2010
Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews.
    Sao Paulo medical journal = Revista paulista de medicina, 2010, Volume: 128, Issue:3

    Topics: Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Humans; Isoxazoles; Meta-Analysis as Topic; Paliperidone Palmitate; Piperazines; Placebos; Pyrimidines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Review Literature as Topic; Risperidone; Schizophrenia; Treatment Outcome

2010
Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials.
    Psychopharmacology bulletin, 2010, Volume: 43, Issue:2

    Topics: Adolescent; Age Factors; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Double-Blind Method; Evidence-Based Medicine; Female; Humans; Male; Multicenter Studies as Topic; Olanzapine; Patient Selection; Piperazines; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome

2010
Switching and combining antipsychotics.
    CNS spectrums, 2010, Volume: 15, Issue:4 Suppl 6

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Decision Making; Female; Humans; Olanzapine; Piperazines; Polypharmacy; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Weight Gain

2010
Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.
    The Cochrane database of systematic reviews, 2010, Dec-08, Issue:12

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Dibenzothiazepines; Drug Substitution; Fasting; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Schizophrenia; Weight Gain

2010
Risperidone versus other atypical antipsychotics for schizophrenia.
    The Cochrane database of systematic reviews, 2011, Jan-19, Issue:1

    Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Imidazoles; Indoles; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Sulpiride; Thiazoles

2011
Aripiprazole versus placebo for schizophrenia.
    The Cochrane database of systematic reviews, 2011, Aug-10, Issue:8

    Topics: Antipsychotic Agents; Aripiprazole; Humans; Patient Dropouts; Piperazines; Placebos; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia

2011
Aripiprazole treatment for patients with schizophrenia: from acute treatment to maintenance treatment.
    Expert review of neurotherapeutics, 2011, Volume: 11, Issue:11

    Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Humans; Piperazines; Quinolones; Schizophrenia

2011
Improvement of tardive dyskinesia and dystonia associated with aripiprazole following a switch to quetiapine: case report and review of the literature.
    Journal of clinical pharmacy and therapeutics, 2012, Volume: 37, Issue:3

    Topics: Adult; Age Factors; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Male; Piperazines; Quetiapine Fumarate; Quinolones; Risk Factors; Schizophrenia; Sex Characteristics; Treatment Outcome; Young Adult

2012
Aripiprazole: a review of its use in the management of schizophrenia in adults.
    CNS drugs, 2012, Feb-01, Volume: 26, Issue:2

    Topics: Adult; Age Factors; Antipsychotic Agents; Aripiprazole; Humans; Hyperglycemia; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Weight Gain

2012
Aripiprazole in pediatric psychosis and bipolar disorder: a clinical review.
    Journal of affective disorders, 2012, Volume: 138 Suppl

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Humans; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia

2012
Is rational antipsychotic polytherapy feasible? A selective review.
    Current psychiatry reports, 2012, Volume: 14, Issue:3

    Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Haloperidol; Humans; Piperazines; Prolactin; Quinolones; Schizophrenia

2012
Efficacy and safety of aripiprazole in child and adolescent patients.
    European child & adolescent psychiatry, 2012, Volume: 21, Issue:7

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Bipolar Disorder; Child; Humans; Piperazines; Quinolones; Schizophrenia

2012
Aripiprazole vs placebo for schizophrenia.
    Schizophrenia bulletin, 2012, Volume: 38, Issue:3

    Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Placebos; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia

2012
Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review.
    Journal of sex & marital therapy, 2012, Volume: 38, Issue:3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Substitution; Drug Therapy, Combination; Erectile Dysfunction; Female; Humans; Hyperprolactinemia; Male; Piperazines; Psychotic Disorders; Purines; Quinolones; Schizophrenia; Schizophrenic Psychology; Sexual Dysfunction, Physiological; Sildenafil Citrate; Sulfones; Vasodilator Agents

2012
[Pharmacology of antipsychotics at human dopamine D2 and D3 receptors].
    Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, 2012, Volume: 32, Issue:1

    Topics: Antipsychotic Agents; Aripiprazole; Cells, Cultured; Colforsin; Dopamine D2 Receptor Antagonists; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Receptors, Dopamine D3; Schizophrenia

2012
Critical review of antipsychotic polypharmacy in the treatment of schizophrenia.
    The international journal of neuropsychopharmacology, 2014, Volume: 17, Issue:7

    Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Clozapine; Humans; Piperazines; Polypharmacy; Practice Patterns, Physicians'; Quinolones; Schizophrenia

2014
Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis.
    Expert opinion on drug safety, 2012, Volume: 11, Issue:5

    Topics: Adult; Affective Disorders, Psychotic; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Humans; Hypercholesterolemia; Incidence; Pharmacovigilance; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Thiazoles

2012
Torticollis after low-dose aripiprazole administration in a Thai schizophrenia patient.
    Asian journal of psychiatry, 2012, Volume: 5, Issue:4

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia; Torticollis; Young Adult

2012
Aripiprazole.
    CNS drugs, 2002, Volume: 16, Issue:11

    Topics: Animals; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Cognition; Humans; Meta-Analysis as Topic; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Time Factors; Treatment Outcome

2002
Aripiprazole: profile on efficacy and safety.
    Expert opinion on pharmacotherapy, 2002, Volume: 3, Issue:12

    Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Brain; Cardiovascular System; Clinical Trials as Topic; Digestive System; Dyskinesia, Drug-Induced; Humans; Mental Disorders; Piperazines; Quinolones; Schizophrenia

2002
Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic.
    Expert opinion on investigational drugs, 2003, Volume: 12, Issue:4

    Topics: Animals; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Dopamine Agonists; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia

2003
Aripiprazole: efficacy and tolerability profile of a novel-acting atypical antipsychotic.
    Drugs of today (Barcelona, Spain : 1998), 2003, Volume: 39, Issue:2

    Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Treatment Outcome

2003
Aripiprazole: a new atypical antipsychotic drug.
    The Annals of pharmacotherapy, 2003, Volume: 37, Issue:5

    Topics: Antipsychotic Agents; Aripiprazole; Controlled Clinical Trials as Topic; Humans; Piperazines; Quinolones; Schizophrenia

2003
Aripiprazole: quite possibly a new type of antipsychotic.
    South Dakota journal of medicine, 2003, Volume: 56, Issue:4

    Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Schizophrenia

2003
Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.
    Schizophrenia research, 2003, Jun-01, Volume: 61, Issue:2-3

    Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Multicenter Studies as Topic; Piperazines; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology

2003
Chlorpromazine equivalent doses for the newer atypical antipsychotics.
    The Journal of clinical psychiatry, 2003, Volume: 64, Issue:6

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chlorpromazine; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; Humans; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Therapeutic Equivalency; Thiazoles

2003
Mechanism of new antipsychotic medications: occupancy is not just antagonism.
    Archives of general psychiatry, 2003, Volume: 60, Issue:10

    Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Corpus Striatum; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Humans; Piperazines; Prolactin; Putamen; Quinolones; Receptors, Dopamine D2; Schizophrenia; Tomography, Emission-Computed

2003
Schizophrenia: from dopamine to glutamate and back.
    Current medicinal chemistry, 2004, Volume: 11, Issue:3

    Topics: Animals; Antipsychotic Agents; Aripiprazole; Disease Models, Animal; Dopamine; Dopamine Agonists; Dopamine Antagonists; Excitatory Amino Acid Antagonists; Glutamic Acid; Mice; Piperazines; Piperidines; Quinolones; Schizophrenia

2004
Naturalistic studies of second generation antipsychotics in the treatment of schizophrenia.
    Current medicinal chemistry, 2004, Volume: 11, Issue:3

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Patient Compliance; Piperazines; Polypharmacy; Quetiapine Fumarate; Quinolones; Research Design; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome

2004
Focus on aripiprazole.
    Current medical research and opinion, 2004, Volume: 20, Issue:2

    Topics: Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Drug Interactions; Humans; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia

2004
Dopamine partial agonists: a new class of antipsychotic.
    CNS drugs, 2004, Volume: 18, Issue:4

    Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Dopamine; Dopamine Agonists; Humans; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Serotonin; Treatment Outcome

2004
Aripiprazole for schizophrenia.
    The Cochrane database of systematic reviews, 2004, Issue:2

    Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia

2004
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update.
    The Journal of clinical psychiatry, 2004, Volume: 65, Issue:4

    Topics: Algorithms; Ambulatory Care; Ambulatory Care Facilities; Antipsychotic Agents; Aripiprazole; Clozapine; Decision Trees; Drug Administration Schedule; Drug Therapy, Combination; Humans; Piperazines; Practice Guidelines as Topic; Quinolones; Schizophrenia; Schizophrenic Psychology; Texas; Thiazoles; Treatment Outcome

2004
Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability.
    Clinical therapeutics, 2004, Volume: 26, Issue:5

    Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia

2004
Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Drugs, 2004, Volume: 64, Issue:15

    Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Humans; Metabolic Clearance Rate; Piperazines; Psychotic Disorders; Quinolones; Receptors, Neurotransmitter; Schizophrenia; Tissue Distribution; Treatment Outcome

2004
Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism.
    Progress in neuro-psychopharmacology & biological psychiatry, 2004, Volume: 28, Issue:8

    Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials, Phase III as Topic; Haloperidol; Humans; Meta-Analysis as Topic; Piperazines; Quinolones; Risperidone; Schizophrenia; Time Factors

2004
Partial agonism and schizophrenia.
    The British journal of psychiatry : the journal of mental science, 2005, Volume: 186

    Topics: Antipsychotic Agents; Aripiprazole; Binding Sites; Brain; Dopamine; Dopamine Agonists; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia

2005
Second-generation antipsychotic medications in the treatment of mood disorders: focus on aripiprazole.
    Drugs of today (Barcelona, Spain : 1998), 2005, Volume: 41, Issue:1

    Topics: Antipsychotic Agents; Aripiprazole; Humans; Mood Disorders; Piperazines; Quinolones; Schizophrenia

2005
Partial dopamine agonists in schizophrenia.
    Hospital medicine (London, England : 1998), 2005, Volume: 66, Issue:5

    Topics: Aripiprazole; Clinical Trials as Topic; Dopamine Agonists; Humans; Piperazines; Quinolones; Schizophrenia; Treatment Outcome

2005
Aripiprazole: pharmacology, efficacy, safety and tolerability.
    Expert review of neurotherapeutics, 2005, Volume: 5, Issue:3

    Topics: Animals; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Piperazines; Quinolones; Schizophrenia

2005
Aripiprazole.
    Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:12

    Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology

2005
Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2005, Volume: 50, Issue:11

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Dyskinesia, Drug-Induced; Humans; Incidence; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles

2005
Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist.
    The journal of medical investigation : JMI, 2005, Volume: 52 Suppl

    Topics: Animals; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Humans; Molecular Structure; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia

2005
Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies.
    The Journal of clinical psychiatry, 2005, Volume: 66, Issue:11

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Double-Blind Method; Female; Haloperidol; Hostility; Humans; Male; Middle Aged; Piperazines; Placebos; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome

2005
Aripiprazole for schizophrenia.
    The Cochrane database of systematic reviews, 2006, Apr-19, Issue:2

    Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia

2006
Aripiprazole for schizophrenia. Systematic review.
    The British journal of psychiatry : the journal of mental science, 2006, Volume: 189

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Patient Compliance; Piperazines; Prolactin; Quinolones; Randomized Controlled Trials as Topic; Recurrence; Schizophrenia; Treatment Outcome

2006
[The antipsychotic drug aripiprazole (ABILIFY)].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2006, Volume: 128, Issue:5

    Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia

2006
Treatment of psychosis: 30 years of progress.
    Journal of clinical pharmacy and therapeutics, 2006, Volume: 31, Issue:6

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Receptors, Dopamine; Receptors, Serotonin; Risperidone; Schizophrenia; Thiazoles

2006
The stable patient with schizophrenia--from antipsychotic effectiveness to adherence.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2007, Volume: 17 Suppl 2

    Topics: Antipsychotic Agents; Aripiprazole; Chronic Disease; Humans; Metabolic Syndrome; Patient Compliance; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology

2007
[The use of atypical antipsychotics in the long-term care of schizophrenia].
    L'Encephale, 2006, Volume: 32 Pt 3

    Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Cognition Disorders; Drug Tolerance; Dyskinesia, Drug-Induced; Haloperidol; Humans; Olanzapine; Piperazines; Quinolones; Risperidone; Schizophrenia; Sulpiride; Time Factors

2006
Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks.
    Schizophrenia research, 2007, Volume: 95, Issue:1-3

    Topics: Acute Disease; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Double-Blind Method; Haloperidol; Humans; Longitudinal Studies; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Research Design; Schizophrenia; Schizophrenic Psychology; Survival Analysis; Treatment Outcome

2007
Metabolic effects of the atypical antipsychotics.
    Southern medical journal, 2007, Volume: 100, Issue:8

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus; Dibenzothiazepines; Dyslipidemias; Glucose Metabolism Disorders; Humans; Insulin Resistance; Mental Disorders; Obesity; Olanzapine; Phenothiazines; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles

2007
Managing the acutely agitated and psychotic patient.
    CNS spectrums, 2007, Volume: 12, Issue:10 Suppl 1

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Emergencies; Humans; Olanzapine; Piperazines; Psychomotor Agitation; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles

2007
Aripiprazole: in adolescents with schizophrenia.
    Paediatric drugs, 2007, Volume: 9, Issue:6

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Schizophrenia

2007
Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials.
    The Journal of clinical psychiatry, 2007, Volume: 68, Issue:11

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Clozapine; Diabetes Mellitus, Type 2; Humans; Olanzapine; Piperazines; Quinolones; Schizophrenia

2007
Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety.
    The Journal of clinical psychiatry, 2007, Volume: 68, Issue:12

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Double-Blind Method; Humans; Injections, Intramuscular; Olanzapine; Piperazines; Psychomotor Agitation; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Thiazoles; Treatment Outcome

2007
A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence.
    The Journal of clinical psychiatry, 2008, Volume: 69, Issue:2

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Double-Blind Method; Haloperidol; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Research Design; Risperidone; Schizophrenia; Sleep Stages; Thiazoles; Treatment Outcome

2008
Aripiprazole versus typicals for schizophrenia.
    The Cochrane database of systematic reviews, 2008, Jan-23, Issue:1

    Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia

2008
Intramuscular aripiprazole : a review of its use in the management of agitation in schizophrenia and bipolar I disorder.
    CNS drugs, 2008, Volume: 22, Issue:4

    Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Injections, Intramuscular; Piperazines; Psychomotor Agitation; Quinolones; Schizophrenia

2008
Antipsychotic drug action: antagonism, inverse agonism or partial agonism.
    Trends in pharmacological sciences, 2008, Volume: 29, Issue:6

    Topics: Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Dopamine Antagonists; Drug Inverse Agonism; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Receptors, Dopamine D3; Schizophrenia; Signal Transduction

2008
Aripiprazole in adolescents with schizophrenia: profile report.
    CNS drugs, 2008, Volume: 22, Issue:6

    Topics: Administration, Oral; Adolescent; Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Schizophrenia

2008
Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents.
    CNS drugs, 2002, Volume: 16, Issue:4

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Clozapine; Dosage Forms; Humans; Isoxazoles; Olanzapine; Piperazines; Piperidines; Pirenzepine; Quinolones; Risperidone; Schizophrenia; Thiazoles

2002
Aripiprazole (Otsuka Pharmaceutical Co).
    Current opinion in investigational drugs (London, England : 2000), 2002, Volume: 3, Issue:1

    Topics: Animals; Aripiprazole; Clinical Trials as Topic; Dopamine Agonists; Dopamine Antagonists; Humans; Piperazines; Quinolones; Schizophrenia; Technology, Pharmaceutical

2002

Trials

147 trial(s) available for carbostyril and Schizophrenia

ArticleYear
Post-hoc analysis investigating the safety and efficacy of brexpiprazole in Japanese patients with schizophrenia who were switched from other antipsychotics in a long-term study (Secondary Publication).
    Neuropsychopharmacology reports, 2020, Volume: 40, Issue:2

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Drug Substitution; Female; Headache; Humans; Japan; Longitudinal Studies; Male; Middle Aged; Quinolones; Schizophrenia; Schizophrenic Psychology; Sleep Initiation and Maintenance Disorders; Thiophenes; Treatment Outcome; Young Adult

2020
Effect of brexpiprazole on control of impulsivity in schizophrenia: A randomized functional magnetic resonance imaging study.
    Psychiatry research. Neuroimaging, 2020, 07-30, Volume: 301

    Topics: Adult; Cerebral Cortex; Dopamine Agonists; Double-Blind Method; Female; Humans; Impulsive Behavior; Inhibition, Psychological; Magnetic Resonance Imaging; Male; Middle Aged; Quinolones; Schizophrenia; Task Performance and Analysis; Thiophenes; Treatment Outcome; Young Adult

2020
Efficacy and safety of brexpiprazole in patients with schizophrenia presenting with severe symptoms:
    Journal of psychopharmacology (Oxford, England), 2020, Volume: 34, Issue:8

    Topics: Adult; Double-Blind Method; Female; Humans; Male; Middle Aged; Neurotransmitter Agents; Outcome Assessment, Health Care; Quinolones; Schizophrenia; Severity of Illness Index; Thiophenes

2020
Pharmacokinetics and Safety of Brexpiprazole Following Multiple-Dose Administration to Japanese Patients With Schizophrenia.
    Journal of clinical pharmacology, 2018, Volume: 58, Issue:1

    Topics: Antipsychotic Agents; Area Under Curve; Asian People; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Quinolones; Schizophrenia; Thiophenes

2018
A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia.
    The international journal of neuropsychopharmacology, 2018, 05-01, Volume: 21, Issue:5

    Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Quinolones; Schizophrenia; Secondary Prevention; Thiophenes

2018
Long-term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: A 52-week, open-label study.
    Psychiatry and clinical neurosciences, 2018, Volume: 72, Issue:6

    Topics: Adult; Aged; Antipsychotic Agents; Female; Humans; Japan; Male; Middle Aged; Outcome Assessment, Health Care; Quinolones; Schizophrenia; Thiophenes

2018
Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: A 6-week, randomized, double-blind, placebo-controlled study.
    Psychiatry and clinical neurosciences, 2018, Volume: 72, Issue:9

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Japan; Male; Middle Aged; Quinolones; Schizophrenia; Thiophenes; Treatment Outcome; Young Adult

2018
Successful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: comparison of clinicians' choice of cross-titration schedules in a post hoc analysis of a randomized, double-blind, maintenance treatment study.
    CNS spectrums, 2019, Volume: 24, Issue:5

    Topics: Adult; Antipsychotic Agents; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Quinolones; Schizophrenia; Thiophenes

2019
Aripiprazole, ziprasidone, and quetiapine in the treatment of first-episode nonaffective psychosis: results of a 6-week, randomized, flexible-dose, open-label comparison.
    Journal of clinical psychopharmacology, 2013, Volume: 33, Issue:2

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Dose-Response Relationship, Drug; Female; Humans; Male; Piperazines; Prospective Studies; Quetiapine Fumarate; Quinolones; Schizophrenia; Thiazoles; Treatment Outcome; Young Adult

2013
Intramuscular aripiprazole in the acute management of psychomotor agitation.
    Pharmacotherapy, 2013, Volume: 33, Issue:6

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Female; Hospitals, University; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Quinolones; Schizophrenia; Time Factors; Treatment Outcome; Young Adult

2013
Sex differences in the effect of four second-generation antipsychotics on QTc interval in patients with schizophrenia.
    Human psychopharmacology, 2013, Volume: 28, Issue:3

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Middle Aged; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Sex Factors; Young Adult

2013
Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia.
    International clinical psychopharmacology, 2013, Volume: 28, Issue:4

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Early Termination of Clinical Trials; Humans; Incidence; Injections, Intramuscular; Maintenance Chemotherapy; Middle Aged; Piperazines; Quinolones; Schizophrenia; Sleep Initiation and Maintenance Disorders; Weight Gain; Young Adult

2013
Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia.
    Journal of medical economics, 2013, Volume: 16, Issue:7

    Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Community Mental Health Services; Cross-Over Studies; Delayed-Action Preparations; Female; Hospitalization; Humans; Injections, Intramuscular; Male; North America; Piperazines; Prospective Studies; Quinolones; Retrospective Studies; Schizophrenia; Severity of Illness Index; Standard of Care

2013
A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia.
    BMC psychiatry, 2013, May-22, Volume: 13

    Topics: Adolescent; Adult; Aged; Amino Acids; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Male; Middle Aged; Olanzapine; Piperazines; Quinolones; Risperidone; Schizophrenia; Standard of Care; Treatment Outcome; Young Adult

2013
Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia: a 12-month, randomized, naturalistic trial.
    Journal of clinical psychopharmacology, 2013, Volume: 33, Issue:4

    Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Disease-Free Survival; Drug Resistance; Drug Therapy, Combination; Haloperidol; Humans; Italy; Kaplan-Meier Estimate; Linear Models; Multivariate Analysis; Piperazines; Proportional Hazards Models; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Time Factors; Treatment Outcome

2013
Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection.
    Journal of clinical psychopharmacology, 2013, Volume: 33, Issue:4

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Biomarkers; Chemistry, Pharmaceutical; Drug Administration Schedule; Female; Humans; Hyperprolactinemia; Injections; Male; Middle Aged; Pilot Projects; Piperazines; Prolactin; Quinolones; Risperidone; Schizophrenia; Spain; Time Factors; Treatment Outcome

2013
Early antipsychotic response to aripiprazole in adolescents with schizophrenia: predictive value for clinical outcomes.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2013, Volume: 52, Issue:7

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Humans; Piperazines; Placebos; Predictive Value of Tests; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Sensitivity and Specificity; Time Factors; Treatment Outcome

2013
Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole.
    Current medical research and opinion, 2013, Volume: 29, Issue:10

    Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Risk Factors; Schizophrenia; Sex Factors; Time Factors

2013
Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study.
    Schizophrenia research, 2013, Volume: 150, Issue:1

    Topics: Adult; Antipsychotic Agents; Area Under Curve; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Time Factors

2013
Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin).
    BMC psychiatry, 2013, Aug-22, Volume: 13

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Clinical Protocols; Dopamine Agonists; Female; Humans; Hyperprolactinemia; Piperazines; Quinolones; Research Design; Schizophrenia

2013
Japan useful medication program for schizophrenia (JUMPs)-long-term study on discontinuation rate, resolution and remission, and improvement in social functioning rate associated with atypical antipsychotic medications in patients with schizophrenia.
    BMC psychiatry, 2013, Oct-03, Volume: 13

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Protocols; Female; Humans; Japan; Longitudinal Studies; Male; Middle Aged; Olanzapine; Piperazines; Quinolones; Remission Induction; Research Design; Risperidone; Schizophrenia; Schizophrenic Psychology; Social Adjustment; Treatment Outcome

2013
Predictive value of prospective memory for remission in first-episode schizophrenia.
    Perspectives in psychiatric care, 2014, Volume: 50, Issue:2

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; China; Female; Humans; Male; Memory, Episodic; Olanzapine; Piperazines; Prognosis; Quinolones; Remission Induction; Risperidone; Schizophrenia; Treatment Outcome; Young Adult

2014
Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone.
    Human psychopharmacology, 2014, Volume: 29, Issue:1

    Topics: Adult; Alleles; Antipsychotic Agents; Aripiprazole; Body Mass Index; Female; Follow-Up Studies; Genotype; Humans; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Piperazines; Polymorphism, Genetic; Quinolones; Receptors, Adrenergic, alpha-2; Schizophrenia; Thiazoles; Weight Gain; Weight Loss

2014
Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China.
    Human psychopharmacology, 2012, Volume: 27, Issue:6

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Body Mass Index; China; Delayed-Action Preparations; Diagnostic and Statistical Manual of Mental Disorders; Female; Follow-Up Studies; Humans; Hyperglycemia; Hyperlipidemias; Isoxazoles; Male; Metabolic Diseases; Paliperidone Palmitate; Piperazines; Psychiatric Status Rating Scales; Pyrimidines; Quinolones; Schizophrenia; Thiazoles; Weight Gain; Young Adult

2012
Effects of risperidone and aripiprazole on neurocognitive rehabilitation for schizophrenia.
    Psychiatry and clinical neurosciences, 2014, Volume: 68, Issue:6

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Drug Synergism; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Piperazines; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Social Behavior; Young Adult

2014
A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia.
    Schizophrenia research, 2014, Volume: 153, Issue:1-3

    Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Aortic Bodies; Aripiprazole; Benzodiazepines; Cohort Studies; Drug Administration Schedule; Drug Substitution; Female; Humans; Isoxazoles; Male; Middle Aged; Olanzapine; Piperazines; Piperidines; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Surveys and Questionnaires; Treatment Outcome; Young Adult

2014
Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia.
    BMC psychiatry, 2014, Feb-23, Volume: 14

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Drug Substitution; Female; Humans; Isoindoles; Lurasidone Hydrochloride; Male; Middle Aged; Olanzapine; Outpatients; Piperazines; Quality of Life; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome

2014
Switching antipsychotics to aripiprazole or blonanserin and plasma monoamine metabolites levels in patients with schizophrenia.
    Human psychopharmacology, 2014, Volume: 29, Issue:2

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Chromatography, High Pressure Liquid; Female; Homovanillic Acid; Humans; Japan; Male; Methoxyhydroxyphenylglycol; Middle Aged; Piperazines; Piperidines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Time Factors; Treatment Outcome

2014
[The use of aripiprazole in the treatment of obesity associated with the administration of neuroleptics of the second generation in patients with schizophrenia].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2014, Volume: 114, Issue:3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Obesity; Piperazines; Quinolones; Schizophrenia; Withholding Treatment

2014
Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study.
    The British journal of psychiatry : the journal of mental science, 2014, Volume: 205, Issue:2

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Piperazines; Quinolones; Recurrence; Schizophrenia; Treatment Outcome; Young Adult

2014
Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial.
    Schizophrenia research, 2014, Volume: 157, Issue:1-3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Asian People; Blood Pressure; China; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Electrocardiography; Female; Heart Rate; Humans; Hyperprolactinemia; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Treatment Outcome; Weight Gain

2014
Quetiapine versus aripiprazole in children and adolescents with psychosis--protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial.
    BMC psychiatry, 2014, Jul-11, Volume: 14

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Dibenzothiazepines; Double-Blind Method; Female; Humans; Male; Patient Selection; Piperazines; Psychotic Disorders; Quality of Life; Quetiapine Fumarate; Quinolones; Sample Size; Schizophrenia

2014
Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study.
    The Journal of clinical psychiatry, 2014, Volume: 75, Issue:11

    Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Placebos; Quinolones; Schizophrenia; Treatment Outcome

2014
Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia.
    Schizophrenia research, 2014, Volume: 159, Issue:2-3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Biological Availability; Buttocks; Delayed-Action Preparations; Deltoid Muscle; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Young Adult

2014
Effects of aripiprazole once-monthly on domains of personal and social performance: results from 2 multicenter, randomized, double-blind studies.
    Schizophrenia research, 2014, Volume: 159, Issue:2-3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Female; Humans; Interpersonal Relations; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Self Care; Social Behavior; Treatment Outcome

2014
Switching to iloperidone: An omnibus of clinically relevant observations from a 12-week, open-label, randomized clinical trial in 500 persons with schizophrenia.
    Clinical schizophrenia & related psychoses, 2015, Volume: 8, Issue:4

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dizziness; Female; Humans; Isoxazoles; Male; Olanzapine; Piperazines; Piperidines; Quinolones; Risperidone; Schizophrenia; Treatment Outcome

2015
Antipsychotic treatment and functional connectivity of the striatum in first-episode schizophrenia.
    JAMA psychiatry, 2015, Volume: 72, Issue:1

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Cerebral Cortex; Connectome; Corpus Striatum; Drug Monitoring; Episode of Care; Female; Humans; Magnetic Resonance Imaging; Male; Neural Pathways; Piperazines; Psychotic Disorders; Quinolones; Risperidone; Schizophrenia; Treatment Outcome

2015
The Chinese First-Episode Schizophrenia Trial: background and study design.
    East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan, 2014, Volume: 24, Issue:4

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; China; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Olanzapine; Piperazines; Quinolones; Research Design; Risperidone; Schizophrenia; Treatment Outcome

2014
A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia.
    Schizophrenia research, 2015, Volume: 164, Issue:1-3

    Topics: Adolescent; Adult; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Serotonin Agents; Thiophenes; Treatment Outcome; Young Adult

2015
Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial.
    The American journal of psychiatry, 2015, Sep-01, Volume: 172, Issue:9

    Topics: Acute Disease; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Blood Glucose; Double-Blind Method; Female; Humans; Lipids; Male; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Thiophenes; Treatment Outcome; Weight Gain

2015
The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study.
    International clinical psychopharmacology, 2016, Volume: 31, Issue:4

    Topics: Acute Disease; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Quinolones; Schizophrenia; Serotonin Agents; Thiophenes; Treatment Outcome; Weight Gain

2016
[Pharmacokinetics and safety of aripiprazole long-acting injection, following multiple deltoid administrations in schizophrenia patients in Japan].
    Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, 2016, Volume: 36, Issue:3

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Drug Combinations; Female; Humans; Japan; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Young Adult

2016
Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study.
    The international journal of neuropsychopharmacology, 2017, 01-01, Volume: 20, Issue:1

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Proportional Hazards Models; Psychiatric Status Rating Scales; Quinolones; Recurrence; Schizophrenia; Thiophenes; Treatment Outcome; Young Adult

2017
The effect of brexpiprazole in adult outpatients with early-episode schizophrenia: an exploratory study.
    International clinical psychopharmacology, 2016, Volume: 31, Issue:6

    Topics: Adult; Ambulatory Care; Antipsychotic Agents; Dose-Response Relationship, Drug; Early Diagnosis; Female; Follow-Up Studies; Humans; Male; Outpatients; Quinolones; Schizophrenia; Serotonin Agents; Thiophenes; Treatment Outcome; Young Adult

2016
Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies.
    Acta neuropsychiatrica, 2017, Volume: 29, Issue:5

    Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Quinolones; Schizophrenia; Thiophenes; Treatment Outcome

2017
Prediction of an Optimal Dose of Aripiprazole in the Treatment of Schizophrenia From Plasma Concentrations of Aripiprazole Plus Its Active Metabolite Dehydroaripiprazole at Week 1.
    Therapeutic drug monitoring, 2017, Volume: 39, Issue:1

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Nomograms; Piperazines; Quinolones; Schizophrenia; Time Factors; Treatment Outcome; Young Adult

2017
Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia.
    Clinical pharmacokinetics, 2008, Volume: 47, Issue:7

    Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Area Under Curve; Aripiprazole; Biological Availability; Biotransformation; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Humans; Injections, Intramuscular; Injections, Intravenous; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Young Adult

2008
A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.
    The Journal of clinical psychiatry, 2008, Volume: 69, Issue:7

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Administration Schedule; Electrocardiography; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Obesity; Olanzapine; Overweight; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Triglycerides

2008
A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.
    The American journal of psychiatry, 2008, Volume: 165, Issue:11

    Topics: Administration, Oral; Adolescent; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Weight; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Piperazines; Prolactin; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Treatment Outcome

2008
Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2008, Volume: 18, Issue:12

    Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Follow-Up Studies; Genotype; Humans; Male; Middle Aged; Piperazines; Polymorphism, Genetic; Prolactin; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Receptors, Dopamine D2; Schizophrenia; Young Adult

2008
A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering.
    Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:5

    Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index

2008
Treatment of psychotic disorders with aripiprazole in the emergency psychiatric setting.
    Psychiatria Danubina, 2008, Volume: 20, Issue:3

    Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Diagnostic and Statistical Manual of Mental Disorders; Dibenzothiazepines; Drug Therapy, Combination; Emergency Services, Psychiatric; Female; Humans; Intensive Care Units; Male; Middle Aged; Piperazines; Psychiatric Department, Hospital; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Severity of Illness Index; Treatment Outcome

2008
Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
    Progress in neuro-psychopharmacology & biological psychiatry, 2008, Dec-12, Volume: 32, Issue:8

    Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Severity of Illness Index; Sulpiride; Young Adult

2008
A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia.
    Biological psychiatry, 2009, Mar-15, Volume: 65, Issue:6

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Double-Blind Method; Electrocardiography; Female; Glucose; Humans; Lipid Metabolism; Male; Middle Aged; Olanzapine; Piperazines; Prolactin; Quinolones; Schizophrenia

2009
Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia.
    Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:6

    Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Dopamine Antagonists; Double-Blind Method; Female; Hospitalization; Humans; Lorazepam; Male; Middle Aged; Olanzapine; Piperazines; Prolactin; Psychiatric Status Rating Scales; Psychomotor Agitation; Quinolones; Schizophrenia; Schizophrenic Psychology; Time Factors; Treatment Outcome; Triglycerides; United States; Young Adult

2008
Aripiprazole in schizophrenia patients with comorbid obsessive-compulsive symptoms: an open-label study of 15 patients.
    The Journal of clinical psychiatry, 2008, Volume: 69, Issue:12

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Comorbidity; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Obsessive-Compulsive Disorder; Pilot Projects; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Young Adult

2008
Results of phase 3 of the CATIE schizophrenia trial.
    Schizophrenia research, 2009, Volume: 107, Issue:1

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chronic Disease; Clozapine; Dibenzothiazepines; Female; Hospitalization; Humans; Male; Middle Aged; Olanzapine; Perphenazine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Treatment Outcome; Young Adult

2009
Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
    Schizophrenia research, 2009, Volume: 107, Issue:2-3

    Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Olanzapine; Piperazines; Prolactin; Psychotic Disorders; Quinolones; Risperidone; Schizophrenia; Sex Factors; Substance Withdrawal Syndrome; Young Adult

2009
The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913).
    BMC psychiatry, 2008, Dec-22, Volume: 8

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Female; Humans; Male; Olanzapine; Patient Satisfaction; Piperazines; Prolactin; Quality of Life; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Sexual Behavior; Treatment Outcome

2008
Aripiprazole for patients with schizophrenia and schizoaffective disorder: an open-label, randomized, study versus haloperidol.
    CNS spectrums, 2009, Volume: 14, Issue:2

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Haloperidol; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Treatment Outcome

2009
UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study).
    European archives of psychiatry and clinical neuroscience, 2009, Volume: 259, Issue:4

    Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Coronary Disease; Cost of Illness; Costs and Cost Analysis; Diabetes Mellitus; Female; Follow-Up Studies; Health Resources; Health Services; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Quinolones; Risk Assessment; Risk Factors; Schizophrenia; United Kingdom; Young Adult

2009
Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors.
    Progress in neuro-psychopharmacology & biological psychiatry, 2009, Apr-30, Volume: 33, Issue:3

    Topics: Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Female; Genotype; Glycine; Humans; Male; Middle Aged; Pharmacogenetics; Piperazines; Polymorphism, Restriction Fragment Length; Psychiatric Status Rating Scales; Quinolones; Receptors, Dopamine D3; Retrospective Studies; Schizophrenia; Serine; Time Factors; Treatment Outcome

2009
A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia.
    The Journal of clinical psychiatry, 2009, Volume: 70, Issue:4

    Topics: Adult; Affect; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Humans; Male; Olanzapine; Piperazines; Quinolones; Schizophrenia; Severity of Illness Index; Surveys and Questionnaires

2009
Aripiprazole prescribing patterns and side effects in elderly psychiatric inpatients.
    Journal of psychiatric practice, 2009, Volume: 15, Issue:2

    Topics: Aged; Aged, 80 and over; Aging; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Inpatients; Male; Mental Disorders; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Quinolones; Retrospective Studies; Schizophrenia; Treatment Outcome

2009
HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients.
    Psychopharmacology, 2009, Volume: 205, Issue:2

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Pharmacogenetics; Piperazines; Polymorphism, Genetic; Psychiatric Status Rating Scales; Quinolones; Receptor, Serotonin, 5-HT2A; Retrospective Studies; Schizophrenia; Schizophrenic Psychology; Statistics, Nonparametric; Young Adult

2009
Aripiprazole for the treatment of schizophrenia with co-occurring social anxiety: an open-label cross-taper study.
    Journal of clinical psychopharmacology, 2009, Volume: 29, Issue:3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Cross-Over Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Phobic Disorders; Piperazines; Prospective Studies; Psychometrics; Quality of Life; Quinolones; Schizophrenia; Severity of Illness Index; Time Factors; Treatment Outcome

2009
Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2009, Volume: 19, Issue:8

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Patient Dropouts; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Young Adult

2009
Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia.
    Trials, 2009, May-15, Volume: 10

    Topics: Antipsychotic Agents; Aripiprazole; Clinical Protocols; Clozapine; Drug Resistance; Drug Therapy, Combination; Government Regulation; Haloperidol; Humans; Italy; Piperazines; Prospective Studies; Quinolones; Research Design; Schizophrenia; Schizophrenic Psychology; Treatment Outcome

2009
A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder.
    International clinical psychopharmacology, 2009, Volume: 24, Issue:4

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Brain; Dopamine Antagonists; Female; Humans; Male; Patient Dropouts; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Severity of Illness Index

2009
Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study.
    Pharmacopsychiatry, 2009, Volume: 42, Issue:3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Cognition; Female; Health Status; Humans; Male; Middle Aged; Outpatients; Patient Satisfaction; Piperazines; Prolactin; Quality of Life; Quinolones; Risperidone; Schizophrenia; Sexuality; Treatment Outcome

2009
Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients.
    Journal of clinical psychopharmacology, 2009, Volume: 29, Issue:2

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; C-Reactive Protein; Cholesterol; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Glucose; Humans; Male; Middle Aged; Obesity; Olanzapine; Overweight; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Triglycerides

2009
Predictors of clinical worsening after a switch to aripiprazole in patients with schizophrenia: a 1-year naturalistic follow-up study.
    Journal of clinical psychopharmacology, 2009, Volume: 29, Issue:4

    Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Japan; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Time Factors; Treatment Failure

2009
Pharmacokinetic and pharmacodynamic interactions between carbamazepine and aripiprazole in patients with schizophrenia.
    Therapeutic drug monitoring, 2009, Volume: 31, Issue:5

    Topics: Antimanic Agents; Aripiprazole; Carbamazepine; Drug Interactions; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia

2009
Comparative utility of aripiprazole and haloperidol in schizophrenia: post hoc analysis of two 52-week, randomized, controlled trials.
    Applied health economics and health policy, 2009, Volume: 7, Issue:2

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Cost-Benefit Analysis; Female; Haloperidol; Humans; Male; Piperazines; Quinolones; Schizophrenia; Treatment Outcome

2009
A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
    The Journal of clinical psychiatry, 2009, Volume: 70, Issue:10

    Topics: Adult; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Diagnostic and Statistical Manual of Mental Disorders; Dibenzothiazepines; Double-Blind Method; Drug Therapy, Combination; Fatigue; Female; Headache; Humans; Male; Piperazines; Placebos; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Severity of Illness Index; Sleep Initiation and Maintenance Disorders; Treatment Outcome

2009
Predictors of early worsening after switch to aripiprazole: a randomized, controlled, open-label study.
    Clinical drug investigation, 2010, Volume: 30, Issue:3

    Topics: Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Treatment Outcome

2010
Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: post hoc analysis of randomized clinical trial data.
    Journal of child and adolescent psychopharmacology, 2010, Volume: 20, Issue:1

    Topics: Administration, Oral; Adolescent; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hostility; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Quinolones; Schizophrenia; Schizophrenic Psychology; Syndrome; Time Factors; Treatment Outcome

2010
Clinical use of aripiprazole in patients with schizophrenia: a real-life setting results from the German Postmarketing Surveillance Study.
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2010, Volume: 11, Issue:2 Pt 2

    Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Female; Germany; Humans; Male; Nausea; Piperazines; Product Surveillance, Postmarketing; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Sleep Initiation and Maintenance Disorders; Vomiting

2010
Effect of aripiprazole on cognition in the treatment of patients with schizophrenia.
    Pharmacopsychiatry, 2010, Volume: 43, Issue:2

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Attention; Cognition; Humans; Inpatients; Memory; Neuropsychological Tests; Piperazines; Psychiatric Status Rating Scales; Quinolones; Reaction Time; Schizophrenia; Time Factors; Treatment Outcome

2010
Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial.
    The international journal of neuropsychopharmacology, 2010, Volume: 13, Issue:8

    Topics: Adolescent; Adult; Aged; Aripiprazole; Body Mass Index; Body Weight; Chemotherapy, Adjuvant; Cholesterol; Clozapine; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Treatment Outcome; Young Adult

2010
Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia.
    Clinical neuropharmacology, 2010, Volume: 33, Issue:3

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Size; Body Weight; Diagnostic and Statistical Manual of Mental Disorders; Female; Hip; Humans; Hyperprolactinemia; Liver Function Tests; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Thiazoles; Treatment Outcome; Waist Circumference; Wakefulness; Young Adult

2010
Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia.
    Schizophrenia research, 2010, Volume: 120, Issue:1-3

    Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Quinolones; Schizophrenia; Schizophrenic Psychology; Sleep Initiation and Maintenance Disorders; Social Behavior Disorders; Young Adult

2010
Aripiprazole versus haloperidol treatment in early-stage schizophrenia.
    Journal of psychiatric research, 2011, Volume: 45, Issue:6

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Treatment Outcome; Young Adult

2011
An unblinded comparison of the clinical and cognitive effects of switching from first-generation antipsychotics to aripiprazole, perospirone or olanzapine in patients with chronic schizophrenia.
    Progress in neuro-psychopharmacology & biological psychiatry, 2011, Jan-15, Volume: 35, Issue:1

    Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Attention; Benzodiazepines; Chronic Disease; Cognition Disorders; Dose-Response Relationship, Drug; Drug Substitution; Executive Function; Female; Humans; Isoindoles; Longitudinal Studies; Male; Memory; Middle Aged; Neuropsychological Tests; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Single-Blind Method; Thiazoles; Time Factors; Verbal Learning

2011
Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controll
    Journal of clinical psychopharmacology, 2010, Volume: 30, Issue:6

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Cholesterol; Drug Monitoring; Female; Humans; Male; Middle Aged; Olanzapine; Piperazines; Quinolones; Schizophrenia; Thiazoles; Time Factors; Triglycerides; Weight Gain

2010
Cost-effectiveness analysis of aripiprazole vs standard-of-care in the management of community-treated patients with schizophrenia: STAR study.
    Current medical research and opinion, 2011, Volume: 27, Issue:2

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Cost-Benefit Analysis; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Quality of Life; Quinolones; Residence Characteristics; Schizophrenia; Standard of Care; Surveys and Questionnaires; Treatment Outcome

2011
Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study.
    Schizophrenia research, 2011, Volume: 127, Issue:1-3

    Topics: Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Clozapine; Double-Blind Method; Drug Interactions; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia; Time Factors

2011
Improvement of serum prolactin and sexual function after switching to aripiprazole from risperidone in schizophrenia: a case series.
    Psychiatry and clinical neurosciences, 2011, Volume: 65, Issue:1

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Middle Aged; Piperazines; Prolactin; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Sexual Dysfunction, Physiological

2011
An open randomized pilot trial on the differential effects of aripiprazole versus risperidone on anhedonia and subjective well-being.
    Pharmacopsychiatry, 2011, Volume: 44, Issue:3

    Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hypnotics and Sedatives; Male; Mood Disorders; Personal Satisfaction; Pilot Projects; Piperazines; Pleasure; Quinolones; Risperidone; Schizophrenia

2011
Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial.
    Journal of clinical psychopharmacology, 2011, Volume: 31, Issue:3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Clozapine; Drug Resistance; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Piperazines; Quinolones; Schizophrenia

2011
The GiSAS study: rationale and design of a pragmatic randomized controlled trial on aripiprazole, olanzapine and haloperidol in the long-term treatment of schizophrenia.
    Contemporary clinical trials, 2011, Volume: 32, Issue:5

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Italy; Logistic Models; Olanzapine; Patient Selection; Piperazines; Proportional Hazards Models; Quinolones; Research Design; Schizophrenia; Time Factors

2011
Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients.
    Journal of psychopharmacology (Oxford, England), 2012, Volume: 26, Issue:6

    Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chemotherapy, Adjuvant; Cognition; Cognition Disorders; Double-Blind Method; Female; Humans; Male; Olanzapine; Piperazines; Quinolones; Receptors, Dopamine D2; Risperidone; Schizophrenia

2012
Changes in weight and other metabolic indicators in persons with schizophrenia following a switch to aripiprazole.
    Clinical schizophrenia & related psychoses, 2011, Volume: 5, Issue:2

    Topics: Antipsychotic Agents; Aripiprazole; Cardiovascular Diseases; Drug Substitution; Female; Humans; Male; Metabolic Syndrome; Middle Aged; Overweight; Piperazines; Quinolones; Schizophrenia; Weight Loss

2011
A randomized open-label comparison of the impact of aripiprazole versus risperidone on sexual functioning (RAS study).
    Journal of clinical psychopharmacology, 2011, Volume: 31, Issue:4

    Topics: Adult; Aripiprazole; Female; Humans; Male; Middle Aged; Piperazines; Prolactin; Quinolones; Risperidone; Schizophrenia; Sexual Dysfunctions, Psychological; Young Adult

2011
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
    The American journal of psychiatry, 2011, Volume: 168, Issue:9

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Cholesterol; Cholesterol, LDL; Combined Modality Therapy; Dibenzothiazepines; Diet, Reducing; Drug Substitution; Exercise; Humans; Hypercholesterolemia; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risk; Risperidone; Schizophrenia; Treatment Outcome; Triglycerides

2011
Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE).
    European archives of psychiatry and clinical neuroscience, 2012, Volume: 262, Issue:2

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Drug Delivery Systems; Female; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risperidone; Schizophrenia; Secondary Prevention; Time Factors

2012
A prospective, multicentre, open-label study to evaluate the effectiveness of aripiprazole in the treatment of a broad range of patients with schizophrenia.
    European psychiatry : the journal of the Association of European Psychiatrists, 2012, Volume: 27, Issue:7

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Male; Piperazines; Prospective Studies; Quality of Life; Quinolones; Schizophrenia; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome

2012
Aripiprazole and dehydroaripiprazole plasma concentrations and clinical responses in patients with schizophrenia.
    Journal of clinical psychopharmacology, 2011, Volume: 31, Issue:6

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Asian People; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Treatment Outcome

2011
Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia.
    Journal of clinical psychopharmacology, 2012, Volume: 32, Issue:1

    Topics: Acute Disease; Adult; Alleles; Antipsychotic Agents; Aripiprazole; Female; Genetic Carrier Screening; Genotype; Homovanillic Acid; Humans; Japan; Male; Methoxyhydroxyphenylglycol; Middle Aged; Piperazines; Polymorphism, Genetic; Psychiatric Status Rating Scales; Quinolones; Receptors, Dopamine D2; Schizophrenia; Taq Polymerase; Treatment Outcome; Young Adult

2012
Aripiprazole altered plasma levels of brain-derived neurotrophic factor and catecholamine metabolites in first-episode untreated Japanese schizophrenia patients.
    Human psychopharmacology, 2012, Volume: 27, Issue:1

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Brain-Derived Neurotrophic Factor; Case-Control Studies; Chromatography, High Pressure Liquid; Enzyme-Linked Immunosorbent Assay; Female; Homovanillic Acid; Humans; Japan; Male; Methoxyhydroxyphenylglycol; Piperazines; Polymorphism, Genetic; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Time Factors; Young Adult

2012
Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study.
    Journal of psychopharmacology (Oxford, England), 2012, Volume: 26, Issue:9

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Atherosclerosis; Bipolar Disorder; Cohort Studies; Diagnostic and Statistical Manual of Mental Disorders; Drug Monitoring; Dyslipidemias; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; North America; Patient Dropouts; Piperazines; Psychotic Disorders; Quinolones; Risk Factors; Schizophrenia; Severity of Illness Index; Thiazoles; Weight Loss

2012
Aripiprazole versus olanzapine in the treatment of schizophrenia: a clinical study from India.
    International journal of psychiatry in clinical practice, 2013, Volume: 17, Issue:1

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Double-Blind Method; Female; Humans; India; Male; Middle Aged; Olanzapine; Piperazines; Quinolones; Schizophrenia; Treatment Outcome; Young Adult

2013
Effects of paroxetine on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
    Therapeutic drug monitoring, 2012, Volume: 34, Issue:2

    Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Asian People; Basal Ganglia Diseases; Chromatography, Liquid; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Japan; Male; Mass Spectrometry; Middle Aged; Paroxetine; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Young Adult

2012
Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.
    The Journal of clinical psychiatry, 2012, Volume: 73, Issue:5

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Injections, Intramuscular; Kaplan-Meier Estimate; Male; Middle Aged; Piperazines; Proportional Hazards Models; Quinolones; Schizophrenia; Secondary Prevention

2012
Effectiveness of aripiprazole in adolescents and young adults with schizophrenia spectrum disorders: comparison of first-episode to recurrent psychosis.
    Early intervention in psychiatry, 2013, Volume: 7, Issue:1

    Topics: Adolescent; Adolescent Behavior; Adult; Aripiprazole; Child; Female; Humans; Male; Piperazines; Psychotic Disorders; Quality of Life; Quinolones; Recurrence; Schizophrenia; Schizophrenic Psychology

2013
Effect of switching to risperidone after unsuccessful treatment with aripiprazole on plasma monoamine metabolites level in the treatment of acute schizophrenia.
    Human psychopharmacology, 2012, Volume: 27, Issue:5

    Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Chromatography, High Pressure Liquid; Female; Homovanillic Acid; Humans; Japan; Male; Methoxyhydroxyphenylglycol; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Treatment Outcome; Young Adult

2012
Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia.
    Acta psychiatrica Scandinavica, 2013, Volume: 127, Issue:3

    Topics: Absorptiometry, Photon; Adult; Antipsychotic Agents; Aripiprazole; Body Composition; Clozapine; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glucose; Glucose Tolerance Test; Humans; Lipoproteins, LDL; Magnetic Resonance Spectroscopy; Male; Piperazines; Quinolones; Schizophrenia

2013
Effect of aripiprazole on verbal memory and fluency in schizophrenic patients : results from the ESCAPE study.
    CNS drugs, 2012, Volume: 26, Issue:11

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Memory; Middle Aged; Piperazines; Prospective Studies; Quality of Life; Quinolones; Schizophrenia; Schizophrenic Psychology; Semantics; Treatment Outcome; Verbal Learning; Young Adult

2012
A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients.
    Progress in neuro-psychopharmacology & biological psychiatry, 2013, Jan-10, Volume: 40

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Female; Humans; Isoindoles; Japan; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Severity of Illness Index; Thiazoles; Treatment Outcome

2013
Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.
    The Journal of clinical psychiatry, 2013, Volume: 74, Issue:1

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol; Dibenzothiazepines; Female; Follow-Up Studies; Humans; Male; Metabolic Syndrome; Middle Aged; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Therapeutic Equipoise; Triglycerides; United States

2013
The neurocognitive effects of aripiprazole compared with risperidone in the treatment of schizophrenia.
    Hiroshima journal of medical sciences, 2012, Volume: 61, Issue:4

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Cognition; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Risperidone; Schizophrenia

2012
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
    The Journal of clinical psychiatry, 2002, Volume: 63, Issue:9

    Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Weight; Double-Blind Method; Drug Administration Schedule; Electroencephalography; Female; Haloperidol; Humans; Hyperprolactinemia; Long QT Syndrome; Male; Piperazines; Placebos; Prolactin; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome

2002
Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study.
    Psychopharmacology, 2003, Volume: 166, Issue:4

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia; Treatment Outcome

2003
Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Archives of general psychiatry, 2003, Volume: 60, Issue:7

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Double-Blind Method; Female; Hospitalization; Humans; Male; Piperazines; Placebos; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome

2003
Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia.
    The international journal of neuropsychopharmacology, 2003, Volume: 6, Issue:4

    Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Haloperidol; Humans; Long-Term Care; Male; Neurologic Examination; Piperazines; Psychiatric Status Rating Scales; Quinolones; Recurrence; Schizophrenia; Schizophrenic Psychology; Treatment Outcome

2003
Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.
    The Journal of clinical psychiatry, 2003, Volume: 64, Issue:9

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Chronic Disease; Double-Blind Method; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome

2003
A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
    The Journal of clinical psychiatry, 2004, Volume: 65 Suppl 18

    Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Double-Blind Method; Female; Humans; Hyperlipidemias; Incidence; Lipids; Male; Obesity; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome; Weight Gain

2004
Aripiprazole in schizophrenia with cocaine dependence: a pilot study.
    Journal of clinical psychopharmacology, 2005, Volume: 25, Issue:4

    Topics: Adult; Alcoholism; Antipsychotic Agents; Aripiprazole; Cocaine-Related Disorders; Diagnosis, Dual (Psychiatry); Humans; Male; Middle Aged; Pilot Projects; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Schizophrenia

2005
An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia.
    Acta psychiatrica Scandinavica, 2006, Volume: 113, Issue:2

    Topics: Adult; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Mass Index; Body Weight; Cholesterol; Clozapine; Community Mental Health Centers; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Triglycerides

2006
Patients with schizophrenia treated with aripiprazole, a multicentre naturalistic study.
    Acta psychiatrica Scandinavica, 2006, Volume: 113, Issue:2

    Topics: Activities of Daily Living; Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Body Mass Index; Denmark; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Psychometrics; Quinolones; Schizophrenia; Treatment Outcome

2006
A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA).
    Schizophrenia research, 2006, Volume: 84, Issue:1

    Topics: Adult; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Female; Humans; Male; Piperazines; Primary Health Care; Prospective Studies; Psychiatry; Psychotic Disorders; Quinolones; Schizophrenia; Treatment Outcome

2006
Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study.
    Progress in neuro-psychopharmacology & biological psychiatry, 2006, Volume: 30, Issue:4

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Female; Humans; Hyperprolactinemia; Middle Aged; Pilot Projects; Piperazines; Prolactin; Quinolones; Schizophrenia; Time Factors

2006
[Clinical observations with aripiprazole in schizophrenia].
    Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2006, Volume: 8, Issue:1

    Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Female; Haloperidol; Humans; Male; Middle Aged; Patient Compliance; Piperazines; Quinolones; Schizophrenia; Single-Blind Method; Treatment Outcome

2006
The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia.
    CNS spectrums, 2006, Volume: 11, Issue:9

    Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia

2006
Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol.
    Psychopharmacology, 2006, Volume: 188, Issue:3

    Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Anti-Dyskinesia Agents; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Blood Glucose; Double-Blind Method; Drug Therapy, Combination; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Piperazines; Psychomotor Agitation; Psychotic Disorders; Quinolones; Schizophrenia; Time Factors; Treatment Outcome; Withholding Treatment

2006
Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.
    Psychopharmacology, 2006, Volume: 189, Issue:2

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Olanzapine; Piperazines; Prolactin; Quinolones; Recurrence; Schizophrenia; Treatment Outcome; Triglycerides

2006
Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study.
    Current medical research and opinion, 2006, Volume: 22, Issue:11

    Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Middle Aged; Multicenter Studies as Topic; Piperazines; Psychomotor Agitation; Quinolones; Schizophrenia; Treatment Outcome

2006
Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: An open-label pilot study.
    Progress in neuro-psychopharmacology & biological psychiatry, 2007, Mar-30, Volume: 31, Issue:2

    Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Synergism; Female; Follow-Up Studies; Humans; Male; Middle Aged; Outpatients; Pilot Projects; Piperazines; Psychiatric Status Rating Scales; Psychometrics; Quinolones; Schizophrenia; Time Factors

2007
Clozapine augmented with aripiprazole in 5 patients with schizophrenia.
    Journal of clinical psychopharmacology, 2006, Volume: 26, Issue:6

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Time Factors; Treatment Outcome

2006
Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial.
    The Journal of clinical psychiatry, 2007, Volume: 68, Issue:1

    Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Psychomotor Agitation; Psychotic Disorders; Quinolones; Schizophrenia; Treatment Outcome

2007
Pharmacokinetics of aripiprazole and concomitant carbamazepine.
    Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:3

    Topics: Adult; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Carbamazepine; Drug Antagonism; Drug Therapy, Combination; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia

2007
Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials.
    The Journal of clinical psychiatry, 2007, Volume: 68, Issue:5

    Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Psychomotor Agitation; Quinolones; Schizophrenia; Severity of Illness Index; Treatment Outcome

2007
Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations.
    Journal of psychiatric practice, 2007, Volume: 13, Issue:3

    Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Quinolones; Schizophrenia

2007
[Clinical observation on effect of Jieyu Anshen Decoction combined with aripiprazole in treating chronic schizophrenia].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2007, Volume: 27, Issue:4

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Humans; Male; Middle Aged; Phytotherapy; Piperazines; Quinolones; Schizophrenia; Treatment Outcome

2007
A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study.
    European psychiatry : the journal of the Association of European Psychiatrists, 2007, Volume: 22, Issue:7

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Blood Glucose; Community Mental Health Services; Female; Humans; Lipoproteins; Male; Middle Aged; Patient Care; Piperazines; Prolactin; Quality of Life; Quinolones; Schizophrenia; Severity of Illness Index; Weight Gain

2007
Schizophrenia symptoms remain stable during decreases from 2 antipsychotics to aripiprazole.
    The Journal of clinical psychiatry, 2007, Volume: 68, Issue:6

    Topics: Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Humans; Pilot Projects; Piperazines; Quinolones; Schizophrenia; Treatment Outcome

2007
A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.
    Journal of psychiatric research, 2007, Volume: 41, Issue:11

    Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Weight; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Piperazines; Prolactin; Psychiatric Status Rating Scales; Quinolones; Schizophrenia

2007
A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA).
    Current medical research and opinion, 2007, Volume: 23, Issue:10

    Topics: Antipsychotic Agents; Aripiprazole; Europe; Humans; Piperazines; Prospective Studies; Quinolones; Schizophrenia; Surveys and Questionnaires; Treatment Outcome

2007
Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
    The American journal of psychiatry, 2007, Volume: 164, Issue:9

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Dopamine Antagonists; Double-Blind Method; Drug Therapy, Combination; Female; Haloperidol; Humans; Hyperprolactinemia; Male; Middle Aged; Piperazines; Placebos; Quinolones; Receptors, Dopamine D2; Schizophrenia; Schizophrenic Psychology; Sex Factors; Treatment Outcome

2007
Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.
    The American journal of psychiatry, 2007, Volume: 164, Issue:9

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia; Basal Ganglia Diseases; Carbon Radioisotopes; Caudate Nucleus; Cerebral Cortex; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorine Radioisotopes; Humans; Male; Piperazines; Positron-Emission Tomography; Psychotic Disorders; Putamen; Pyridines; Pyrimidinones; Quinolones; Raclopride; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine; Receptors, Dopamine D2; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Treatment Outcome

2007
Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study.
    International clinical psychopharmacology, 2007, Volume: 22, Issue:6

    Topics: Acute Disease; Adult; Affective Disorders, Psychotic; Antipsychotic Agents; Aripiprazole; Blood Glucose; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Dyspepsia; Electrocardiography; Fasting; Humans; Lipids; Nausea; Piperazines; Prolactin; Quinolones; Schizophrenia; Severity of Illness Index; Thiazoles; Time Factors; Treatment Outcome; Weight Loss

2007
Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial.
    The Journal of clinical psychiatry, 2008, Volume: 69, Issue:5

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Clozapine; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Severity of Illness Index; Surveys and Questionnaires

2008
Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care.
    European psychiatry : the journal of the Association of European Psychiatrists, 2008, Volume: 23, Issue:8

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Dibenzothiazepines; Dose-Response Relationship, Drug; Europe; Female; Humans; Male; Middle Aged; Obesity; Olanzapine; Piperazines; Quality of Life; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Self Concept; Social Adjustment

2008
Preference of medicine and patient-reported quality of life in community-treated schizophrenic patients receiving aripiprazole vs standard of care: results from the STAR study.
    European psychiatry : the journal of the Association of European Psychiatrists, 2008, Volume: 23, Issue:5

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Choice Behavior; Community Mental Health Services; Consumer Behavior; Diagnostic and Statistical Manual of Mental Disorders; Drug Therapy; Female; Humans; Male; Middle Aged; Piperazines; Quality of Life; Quinolones; Schizophrenia; Surveys and Questionnaires

2008
Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care.
    The Journal of clinical psychiatry, 2008, Volume: 69, Issue:5

    Topics: Adult; Algorithms; Aripiprazole; Blood Glucose; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Comorbidity; Coronary Disease; Diabetes Mellitus; Female; Humans; Hypertension; Incidence; Male; Piperazines; Prevalence; Prospective Studies; Quinolones; Risk Assessment; Risk Factors; Schizophrenia

2008
Neuroendocrine profile of SDZ HDC-912 and OPC-4392, two new atypical antipsychotic drugs, in schizophrenic patients.
    Psychopharmacology, 1993, Volume: 110, Issue:1-2

    Topics: Adult; Amisulpride; Antipsychotic Agents; Apomorphine; Dopamine Agonists; Ergolines; Female; Growth Hormone; Humans; Male; Neurosecretory Systems; Piperazines; Prolactin; Quinolones; Schizophrenia; Sulpiride

1993
Spontaneous brain magnetic activity in schizophrenia patients treated with aripiprazole.
    Psychopharmacology bulletin, 1998, Volume: 34, Issue:1

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Electroencephalography; Humans; Male; Piperazines; Quinolones; Schizophrenia

1998

Other Studies

313 other study(ies) available for carbostyril and Schizophrenia

ArticleYear
Continuation rate for asenapine and brexpiprazole treatment in elderly patients with schizophrenia.
    Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, 2021, Volume: 21, Issue:6

    Topics: Aged; Antipsychotic Agents; Dibenzocycloheptenes; Humans; Quinolones; Schizophrenia; Thiophenes

2021
Hyperprolactinemia induced by brexpiprazole in patients with schizophrenia: A case report.
    Psychiatry research, 2021, Volume: 305

    Topics: Antipsychotic Agents; Humans; Hyperprolactinemia; Quinolones; Schizophrenia; Thiophenes

2021
[Therapeutic drug monitoring of aripiprazole as part of the individualization of the pharmacotherapy of schizophrenia].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2022, Volume: 122, Issue:1

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Drug Monitoring; Humans; Piperazines; Quinolones; Schizophrenia; Young Adult

2022
N-Acetylcysteine and Aripiprazole Improve Social Behavior and Cognition and Modulate Brain BDNF Levels in a Rat Model of Schizophrenia.
    International journal of molecular sciences, 2022, Feb-15, Volume: 23, Issue:4

    Topics: Acetylcysteine; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cognition; Cognition Disorders; Disease Models, Animal; Female; Hippocampus; Prefrontal Cortex; Pregnancy; Quinolones; Rats; Rats, Sprague-Dawley; Schizophrenia; Social Behavior

2022
Functional Outcomes of an Antipsychotic Medication in Schizophrenia: A Generalizable or Specific Effect?
    The Journal of clinical psychiatry, 2022, 03-01, Volume: 83, Issue:2

    Topics: Antipsychotic Agents; Humans; Quinolones; Schizophrenia; Thiophenes

2022
A case report of clozapine-treatment-resistant schizophrenia successfully managed with brexpiprazole combination therapy.
    Asian journal of psychiatry, 2022, Volume: 72

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Humans; Quinolones; Schizophrenia; Schizophrenia, Treatment-Resistant; Thiophenes; Young Adult

2022
Treatment Discontinuation Among Patients with Schizophrenia Treated with Brexpiprazole and Other Oral Atypical Antipsychotics in Japan: A Retrospective Observational Study.
    Advances in therapy, 2022, Volume: 39, Issue:9

    Topics: Antipsychotic Agents; Humans; Japan; Quinolones; Retrospective Studies; Schizophrenia; Thiophenes

2022
[Modern possibilities of anti-relapse therapy of schizophrenia (experience with the use of aripiprazole)].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2022, Volume: 122, Issue:12

    Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Recurrence; Schizophrenia

2022
Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics.
    Psychiatry research, 2023, Volume: 322

    Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chronic Disease; Humans; Hyperprolactinemia; Olanzapine; Piperazines; Quinolones; Recurrence; Schizophrenia

2023
Comparison between olanzapine and aripiprazole treatment for 104 weeks after hospital discharge in schizophrenia spectrum disorders: a multicenter retrospective cohort study in a real-world setting.
    Psychopharmacology, 2023, Volume: 240, Issue:9

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Hospitals; Humans; Olanzapine; Patient Discharge; Piperazines; Quinolones; Retrospective Studies; Schizophrenia

2023
Population Pharmacokinetic Analysis of Brexpiprazole to Support its Indication and Dose Selection in Adolescents With Schizophrenia.
    Journal of clinical pharmacology, 2023, Volume: 63, Issue:11

    Topics: Adolescent; Adult; Antipsychotic Agents; Child; Humans; Quinolones; Schizophrenia; Thiophenes

2023
Brexpiprazole for the Treatment of Tics in a Patient With Schizophrenia.
    The primary care companion for CNS disorders, 2023, 07-27, Volume: 25, Issue:4

    Topics: Antipsychotic Agents; Humans; Quinolones; Schizophrenia; Thiophenes; Tics

2023
Widespread Changes in Positive Allosteric Modulation of the Muscarinic M1 Receptor in Some Participants With Schizophrenia.
    The international journal of neuropsychopharmacology, 2019, 10-01, Volume: 22, Issue:10

    Topics: Allosteric Regulation; Autoradiography; Case-Control Studies; Cerebral Cortex; Corpus Striatum; Female; Hippocampus; Humans; Male; Middle Aged; N-Methylscopolamine; Protein Binding; Quinolones; Radioligand Assay; Receptor, Muscarinic M1; Schizophrenia; Tritium

2019
Treatment-resistant schizophrenia successfully maintained with brexpiprazole following abrupt withdrawal of clozapine due to neutropenia.
    Asian journal of psychiatry, 2020, Volume: 47

    Topics: Adolescent; Antipsychotic Agents; Clozapine; Female; Humans; Neutropenia; Quinolones; Schizophrenia; Serotonin Agents; Thiophenes

2020
[Preclinical pharmacological profiles and clinical efficacy of the novel antipsychotic drug brexpiprazole (REXULTI
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2019, Volume: 154, Issue:5

    Topics: Antipsychotic Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Quinolones; Schizophrenia; Tablets; Thiophenes; Treatment Outcome

2019
Association between previous high-dose antipsychotic therapy and brexpiprazole discontinuation after the initiation of brexpiprazole in patients with schizophrenia or schizoaffective disorder.
    International clinical psychopharmacology, 2020, Volume: 35, Issue:2

    Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Psychotic Disorders; Quinolones; Retrospective Studies; Schizophrenia; Serotonin Agents; Thiophenes; Withholding Treatment

2020
Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy.
    Clinical therapeutics, 2020, Volume: 42, Issue:1

    Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Female; Health Care Costs; Hospitalization; Humans; Lurasidone Hydrochloride; Male; Medicaid; Medicare; Middle Aged; Olanzapine; Paliperidone Palmitate; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles; Thiophenes; United States

2020
Brexpiprazole in the treatment of schizophrenia and agitation in Alzheimer's disease.
    Neurodegenerative disease management, 2020, Volume: 10, Issue:4

    Topics: Alzheimer Disease; Antipsychotic Agents; Humans; Quinolones; Schizophrenia; Thiophenes

2020
Combination therapy of brexpiprazole and aripiprazole for an adolescent patient with a first episode of schizophrenia: A case report.
    Psychiatry and clinical neurosciences, 2020, Volume: 74, Issue:12

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Female; Humans; Quinolones; Schizophrenia; Serotonin Agents; Thiophenes

2020
Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post-hoc analysis of a long-term open-label study.
    Human psychopharmacology, 2021, Volume: 36, Issue:4

    Topics: Antipsychotic Agents; Aripiprazole; Humans; Japan; Quinolones; Schizophrenia; Thiophenes; Treatment Outcome

2021
[Brexpiprazole for treatment of schizophrenia: a critical literature study].
    Tijdschrift voor psychiatrie, 2021, Volume: 63, Issue:1

    Topics: Antipsychotic Agents; Belgium; Humans; Netherlands; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Thiophenes; Treatment Outcome

2021
Continuation rate for asenapine and brexpiprazole treatment in patients with schizophrenia.
    Brain and behavior, 2021, Volume: 11, Issue:5

    Topics: Antipsychotic Agents; Dibenzocycloheptenes; Humans; Quinolones; Retrospective Studies; Schizophrenia; Thiophenes; Treatment Outcome

2021
Brexpiprazole Pharmacokinetics in CYP2D6 Poor Metabolizers: Using Physiologically Based Pharmacokinetic Modeling to Optimize Time to Effective Concentrations.
    Journal of clinical pharmacology, 2022, Volume: 62, Issue:1

    Topics: Antipsychotic Agents; Area Under Curve; Cytochrome P-450 CYP2D6; Drug Administration Schedule; Genotype; Half-Life; Humans; Metabolic Clearance Rate; Models, Biological; Phenotype; Quinolones; Schizophrenia; Thiophenes

2022
SIMULTANEOUS ASSAY OF ARIPIPRAZOLE AND ITS ACTIVE METABOLITE IN SERUM BY HPLC.
    Acta poloniae pharmaceutica, 2017, Volume: 74, Issue:2

    Topics: Acetonitriles; Activation, Metabolic; Antipsychotic Agents; Aripiprazole; Buffers; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Drug Compounding; Drug Monitoring; Humans; Hydrogen-Ion Concentration; Phosphoric Acids; Piperazines; Quinolones; Schizophrenia; Solvents; Water

2017
The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies.
    International clinical psychopharmacology, 2018, Volume: 33, Issue:5

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Female; Humans; Longitudinal Studies; Male; Meta-Analysis as Topic; Middle Aged; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Thiophenes; Weight Gain

2018
Clinical Use of Dopamine Modulators as Third-Generation Antipsychotic Agents.
    Journal of psychosocial nursing and mental health services, 2019, Feb-01, Volume: 57, Issue:2

    Topics: Antipsychotic Agents; Aripiprazole; Dopamine D2 Receptor Antagonists; Humans; Quinolones; Receptors, Dopamine D2; Schizophrenia; Serotonin Antagonists; Thiophenes

2019
White-matter microstructure in previously drug-naive patients with schizophrenia after 6 weeks of treatment.
    Psychological medicine, 2013, Volume: 43, Issue:11

    Topics: Adolescent; Adult; Anisotropy; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain; Brain Mapping; Case-Control Studies; Dibenzothiazepines; Diffusion Tensor Imaging; Female; Frontal Lobe; Gyrus Cinguli; Haloperidol; Humans; Image Processing, Computer-Assisted; Male; Nerve Fibers, Myelinated; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Sulpiride; Treatment Outcome; Young Adult

2013
The effects of antipsychotics on behavioral abnormalities of the Gunn rat (unconjugated hyperbilirubinemia rat), a rat model of schizophrenia.
    Asian journal of psychiatry, 2013, Volume: 6, Issue:2

    Topics: Animals; Antipsychotic Agents; Aripiprazole; Disease Models, Animal; Haloperidol; Hyperbilirubinemia; Inhibition, Psychological; Locomotion; Male; Neuropsychological Tests; Piperazines; Quinolones; Rats; Rats, Gunn; Reflex, Startle; Risperidone; Schizophrenia; Social Behavior; Treatment Outcome

2013
Dose-related reversible hypotension during aripiprazole treatment.
    The Journal of neuropsychiatry and clinical neurosciences, 2013,Winter, Volume: 25, Issue:1

    Topics: Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Humans; Hypotension; Male; Piperazines; Quinolones; Schizophrenia; Young Adult

2013
Association of estrogen receptor alpha gene polymorphism with age at onset, general psychopathology symptoms, and therapeutic effect of schizophrenia.
    Behavioral and brain functions : BBF, 2013, Mar-15, Volume: 9

    Topics: Adult; Age of Onset; Antipsychotic Agents; Aripiprazole; Asian People; Data Interpretation, Statistical; Diagnostic and Statistical Manual of Mental Disorders; DNA; Estrogen Receptor alpha; Female; Genotype; Haplotypes; Humans; Kaplan-Meier Estimate; Male; Piperazines; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome

2013
Influence of aripiprazole and olanzapine on behavioral dysfunctions of adolescent rats exposed to stress in perinatal period.
    Pharmacological reports : PR, 2013, Volume: 65, Issue:1

    Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Benzodiazepines; Cognition Disorders; Depression; Disease Models, Animal; Drug Administration Schedule; Female; Male; Maze Learning; Memory Disorders; Olanzapine; Piperazines; Pregnancy; Prenatal Exposure Delayed Effects; Quinolones; Rats; Rats, Wistar; Schizophrenia; Stress, Psychological; Time Factors

2013
Innovative potential treatment strategies for schizophrenia and biomarkers for Alzheimer's disease.
    European archives of psychiatry and clinical neuroscience, 2013, Volume: 263, Issue:4

    Topics: Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Biomarkers; Disease Progression; Histone Deacetylase Inhibitors; Humans; Piperazines; Quinolones; Schizophrenia

2013
Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison.
    The Australian and New Zealand journal of psychiatry, 2014, Volume: 48, Issue:1

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Female; Humans; Inpatients; Male; Middle Aged; Piperazines; Polypharmacy; Practice Patterns, Physicians'; Quetiapine Fumarate; Quinolones; Republic of Korea; Schizophrenia

2014
Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data.
    Journal of medical economics, 2013, Volume: 16, Issue:7

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Cardiovascular Diseases; Clinical Trials as Topic; Clozapine; Comorbidity; Cost-Benefit Analysis; Diabetes Mellitus; Hospitalization; Humans; Isoindoles; Lurasidone Hydrochloride; Markov Chains; Models, Economic; Outcome Assessment, Health Care; Piperazines; Quinolones; Recurrence; Schizophrenia; Thiazoles; United States

2013
A case report of partial bowel obstruction after aripiprazole addition to clozapine in a young male with schizophrenia.
    Journal of clinical psychopharmacology, 2013, Volume: 33, Issue:4

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Defecation; Drug Substitution; Drug Therapy, Combination; Humans; Intestinal Obstruction; Lamotrigine; Male; Piperazines; Quinolones; Risk Factors; Schizophrenia; Treatment Outcome; Triazines

2013
Neurocognitive effects of aripiprazole in adolescents and young adults with schizophrenia.
    Nordic journal of psychiatry, 2014, Volume: 68, Issue:3

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brief Psychiatric Rating Scale; Child; Cognition; Female; Humans; Male; Neuropsychological Tests; Piperazines; Prospective Studies; Psychotic Disorders; Quality of Life; Quinolones; Schizophrenia; Taiwan; Treatment Outcome; Young Adult

2014
Indirect comparison analysis of efficacy and safety between olanzapine and aripiprazole for schizophrenia.
    British journal of clinical pharmacology, 2014, Volume: 77, Issue:5

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Olanzapine; Patient Dropouts; Piperazines; Quinolones; Schizophrenia

2014
Aspirin as an adjunctive treatment for childhood onset schizophrenia.
    Journal of child and adolescent psychopharmacology, 2013, Volume: 23, Issue:8

    Topics: Adolescent; Age of Onset; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Aripiprazole; Aspirin; Drug Therapy, Combination; Humans; Male; Piperazines; Quinolones; Schizophrenia

2013
The effects of antipsychotic switching on diabetes in chronic schizophrenia.
    Diabetic medicine : a journal of the British Diabetic Association, 2014, Volume: 31, Issue:3

    Topics: Antipsychotic Agents; Aripiprazole; Blood Glucose; Clozapine; Diabetes Mellitus, Type 2; Drug Administration Schedule; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Obesity; Piperazines; Quinolones; Schizophrenia; Treatment Outcome; Weight Loss

2014
Aripiprazole: a new risk factor for pathological gambling? A report of 8 case reports.
    Addictive behaviors, 2014, Volume: 39, Issue:3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Dopamine Agonists; Female; Gambling; Humans; Male; Middle Aged; Piperazines; Quinolones; Risk Factors; Schizophrenia; Young Adult

2014
Combination of escitalopram and aripiprazole causes significant improvement of negative symptoms of simple schizophrenia.
    Psychiatry and clinical neurosciences, 2014, Volume: 68, Issue:7

    Topics: Aripiprazole; Citalopram; Drug Therapy, Combination; Female; Humans; Middle Aged; Piperazines; Quinolones; Schizophrenia; Treatment Outcome

2014
Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
    Therapeutic drug monitoring, 2014, Volume: 36, Issue:5

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Asian People; ATP Binding Cassette Transporter, Subfamily B; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Female; Genotype; Humans; Male; Middle Aged; Piperazines; Polymorphism, Genetic; Quinolones; Schizophrenia; Young Adult

2014
Serotonin(1A) receptors in the action of aripiprazole.
    Journal of clinical psychopharmacology, 2014, Volume: 34, Issue:3

    Topics: Antipsychotic Agents; Benzodiazepines; Cerebral Cortex; Female; Humans; Male; Piperazines; Quinolones; Receptor, Serotonin, 5-HT1A; Risperidone; Schizophrenia

2014
Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12-month prospective study.
    Human psychopharmacology, 2014, Volume: 29, Issue:2

    Topics: Adult; Alkaline Phosphatase; Antipsychotic Agents; Aripiprazole; Bone Density; Chlorpromazine; Clozapine; Dibenzothiazepines; Estrogens; Female; Humans; Male; Middle Aged; Osteoporosis; Perphenazine; Piperazines; Prolactin; Prospective Studies; Quetiapine Fumarate; Quinolones; Risk Factors; Schizophrenia; Sulpiride

2014
Lack of correlation between the steady-state plasma concentrations of aripiprazole and haloperidol in Japanese patients with schizophrenia.
    Therapeutic drug monitoring, 2014, Volume: 36, Issue:6

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Asian People; Female; Haloperidol; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia

2014
Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States.
    Journal of medical economics, 2014, Volume: 17, Issue:8

    Topics: Antipsychotic Agents; Aripiprazole; Cost-Benefit Analysis; Decision Support Techniques; Drug Administration Schedule; Humans; Injections, Intramuscular; Isoxazoles; Paliperidone Palmitate; Palmitates; Piperazines; Quinolones; Schizophrenia; United States

2014
Effects of antipsychotic drugs on insight in schizophrenia.
    Psychiatry research, 2014, Aug-15, Volume: 218, Issue:1-2

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Awareness; Benzodiazepines; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Thiazoles

2014
Olanzapine-induced triglyceride and aminotransferase elevations without weight gain or hyperglycemia normalized after switching to aripiprazole.
    Journal of psychiatric practice, 2014, Volume: 20, Issue:4

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Hypertriglyceridemia; Liver; Male; Olanzapine; Piperazines; Quinolones; Schizophrenia; Transaminases; Treatment Outcome

2014
Association of microRNA137 gene polymorphisms with age at onset and positive symptoms of schizophrenia in a Han Chinese population.
    International journal of psychiatry in medicine, 2014, Volume: 47, Issue:2

    Topics: Adult; Age of Onset; Aripiprazole; China; Female; Genetic Predisposition to Disease; Genotype; Humans; Male; MicroRNAs; Phenotype; Piperazines; Polymorphism, Genetic; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome

2014
High doses of aripiprazole therapy for a patient with treatment-resistant schizophrenia responsive to, but intolerant of, clozapine.
    The Australian and New Zealand journal of psychiatry, 2015, Volume: 49, Issue:2

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Female; Humans; Piperazines; Quinolones; Schizophrenia

2015
No better solution for antipsychotic treatment with regard to long-term safety and effectiveness.
    Evidence-based mental health, 2015, Volume: 18, Issue:1

    Topics: Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Humans; Male; Piperazines; Psychotic Disorders; Quinolones; Risperidone; Schizophrenia

2015
Increased orbitofrontal cortex activation associated with "pro-obsessive" antipsychotic treatment in patients with schizophrenia.
    Journal of psychiatry & neuroscience : JPN, 2015, Volume: 40, Issue:2

    Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain Mapping; Clozapine; Executive Function; Female; Humans; Inhibition, Psychological; Magnetic Resonance Imaging; Male; Neuropsychological Tests; Obsessive Behavior; Olanzapine; Piperazines; Prefrontal Cortex; Psychiatric Status Rating Scales; Psychomotor Performance; Quinolones; Schizophrenia; Sulpiride

2015
What is the role of long-acting injectable antipsychotics in the treatment of schizophrenia?
    The Journal of clinical psychiatry, 2014, Volume: 75, Issue:11

    Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia

2014
Long-acting injectable antipsychotics: an underutilized treatment option.
    The Journal of clinical psychiatry, 2014, Volume: 75, Issue:11

    Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia

2014
Differential effects of short- and long-term antipsychotic treatment on the expression of neuregulin-1 and ErbB4 receptors in the rat brain.
    Psychiatry research, 2015, Feb-28, Volume: 225, Issue:3

    Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cerebral Cortex; Female; Haloperidol; Hippocampus; Neuregulin-1; Olanzapine; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Receptor, ErbB-4; Schizophrenia; Signal Transduction; Time Factors; Up-Regulation

2015
The 'unknown' safety concern for aripiprazole once monthly.
    The British journal of psychiatry : the journal of mental science, 2015, Volume: 206, Issue:2

    Topics: Antipsychotic Agents; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia

2015
Authors' reply.
    The British journal of psychiatry : the journal of mental science, 2015, Volume: 206, Issue:2

    Topics: Antipsychotic Agents; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia

2015
Switching antipsychotic medication to aripiprazole: position paper by a panel of Italian psychiatrists.
    Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:5

    Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Clozapine; Drug Substitution; Humans; Italy; Piperazines; Quinolones; Schizophrenia

2015
Aripiprazole-induced chorioretinopathy: multimodal imaging and electrophysiological features.
    Documenta ophthalmologica. Advances in ophthalmology, 2015, Volume: 131, Issue:1

    Topics: Antipsychotic Agents; Aripiprazole; Coloring Agents; Dark Adaptation; Electrooculography; Electroretinography; Female; Fluorescein Angiography; Humans; Indocyanine Green; Middle Aged; Multimodal Imaging; Piperazines; Quinolones; Retina; Retinal Diseases; Retinal Pigment Epithelium; Schizophrenia; Tomography, Optical Coherence; Visual Acuity

2015
Brexpiprazole: another multipurpose antipsychotic drug?
    Journal of psychosocial nursing and mental health services, 2015, Volume: 53, Issue:4

    Topics: Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Depressive Disorder, Major; Humans; Psychomotor Agitation; Quinolones; Schizophrenia; Stress Disorders, Post-Traumatic; Thiophenes

2015
American Psychiatric Association - 168th Annual Meeting (May 16-20, 2015 - Toronto, Canada).
    Drugs of today (Barcelona, Spain : 1998), 2015, Volume: 51, Issue:6

    Topics: Alcoholism; Benzofurans; Canada; Drug Discovery; Humans; Indoles; Mental Disorders; Piperazines; Psychiatry; Quinolones; Schizophrenia; Thiophenes; Vilazodone Hydrochloride

2015
Brexpiprazole: A New Antipsychotic Following in the Footsteps of Aripiprazole.
    The American journal of psychiatry, 2015, Sep-01, Volume: 172, Issue:9

    Topics: Antipsychotic Agents; Female; Humans; Male; Quinolones; Schizophrenia; Thiophenes

2015
The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out.
    International journal of clinical practice, 2015, Volume: 69, Issue:11

    Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Dopamine Agonists; Drug Administration Schedule; Drug Interactions; Humans; Piperazines; Quinolones; Schizophrenia; Thiophenes

2015
Mechanism of action of brexpiprazole: comparison with aripiprazole.
    CNS spectrums, 2016, Volume: 21, Issue:1

    Topics: Adrenergic alpha-1 Receptor Antagonists; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Dopamine Agonists; Humans; Quinolones; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Adrenergic, alpha-1; Receptors, Dopamine D2; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin Agents; Thiophenes

2016
Aripiprazole for the Treatment of Antipsychotic-Induced Hyperprolactinemia in an Adolescent Boy.
    Journal of child and adolescent psychopharmacology, 2016, Volume: 26, Issue:5

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Hyperprolactinemia; Male; Prolactin; Quinolones; Schizophrenia

2016
Diabetic ketoacidosis induced by aripiprazole in a 12-year-old boy.
    Diabetes care, 2008, Volume: 31, Issue:6

    Topics: Antipsychotic Agents; Aripiprazole; Child; Diabetic Ketoacidosis; Humans; Male; Piperazines; Quinolones; Schizophrenia

2008
A case of aripiprazole and tardive dyskinesia.
    Journal of psychopharmacology (Oxford, England), 2009, Volume: 23, Issue:2

    Topics: Antipsychotic Agents; Aripiprazole; Dyskinesia, Drug-Induced; Female; Humans; Piperazines; Quinolones; Schizophrenia; Young Adult

2009
The safety of the electroconvulsive therapy-aripiprazole combination: four case reports.
    The journal of ECT, 2008, Volume: 24, Issue:3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Combined Modality Therapy; Depressive Disorder, Major; Electroconvulsive Therapy; Female; Humans; Inpatients; Middle Aged; Piperazines; Quinolones; Safety; Schizophrenia

2008
Case report of aripiprazole usage during pregnancy.
    Archives of women's mental health, 2008, Volume: 11, Issue:3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Infant, Newborn; Maternal Behavior; Piperazines; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Quinolones; Schizophrenia; Treatment Outcome

2008
Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia.
    Psychopharmacology, 2008, Volume: 200, Issue:2

    Topics: Animals; Behavior, Animal; Carrier Proteins; Clozapine; Disease Models, Animal; Glycine; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Nerve Tissue Proteins; Phenotype; Quinolones; Receptors, N-Methyl-D-Aspartate; Recognition, Psychology; Sarcosine; Schizophrenia; Schizophrenic Psychology; Serine; Social Behavior; Space Perception

2008
D-optimal designing and optimization of long acting microsphere-based injectable formulation of aripiprazole.
    Drug development and industrial pharmacy, 2008, Volume: 34, Issue:7

    Topics: Antipsychotic Agents; Aripiprazole; Cholesterol; Delayed-Action Preparations; Lactic Acid; Microspheres; Particle Size; Piperazines; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Quinolones; Schizophrenia; Solubility; Solvents

2008
Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation study.
    Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:4

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia

2008
Large variability of aripiprazole and dehydroaripiprazole serum concentrations in adolescent patients with schizophrenia.
    Therapeutic drug monitoring, 2008, Volume: 30, Issue:4

    Topics: Adolescent; Adult; Aging; Antipsychotic Agents; Aripiprazole; Biotransformation; Body Mass Index; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Male; Piperazines; Quinolones; Regression Analysis; Schizophrenia; Sex Characteristics; Young Adult

2008
New insights into clinical response in schizophrenia: from dopamine D2 receptor occupancy to patients' quality of life.
    The American journal of psychiatry, 2008, Volume: 165, Issue:8

    Topics: Antipsychotic Agents; Aripiprazole; Corpus Striatum; Humans; Piperazines; Positron-Emission Tomography; Quality of Life; Quinolones; Receptors, Dopamine D2; Schizophrenia; Schizophrenic Psychology; Time Factors

2008
Combination of aripiprazole and other psychopharmacological treatments in resistant and multi-resistant patients.
    Current drug safety, 2008, Volume: 3, Issue:3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Resistance; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Humans; Male; Mental Disorders; Middle Aged; Obsessive-Compulsive Disorder; Outcome Assessment, Health Care; Personality Disorders; Piperazines; Psychotropic Drugs; Quinolones; Retrospective Studies; Schizophrenia; Spain

2008
Insulin sensitivity, adjusted beta-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: a nine-month prospective study.
    Diabetes & metabolism, 2008, Volume: 34, Issue:5

    Topics: Adiponectin; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Dibenzothiazepines; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Insulin-Secreting Cells; Male; Olanzapine; Piperazines; Prospective Studies; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia

2008
A 12-month follow-up study of treating overweight schizophrenic patients with aripiprazole.
    Acta psychiatrica Scandinavica, 2008, Volume: 118, Issue:3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Cohort Studies; Feasibility Studies; Female; Follow-Up Studies; Humans; Male; Netherlands; Olanzapine; Overweight; Piperazines; Quinolones; Schizophrenia

2008
Aripiprazole and its human metabolite OPC14857 reduce, through a presynaptic mechanism, glutamate release in rat prefrontal cortex: possible relevance to neuroprotective interventions in schizophrenia.
    Synapse (New York, N.Y.), 2008, Volume: 62, Issue:11

    Topics: Animals; Aripiprazole; Dose-Response Relationship, Drug; Glutamic Acid; Humans; Male; Neuroprotective Agents; Piperazines; Prefrontal Cortex; Presynaptic Terminals; Quinolones; Rats; Rats, Sprague-Dawley; Schizophrenia

2008
Aripiprazole-induced orthostatic hypotension and cardiac arrhythmia.
    Psychiatry and clinical neurosciences, 2008, Volume: 62, Issue:4

    Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Dose-Response Relationship, Drug; Female; Humans; Hypotension, Orthostatic; Middle Aged; Piperazines; Quinolones; Schizophrenia; Tachycardia, Supraventricular

2008
Aripiprazole induced hypersexuality in a 24-year-old female patient with schizoaffective disorder?
    Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:5

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Follow-Up Studies; Humans; Libido; Piperazines; Quinolones; Schizophrenia; Sexual Dysfunction, Physiological

2008
Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients.
    Journal of psychiatric research, 2009, Volume: 43, Issue:6

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Follow-Up Studies; Genetic Predisposition to Disease; Hospitalization; Humans; Male; Middle Aged; Piperazines; Polymorphism, Genetic; Protein Serine-Threonine Kinases; Psychiatric Status Rating Scales; Quinolones; Receptors, Dopamine D2; Schizophrenia; Taiwan; Treatment Outcome; Young Adult

2009
Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK .
    Current medical research and opinion, 2008, Volume: 24, Issue:11

    Topics: Algorithms; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials, Phase I as Topic; Cost-Benefit Analysis; Decision Support Techniques; Follow-Up Studies; Health Care Costs; Health Resources; Humans; Olanzapine; Patient Acceptance of Health Care; Piperazines; Quality-Adjusted Life Years; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; United Kingdom

2008
Extreme elevation of creatinine phosphokinase levels in neuroleptic malignant syndrome associated with atypical antipsychotics.
    The American journal of psychiatry, 2009, Volume: 166, Issue:1

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Creatine Kinase; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Humans; Male; Myocardial Infarction; Neuroleptic Malignant Syndrome; Piperazines; Quinolones; Risperidone; Schizophrenia; Valproic Acid

2009
Successful switch from clozapine to aripiprazole: a case report.
    Journal of clinical psychopharmacology, 2009, Volume: 29, Issue:1

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Administration Schedule; Drug Resistance; Humans; Male; Piperazines; Quinolones; Schizophrenia; Treatment Outcome

2009
Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study.
    Psychiatry and clinical neurosciences, 2009, Volume: 63, Issue:1

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Mass Index; Body Weight; Female; Humans; Korea; Male; Middle Aged; Piperazines; Prolactin; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Suicide; Young Adult

2009
Comparing the effectiveness of aripiprazole and quetiapine in schizophrenia and related psychoses: a naturalistic, retrospective chart review study.
    The Journal of clinical psychiatry, 2009, Volume: 70, Issue:5

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Drug Administration Schedule; Female; Humans; Male; Medical Records Systems, Computerized; Mental Health Services; Patient Dropouts; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Retrospective Studies; Schizophrenia; Severity of Illness Index

2009
Resolution of risperidone-induced tardive dyskinesia with a switch to aripiprazole monotherapy.
    Progress in neuro-psychopharmacology & biological psychiatry, 2009, Apr-30, Volume: 33, Issue:3

    Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Female; Humans; Piperazines; Quinolones; Risperidone; Schizophrenia

2009
Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials.
    BMC psychiatry, 2009, Mar-31, Volume: 9

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Female; Humans; Male; Middle Aged; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Thiazoles; Time Factors; Treatment Outcome

2009
Influence of TAAR6 polymorphisms on response to aripiprazole.
    Progress in neuro-psychopharmacology & biological psychiatry, 2009, Aug-01, Volume: 33, Issue:5

    Topics: Adult; Aripiprazole; Cell Cycle Proteins; Female; Genetic Linkage; Genetic Markers; Haplotypes; Humans; Male; Middle Aged; Nuclear Proteins; Piperazines; Polymorphism, Single Nucleotide; Prospective Studies; Quinolones; Receptors, G-Protein-Coupled; Schizophrenia

2009
Psychosocial functioning in patients with schizophrenia treated with aripiprazole - an office-based real-world setting. Results from the German post-marketing surveillance study.
    Pharmacopsychiatry, 2009, Volume: 42, Issue:3

    Topics: Antipsychotic Agents; Aripiprazole; Germany; Health Status Indicators; Humans; Physicians' Offices; Piperazines; Product Surveillance, Postmarketing; Prospective Studies; Psychology; Quinolones; Schizophrenia; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome

2009
Aripiprazole in treatment-refractory schizophrenia.
    Journal of psychiatric practice, 2009, Volume: 15, Issue:3

    Topics: Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Clozapine; Consciousness Disorders; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Female; Hospitalization; Humans; Middle Aged; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology

2009
Use of aripiprazole in tardive dyskinesia: an open label study of six cases.
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2009, Volume: 10, Issue:4 Pt 2

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Fluphenazine; Follow-Up Studies; Haloperidol; Humans; Male; Middle Aged; Neurologic Examination; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Risperidone; Schizophrenia

2009
Aripiprazole as an adjunct to clozapine therapy in adolescents with early-onset schizophrenia: a retrospective chart review.
    Pharmacopsychiatry, 2009, Volume: 42, Issue:4

    Topics: Adolescent; Age of Onset; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Retrospective Studies; Schizophrenia; Treatment Outcome; Young Adult

2009
Aripiprazole for the management of olanzapine-induced weight gain.
    Pharmacopsychiatry, 2009, Volume: 42, Issue:4

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Central Nervous System Agents; Cholesterol; Drug Therapy, Combination; Female; Glucose; Humans; Male; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Treatment Outcome; Triglycerides; Weight Gain

2009
Aripiprazole treatment of risperidone-induced hyperprolactinemia.
    The Journal of clinical psychiatry, 2009, Volume: 70, Issue:7

    Topics: Antipsychotic Agents; Aripiprazole; Humans; Hyperprolactinemia; Piperazines; Prospective Studies; Quinolones; Risperidone; Schizophrenia

2009
Remission of schizophrenia psychosis and strong reduction of obsessive-compulsive disorder after adding clozapine to aripiprazole.
    Progress in neuro-psychopharmacology & biological psychiatry, 2009, Nov-13, Volume: 33, Issue:8

    Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Humans; Male; Obsessive-Compulsive Disorder; Piperazines; Quinolones; Schizophrenia; Young Adult

2009
Improvement in Pisa syndrome and tardive dyskinesia following aripiprazole treatment.
    The Journal of neuropsychiatry and clinical neurosciences, 2009,Summer, Volume: 21, Issue:3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Piperazines; Quinolones; Schizophrenia; Syndrome; Treatment Outcome

2009
Therapy and quality of life of patients with psychosis.
    Psychiatria Danubina, 2009, Volume: 21 Suppl 1

    Topics: Adult; Animal Assisted Therapy; Antipsychotic Agents; Aripiprazole; Combined Modality Therapy; Family Therapy; Humans; Male; Object Attachment; Piperazines; Psychotherapy; Psychotherapy, Group; Quality of Life; Quinolones; Schizophrenia; Schizophrenic Psychology; Social Environment

2009
Clozapine-aripiprazole association in a 7-year-old girl with schizophrenia: clinical efficacy and successful management of neutropenia with lithium.
    Journal of child and adolescent psychopharmacology, 2009, Volume: 19, Issue:5

    Topics: Antimanic Agents; Antipsychotic Agents; Aripiprazole; Child; Clozapine; Female; Humans; Lithium Carbonate; Neutropenia; Piperazines; Quinolones; Schizophrenia

2009
No influence of FAT polymorphisms in response to aripiprazole.
    Journal of human genetics, 2010, Volume: 55, Issue:1

    Topics: Adult; Alleles; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Cadherins; Female; Genotype; Humans; Male; Middle Aged; Piperazines; Polymorphism, Single Nucleotide; Quinolones; Schizophrenia; Severity of Illness Index; Treatment Outcome

2010
Effectiveness of intramuscular aripiprazole injection in patients with catatonia: report on three cases.
    Pharmacopsychiatry, 2009, Volume: 42, Issue:6

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Catatonia; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Treatment Outcome

2009
Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: One-year follow-up study.
    Psychiatry and clinical neurosciences, 2010, Volume: 64, Issue:1

    Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Body Weight; Cholesterol; Electrocardiography; Female; Follow-Up Studies; Heart; Hormones; Humans; Japan; Male; Middle Aged; Piperazines; Prolactin; Quinolones; Schizophrenia; Triglycerides

2010
Aripiprazole and adolescent schizophrenia: a simple neuroleptic. No comparison with standard neuroleptic in adolescents.
    Prescrire international, 2009, Volume: 18, Issue:104

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Drug Approval; Europe; Humans; Piperazines; Quinolones; Schizophrenia

2009
[Aripiprazole-induced stuttering treated with risperidone].
    Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), 2009, Volume: 31, Issue:4

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Piperazines; Quinolones; Risperidone; Schizophrenia; Stuttering

2009
Effect of aripiprazole, risperidone, and olanzapine on the acoustic startle response in Japanese chronic schizophrenia.
    Psychopharmacology, 2010, Volume: 209, Issue:2

    Topics: Acoustic Stimulation; Adult; Aged; Antipsychotic Agents; Aripiprazole; Asian People; Benzodiazepines; Blinking; Female; Humans; Japan; Male; Middle Aged; Olanzapine; Piperazines; Quinolones; Reflex, Startle; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome

2010
Benefits of switching women schizophrenic patients to aripiprazole: a case study and brief review of the literature.
    Archives of women's mental health, 2010, Volume: 13, Issue:5

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Diagnostic and Statistical Manual of Mental Disorders; Dopamine Antagonists; Drug Substitution; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Middle Aged; Piperazines; Prolactin; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Secondary Prevention

2010
Pathological gambling and compulsive eating associated with aripiprazole.
    The Australian and New Zealand journal of psychiatry, 2010, Volume: 44, Issue:3

    Topics: Antipsychotic Agents; Aripiprazole; Compulsive Behavior; Dose-Response Relationship, Drug; Eating; Female; Gambling; Humans; Middle Aged; Piperazines; Quinolones; Receptors, Dopamine D3; Schizophrenia; Weight Gain

2010
[Disappearance of paroxysmal perceptual alteration by switching to aripiprazole in a schizophrenic patient].
    Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, 2010, Volume: 112, Issue:1

    Topics: Antipsychotic Agents; Aripiprazole; Humans; Male; Perceptual Distortion; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Young Adult

2010
Switching schizophrenia patients from typical neuroleptics to aripiprazole: effects on working memory dependent functional activation.
    Schizophrenia research, 2010, Volume: 118, Issue:1-3

    Topics: Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Brain Mapping; Chlorpromazine; Female; Gyrus Cinguli; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Memory Disorders; Memory, Short-Term; Middle Aged; Neuropsychological Tests; Oxygen; Photic Stimulation; Piperazines; Quinolones; Reaction Time; Schizophrenia; Schizophrenic Psychology; Time Factors; Visual Cortex; Young Adult

2010
Drug-induced Pisa syndrome associated with aripiprazole during clozapine treatment.
    Progress in neuro-psychopharmacology & biological psychiatry, 2010, May-30, Volume: 34, Issue:4

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Piperazines; Quinolones; Schizophrenia

2010
Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients.
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2010, Volume: 11, Issue:2 Pt 2

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain-Derived Neurotrophic Factor; Female; Homovanillic Acid; Humans; Longitudinal Studies; Male; Methoxyhydroxyphenylglycol; Middle Aged; Olanzapine; Piperazines; Quinolones; Risperidone; Schizophrenia; Young Adult

2010
Favourable results in treatment-resistant schizophrenic patients under combination of aripiprazole with clozapine.
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2010, Volume: 11, Issue:2 Pt 2

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Schizophrenia, Paranoid; Treatment Failure; Young Adult

2010
[Difficulties in changing drugs--from clozapine to aripiprazole in ambulatory care].
    Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2010, Volume: 12, Issue:1

    Topics: Ambulatory Care; Antipsychotic Agents; Aripiprazole; Clozapine; Depressive Disorder, Major; Drug Administration Schedule; Humans; Interpersonal Relations; Male; Middle Aged; Obesity; Patient Education as Topic; Patient Satisfaction; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Spouses

2010
Comparison of short-acting intramuscular antipsychotic medication: impact on length of stay and cost.
    American journal of therapeutics, 2011, Volume: 18, Issue:4

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cohort Studies; Drug Costs; Female; Haloperidol; Humans; Injections, Intramuscular; Length of Stay; Male; Middle Aged; Olanzapine; Piperazines; Psychomotor Agitation; Quinolones; Retrospective Studies; Schizophrenia; Thiazoles

2011
Potent dihydroquinolinone dopamine D2 partial agonist/serotonin reuptake inhibitors for the treatment of schizophrenia.
    Bioorganic & medicinal chemistry letters, 2010, May-01, Volume: 20, Issue:9

    Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dopamine Agonists; Quinolones; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Structure-Activity Relationship

2010
Potential control of antipsychotic-induced hyperprolactinemia and obesity in children and adolescents by aripiprazole.
    Progress in neuro-psychopharmacology & biological psychiatry, 2010, Aug-16, Volume: 34, Issue:6

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Humans; Hyperprolactinemia; Obesity; Piperazines; Quinolones; Schizophrenia

2010
Trial of aripiprazole in the treatment of first-episode schizophrenia.
    Psychiatry and clinical neurosciences, 2010, Volume: 64, Issue:1

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Body Weight; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Prolactin; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Young Adult

2010
Influence of DAOA gene variants on antipsychotic response after switch to aripiprazole.
    Psychiatry research, 2010, Jul-30, Volume: 178, Issue:2

    Topics: Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Carrier Proteins; Female; Humans; Intracellular Signaling Peptides and Proteins; Korea; Male; Neuropsychological Tests; Pharmacogenetics; Piperazines; Polymorphism, Single Nucleotide; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Time Factors; Treatment Outcome

2010
Aripiprazole in pregnancy and lactation: a case report.
    Journal of clinical psychopharmacology, 2010, Volume: 30, Issue:2

    Topics: Adult; Aripiprazole; Breast Feeding; Female; Humans; Infant, Newborn; Lactation; Male; Milk, Human; Piperazines; Pregnancy; Quinolones; Schizophrenia

2010
Cochrane for clinicians. Aripiprazole vs. other atypical antipsychotics for schizophrenia.
    American family physician, 2010, Jun-01, Volume: 81, Issue:11

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Olanzapine; Piperazines; Quinolones; Risperidone; Schizophrenia

2010
The use of aripiprazole in early onset schizophrenia: safety and efficacy.
    The Medical journal of Malaysia, 2009, Volume: 64, Issue:3

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Female; Humans; Piperazines; Quinolones; Schizophrenia

2009
Changes in values of cholesterol and tryglicerides after weight loss during treatment with aripiprazole in a patient with schizophrenia - Case report.
    Psychiatria Danubina, 2010, Volume: 22, Issue:2

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Cholesterol; Croatia; Dose-Response Relationship, Drug; Feeding Behavior; Humans; Life Style; Male; Metabolic Syndrome; Piperazines; Quinolones; Schizophrenia; Triglycerides; Weight Loss

2010
Partial agonist therapy in schizophrenia: relevance to diminished criminal responsibility.
    Journal of forensic sciences, 2010, Volume: 55, Issue:6

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Crime; Forensic Psychiatry; Gambling; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Violence

2010
Diabetic ketoacidosis and elevated serum lipase in the setting of aripiprazole therapy.
    Diabetes care, 2010, Volume: 33, Issue:7

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Diabetic Ketoacidosis; Humans; Lipase; Male; Piperazines; Quinolones; Schizophrenia

2010
What is the mechanism for aripiprazole's effect on reducing olanzapine-associated obesity?
    Journal of clinical psychopharmacology, 2010, Volume: 30, Issue:4

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Controlled Clinical Trials as Topic; Double-Blind Method; Humans; Obesity; Olanzapine; Piperazines; Quinolones; Schizophrenia; Weight Gain

2010
Adjunctive treatment with low-dosage aripiprazole for blonanserin-induced hyperprolactinemia in a female patient with schizophrenia.
    Progress in neuro-psychopharmacology & biological psychiatry, 2010, Oct-01, Volume: 34, Issue:7

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Dopamine Antagonists; Female; Humans; Hyperprolactinemia; Piperazines; Piperidines; Quinolones; Schizophrenia

2010
Neuroleptic malignant syndrome secondary to aripiprazole initiation in a clozapine-intolerant patient.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2010, Volume: 67, Issue:15

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Female; Humans; Isoxazoles; Neuroleptic Malignant Syndrome; Paliperidone Palmitate; Piperazines; Pyrimidines; Quinolones; Schizophrenia

2010
Simultaneous determination of aripiprazole and its active metabolite, dehydroaripiprazole, in plasma by capillary electrophoresis combining on-column field-amplified sample injection and application in schizophrenia.
    Electrophoresis, 2010, Volume: 31, Issue:16

    Topics: Adult; Amlodipine; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Electrophoresis, Capillary; Female; Humans; Hydrogen-Ion Concentration; Male; Piperazines; Quinolones; Reference Values; Schizophrenia; Solvents

2010
Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia.
    Journal of clinical psychopharmacology, 2010, Volume: 30, Issue:5

    Topics: Adult; Aripiprazole; Dose-Response Relationship, Drug; Female; Humans; Hyperprolactinemia; Middle Aged; Piperazines; Prolactin; Quinolones; Risperidone; Schizophrenia; Treatment Outcome

2010
No influence of DTNBP1 polymorphisms on the response to aripiprazole.
    Neuropsychobiology, 2010, Volume: 62, Issue:4

    Topics: Adult; Alleles; Antipsychotic Agents; Aripiprazole; Carrier Proteins; Dysbindin; Dystrophin-Associated Proteins; Female; Haplotypes; Humans; Linkage Disequilibrium; Male; Piperazines; Polymorphism, Single Nucleotide; Quinolones; Schizophrenia

2010
Effects of aripiprazole and haloperidol on progression to schizophrenia-like behavioural abnormalities and apoptosis in rodents.
    Schizophrenia research, 2011, Volume: 125, Issue:1

    Topics: Acoustic Stimulation; Analysis of Variance; Animals; Antipsychotic Agents; Apoptosis; Aripiprazole; Behavioral Symptoms; Disease Models, Animal; Dizocilpine Maleate; Haloperidol; In Situ Nick-End Labeling; Inhibition, Psychological; Male; Methamphetamine; Microdialysis; Motor Activity; Neuroprotective Agents; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Reflex, Startle; Schizophrenia

2011
A case of schizophrenia with Meige syndrome induced by long-term aripiprazole successfully treated with perospirone.
    Progress in neuro-psychopharmacology & biological psychiatry, 2011, Jan-15, Volume: 35, Issue:1

    Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Isoindoles; Meige Syndrome; Piperazines; Quinolones; Schizophrenia; Thiazoles; Young Adult

2011
Prolonged catatonic stupor successfully treated with aripiprazole in an adolescent male with schizophrenia: a case report.
    Clinical schizophrenia & related psychoses, 2010, Volume: 4, Issue:3

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Catatonia; Humans; Japan; Male; Piperazines; Quinolones; Schizophrenia; Stupor; Treatment Outcome

2010
Epidemiologic study of aripiprazole use and the incidence of suicide events.
    Pharmacoepidemiology and drug safety, 2010, Volume: 19, Issue:11

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Databases, Factual; Female; Humans; Incidence; Male; Middle Aged; Piperazines; Quinolones; Risk; Schizophrenia; Suicide; Suicide, Attempted; Young Adult

2010
Clock genes and body composition in patients with schizophrenia under treatment with antipsychotic drugs.
    Schizophrenia research, 2011, Volume: 125, Issue:2-3

    Topics: Adult; Age Factors; Alleles; Amisulpride; Anthropometry; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Composition; Body Mass Index; CLOCK Proteins; Clozapine; Dibenzothiazepines; Drug Therapy, Combination; Female; Genetic Association Studies; Genetic Carrier Screening; Genotype; Humans; Long-Term Care; Male; Middle Aged; Mutation, Missense; Olanzapine; Period Circadian Proteins; Piperazines; Polymorphism, Single Nucleotide; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Receptor, Melanocortin, Type 3; Receptors, Glucocorticoid; Receptors, Leptin; Risperidone; Schizophrenia; Sex Factors; Sulpiride; Syndecan-3

2011
Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: relationship with glutamate release in the medial prefrontal cortex.
    Psychopharmacology, 2011, Volume: 214, Issue:3

    Topics: Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Benzodiazepines; Choice Behavior; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Glutamic Acid; Haloperidol; Impulsive Behavior; Male; Microdialysis; Neuropsychological Tests; Olanzapine; Piperazines; Prefrontal Cortex; Quinolones; Rats; Reaction Time; Schizophrenia; Serotonin; Time Factors

2011
Neutropenia associated with quetiapine, olanzapine, and aripiprazole.
    The Australian and New Zealand journal of psychiatry, 2011, Volume: 45, Issue:1

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Female; Humans; Middle Aged; Neutropenia; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Schizophrenia

2011
Partial agonists in schizophrenia--why some work and others do not: insights from preclinical animal models.
    The international journal of neuropsychopharmacology, 2011, Volume: 14, Issue:9

    Topics: Animals; Antipsychotic Agents; Aripiprazole; Avoidance Learning; Corpus Striatum; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Immunohistochemistry; Locomotion; Male; Nerve Tissue Proteins; Neurons; Nucleus Accumbens; Piperazines; Proto-Oncogene Proteins c-fos; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Schizophrenia

2011
Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia.
    Current medical research and opinion, 2011, Volume: 27, Issue:1

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cost-Benefit Analysis; Double-Blind Method; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Olanzapine; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Retrospective Studies; Schizophrenia; Treatment Outcome; United States; Young Adult

2011
A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.
    Progress in neuro-psychopharmacology & biological psychiatry, 2011, Mar-30, Volume: 35, Issue:2

    Topics: Age Factors; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Dibenzothiazepines; Female; Humans; Inpatients; Male; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risk; Risk Factors; Risperidone; Schizophrenia; Sex Factors; Time Factors; Weight Gain

2011
Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
    Therapeutic drug monitoring, 2011, Volume: 33, Issue:1

    Topics: Alleles; Antipsychotic Agents; Aripiprazole; Asian People; Cytochrome P-450 CYP2D6; Drug Monitoring; Female; Genotype; Humans; Male; Piperazines; Quinolones; Schizophrenia

2011
Management of a patient with schizophrenia and underlying pituitary macroadenoma.
    Annals of the Academy of Medicine, Singapore, 2010, Volume: 39, Issue:11

    Topics: Adenoma; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bromocriptine; Dopamine Antagonists; Female; Hormone Antagonists; Humans; Hyperprolactinemia; Olanzapine; Piperazines; Pituitary Neoplasms; Quinolones; Risperidone; Schizophrenia; Serotonin Antagonists; Trifluoperazine

2010
Preliminary report: a naturalistic study of the effect of aripiprazole addition on risperidone-related hyperprolactinemia in patients treated with risperidone long-acting injection.
    Journal of clinical psychopharmacology, 2011, Volume: 31, Issue:1

    Topics: Adult; Aripiprazole; Delayed-Action Preparations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hyperprolactinemia; Injections; Male; Middle Aged; Piperazines; Quinolones; Risperidone; Schizophrenia

2011
Aripiprazole-induced pathological gambling: a report of 3 cases.
    Current drug safety, 2011, Feb-01, Volume: 6, Issue:1

    Topics: Adolescent; Aripiprazole; Gambling; Humans; Male; Piperazines; Quinolones; Schizophrenia; Young Adult

2011
Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia.
    Schizophrenia bulletin, 2012, Volume: 38, Issue:4

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Dibenzothiazepines; Female; Hospitalization; Hospitals, Psychiatric; Humans; Male; Medication Adherence; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome

2012
Prevalence and severity of antipsychotic related constipation in patients with schizophrenia: a retrospective descriptive study.
    BMC gastroenterology, 2011, Mar-08, Volume: 11

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Clozapine; Constipation; Enema; Fecal Impaction; Female; Gastrointestinal Agents; Humans; Lactulose; Male; Middle Aged; Piperazines; Polyethylene Glycols; Prevalence; Quinolones; Retrospective Studies; Risperidone; Schizophrenia; Severity of Illness Index; Young Adult

2011
Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis.
    Schizophrenia bulletin, 2012, Volume: 38, Issue:5

    Topics: Animals; Antipsychotic Agents; Aripiprazole; Corpus Striatum; Dopamine D2 Receptor Antagonists; Dopamine Uptake Inhibitors; Haloperidol; Long-Term Care; Male; Methamphetamine; Motor Activity; Piperazines; Psychoses, Substance-Induced; Quinolones; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Schizophrenia

2012
Placental transfer of aripiprazole.
    The Australian and New Zealand journal of psychiatry, 2011, Volume: 45, Issue:6

    Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Maternal-Fetal Exchange; Piperazines; Pregnancy; Quinolones; Schizophrenia

2011
Add-on of aripiprazole improves outcome in clozapine-resistant schizophrenia.
    Progress in neuro-psychopharmacology & biological psychiatry, 2011, Jun-01, Volume: 35, Issue:4

    Topics: Activities of Daily Living; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Clozapine; Dose-Response Relationship, Drug; Drug Resistance; Female; Humans; Linear Models; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Social Behavior; Treatment Outcome; Young Adult

2011
Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia.
    Psychological medicine, 2011, Volume: 41, Issue:11

    Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Comorbidity; Female; Germany; Humans; Male; Matched-Pair Analysis; Obsessive-Compulsive Disorder; Olanzapine; Piperazines; Prevalence; Quinolones; Schizophrenia; Serotonin Antagonists; Severity of Illness Index; Sulpiride

2011
The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone.
    Progress in neuro-psychopharmacology & biological psychiatry, 2011, Jul-01, Volume: 35, Issue:5

    Topics: Adult; Age Factors; Antipsychotic Agents; Aripiprazole; Asian People; Benzodiazepines; Cohort Studies; Databases, Factual; Female; Hospitals, University; Humans; Male; Medical Records; Metabolic Syndrome; Middle Aged; Olanzapine; Piperazines; Quinolones; Republic of Korea; Retrospective Studies; Risperidone; Schizophrenia; Sex Factors; Young Adult

2011
Influence of prenatal undernutrition on the effects of clozapine and aripiprazole in the adult male rats: relevance to a neurodevelopmental origin of schizophrenia?
    European journal of pharmacology, 2011, Sep-30, Volume: 667, Issue:1-3

    Topics: Animals; Antipsychotic Agents; Aripiprazole; Body Weight; Clozapine; Disease Susceptibility; Eating; Female; Gene Expression Regulation; Hormones; Hypothalamus; Male; Malnutrition; Nervous System; Obesity; Piperazines; Pregnancy; Prenatal Nutritional Physiological Phenomena; Quinolones; Rats; Rats, Wistar; Schizophrenia

2011
Calculating occupancy when one does not have baseline: a comparison of different options.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2011, Volume: 31, Issue:8

    Topics: Adult; Alkaloids; Antipsychotic Agents; Aripiprazole; Humans; Male; Methods; Piperazines; Positron-Emission Tomography; Protein Binding; Quinolones; Receptors, Dopamine D2; Reproducibility of Results; Schizophrenia; Young Adult

2011
Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.
    The Journal of clinical psychiatry, 2011, Volume: 72, Issue:4

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Clozapine; Crime; Delayed-Action Preparations; Dibenzothiazepines; Female; Florida; Humans; Isoxazoles; Male; Medicaid; Middle Aged; Olanzapine; Outpatients; Paliperidone Palmitate; Piperazines; Propensity Score; Pyrimidines; Quetiapine Fumarate; Quinolones; Risk Factors; Risperidone; Schizophrenia; Treatment Outcome; United States; Young Adult

2011
Perinatal use of aripiprazole: a case report.
    Journal of clinical psychopharmacology, 2011, Volume: 31, Issue:3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Fetal Blood; Humans; Maternal-Fetal Exchange; Milk, Human; Piperazines; Postnatal Care; Pregnancy; Prenatal Care; Quinolones; Schizophrenia

2011
Comment on "dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia".
    Journal of clinical psychopharmacology, 2011, Volume: 31, Issue:3

    Topics: Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Piperazines; Quinolones; Risperidone; Schizophrenia

2011
High dosage of aripiprazole-induced dysphagia.
    The International journal of eating disorders, 2012, Volume: 45, Issue:2

    Topics: Antipsychotic Agents; Aripiprazole; Deglutition Disorders; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Treatment Outcome

2012
Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder.
    Acta psychiatrica Scandinavica, 2011, Volume: 124, Issue:3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Coronary Disease; Costs and Cost Analysis; Female; Humans; Male; Metabolic Diseases; Metabolism; Middle Aged; Olanzapine; Piperazines; Quality-Adjusted Life Years; Quinolones; Risk Assessment; Schizophrenia; Sweden

2011
Combination loxapine and aripiprazole for refractory hallucinations in schizophrenia.
    The Annals of pharmacotherapy, 2011, Volume: 45, Issue:7-8

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Hallucinations; Humans; Loxapine; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome

2011
Aripiprazole-related body-weight gain and nutritional counseling.
    The Journal of neuropsychiatry and clinical neurosciences, 2011,Spring, Volume: 23, Issue:2

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Piperazines; Quinolones; Schizophrenia; Weight Gain

2011
Changes in the metabolic parameters and QTc interval after switching from olanzapine to aripiprazole in Japanese patients with stable schizophrenia.
    Journal of clinical psychopharmacology, 2011, Volume: 31, Issue:4

    Topics: Adolescent; Adult; Aripiprazole; Asian People; Benzodiazepines; Drug Substitution; Female; Heart Rate; Humans; Male; Middle Aged; Olanzapine; Piperazines; Quinolones; Schizophrenia; Young Adult

2011
A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden.
    Nordic journal of psychiatry, 2011, Volume: 65, Issue:6

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cost-Benefit Analysis; Economics, Pharmaceutical; Female; Haloperidol; Humans; Imidazoles; Indoles; Male; Models, Economic; National Health Programs; Olanzapine; Piperazines; Quinolones; Risperidone; Schizophrenia; Sweden

2011
Pathological gambling and the treatment of psychosis with aripiprazole: case reports.
    The British journal of psychiatry : the journal of mental science, 2011, Volume: 199, Issue:2

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Disruptive, Impulse Control, and Conduct Disorders; Gambling; Humans; Male; Piperazines; Quinolones; Recurrence; Schizophrenia

2011
Aripiprazole induced transient myopia: a case report and review of literature.
    Cutaneous and ocular toxicology, 2012, Volume: 31, Issue:1

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Myopia; Piperazines; Quinolones; Schizophrenia

2012
Granulomatous cutaneous lesions associated with risperidone-induced hyperprolactinemia in an amputated upper limb.
    International journal of dermatology, 2012, Volume: 51, Issue:1

    Topics: Amputation Stumps; Antipsychotic Agents; Aripiprazole; Forearm; Granuloma; Humans; Hyperprolactinemia; Male; Middle Aged; Piperazines; Quinolones; Risperidone; Schizophrenia; Skin Diseases; Treatment Outcome

2012
Neurobehavioral and genotoxic parameters of antipsychotic agent aripiprazole in mice.
    Acta pharmacologica Sinica, 2011, Volume: 32, Issue:10

    Topics: Animals; Antipsychotic Agents; Aripiprazole; Avoidance Learning; Behavior, Animal; Brain; Comet Assay; Humans; Lipid Peroxidation; Male; Mice; Micronucleus Tests; Mutagens; Piperazines; Quinolones; Schizophrenia

2011
[Clinical characteristics of cannabis-induced schizophrenia spectrum disorder].
    Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2011, Volume: 13, Issue:3

    Topics: Adolescent; Adult; Aggression; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Hallucinations; Haloperidol; Humans; Hungary; Male; Marijuana Abuse; Olanzapine; Paranoid Disorders; Piperazines; Psychomotor Performance; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risperidone; Schizophrenia; Schizophrenic Psychology

2011
Switching antipsychotic medications: not enough, too often, or just right?
    The American journal of psychiatry, 2011, Volume: 168, Issue:9

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Drug Substitution; Humans; Hypercholesterolemia; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia

2011
Effects of antipsychotic drugs on BDNF, GSK-3β, and β-catenin expression in rats subjected to immobilization stress.
    Neuroscience research, 2011, Volume: 71, Issue:4

    Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; beta Catenin; Blotting, Western; Brain-Derived Neurotrophic Factor; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Haloperidol; Hippocampus; Male; Olanzapine; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Restraint, Physical; Schizophrenia; Stress, Psychological

2011
Confounding by indication of a specific antipsychotic and the increase of body mass index among children and adolescents.
    European child & adolescent psychiatry, 2011, Volume: 20, Issue:11-12

    Topics: Adolescent; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Benzodiazepines; Bipolar Disorder; Body Mass Index; Body Weight; Child; Dibenzothiazepines; Female; Follow-Up Studies; Humans; Male; Mental Disorders; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Spain; Time Factors

2011
Improvement of oral dyskinesia after switching from aripiprazole to paliperidone: a case report.
    The Journal of neuropsychiatry and clinical neurosciences, 2011,Summer, Volume: 23, Issue:3

    Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Isoxazoles; Movement Disorders; Paliperidone Palmitate; Piperazines; Pyrimidines; Quinolones; Schizophrenia

2011
Aripiprazole-associated rhabdomyolysis in a patient with schizophrenia.
    The Journal of neuropsychiatry and clinical neurosciences, 2011,Summer, Volume: 23, Issue:3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Piperazines; Quinolones; Rhabdomyolysis; Schizophrenia; Taiwan

2011
Manic induction with interferon alpha therapy.
    The Australian and New Zealand journal of psychiatry, 2011, Volume: 45, Issue:11

    Topics: Adult; Antipsychotic Agents; Antiviral Agents; Aripiprazole; Bipolar Disorder; Hepatitis C; Humans; Interferon-alpha; Male; Piperazines; Quinolones; Schizophrenia

2011
Cerebral blood flow changes in very-late-onset schizophrenia-like psychosis with catatonia before and after successful treatment.
    Psychiatry and clinical neurosciences, 2011, Volume: 65, Issue:6

    Topics: Antipsychotic Agents; Aripiprazole; Brain; Brain Mapping; Catatonia; Cerebrovascular Circulation; Female; Haloperidol; Humans; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Tomography, Emission-Computed, Single-Photon; Treatment Outcome

2011
Intermittent aripiprazole for schizophrenia.
    Schizophrenia research, 2012, Volume: 134, Issue:2-3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Retrospective Studies; Schizophrenia

2012
The impact of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) on prescribing practices: an analysis of data from a large midwestern state.
    The Journal of clinical psychiatry, 2012, Volume: 73, Issue:4

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chi-Square Distribution; Clozapine; Dibenzothiazepines; Humans; Missouri; Olanzapine; Piperazines; Practice Patterns, Physicians'; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome

2012
Aripiprazole may be free from tachyphylaxis: preliminary findings.
    Psychiatry and clinical neurosciences, 2012, Volume: 66, Issue:2

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Tachyphylaxis; Treatment Outcome

2012
Hypogonadism due to hyperprolactinemia and subsequent first episode of psychosis.
    Gender medicine, 2012, Volume: 9, Issue:1

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Cabergoline; Ergolines; Humans; Hyperprolactinemia; Hypogonadism; Male; Obesity, Morbid; Piperazines; Pituitary Neoplasms; Prolactin; Prolactinoma; Psychotic Disorders; Quinolones; Schizophrenia

2012
Fluoxetine and aripiprazole treatment following prenatal immune activation exert longstanding effects on rat locomotor response.
    Physiology & behavior, 2012, May-15, Volume: 106, Issue:2

    Topics: Acute-Phase Reaction; Amphetamine; Animals; Antipsychotic Agents; Aripiprazole; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Fluoxetine; Immune System; Male; Motor Activity; Piperazines; Poly I-C; Pregnancy; Prenatal Exposure Delayed Effects; Quinolones; Rats; Rats, Sprague-Dawley; Schizophrenia; Selective Serotonin Reuptake Inhibitors

2012
Tardive laryngeal dystonia associated with aripiprazole monotherapy.
    Journal of clinical psychopharmacology, 2012, Volume: 32, Issue:2

    Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Laryngeal Diseases; Movement Disorders; Piperazines; Quinolones; Schizophrenia; Young Adult

2012
Changes in sexual function and gonadal axis hormones after switching to aripiprazole in male schizophrenia patients: a prospective pilot study.
    International clinical psychopharmacology, 2012, Volume: 27, Issue:4

    Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Estradiol; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Male; Middle Aged; Olanzapine; Pilot Projects; Piperazines; Prolactin; Prospective Studies; Quinolones; Retreatment; Risperidone; Schizophrenia; Sex Hormone-Binding Globulin; Sexual Dysfunction, Physiological; Sexual Dysfunctions, Psychological; Sulpiride; Testosterone

2012
Hyperhidrosis under combination of zotepine and haloperidol alleviated by aripiprazole.
    Psychiatry and clinical neurosciences, 2012, Volume: 66, Issue:3

    Topics: Antipsychotic Agents; Aripiprazole; Diabetes Complications; Dibenzothiepins; Dopamine; Drug Interactions; Female; Haloperidol; Humans; Hyperhidrosis; Middle Aged; Piperazines; Quinolones; Schizophrenia

2012
The cognitive profile of aripiprazole differs from that of other atypical antipsychotics in schizophrenia patients.
    Journal of psychiatric research, 2012, Volume: 46, Issue:6

    Topics: Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Dose-Response Relationship, Drug; Female; Humans; Japan; Male; Middle Aged; Neuropsychological Tests; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Statistics as Topic; Treatment Outcome; Young Adult

2012
Effects of drop-out on efficacy estimates in five Cochrane reviews of popular antipsychotics for schizophrenia.
    Acta psychiatrica Scandinavica, 2012, Volume: 126, Issue:1

    Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Data Interpretation, Statistical; Dibenzothiazepines; Humans; Olanzapine; Patient Dropouts; Piperazines; Quetiapine Fumarate; Quinolones; Review Literature as Topic; Risperidone; Schizophrenia; Sulpiride

2012
Hyperprolactinaemia on depot risperidone treated with aripiprazole.
    The Australian and New Zealand journal of psychiatry, 2012, Volume: 46, Issue:8

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Drug Monitoring; Drug Substitution; Female; Humans; Hyperprolactinemia; Medication Therapy Management; Pharmacovigilance; Piperazines; Quinolones; Risperidone; Schizophrenia; Treatment Outcome

2012
Upregulation of adenosine A2A receptors induced by atypical antipsychotics and its correlation with sensory gating in schizophrenia patients.
    Psychiatry research, 2012, Dec-30, Volume: 200, Issue:2-3

    Topics: Acoustic Stimulation; Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Auditory Cortex; Benzodiazepines; Dibenzothiazepines; Electroencephalography; Evoked Potentials, Auditory; Female; Humans; Male; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Reaction Time; Receptor, Adenosine A2A; Risperidone; Schizophrenia; Sensory Gating; Up-Regulation

2012
Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge: a retrospective cohort study.
    BMC psychiatry, 2012, Aug-02, Volume: 12

    Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Databases, Factual; Dibenzothiazepines; Female; Humans; Male; Medication Adherence; Patient Discharge; Piperazines; Quetiapine Fumarate; Quinolones; Retrospective Studies; Schizophrenia; Thiazoles

2012
Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia.
    Journal of clinical psychopharmacology, 2012, Volume: 32, Issue:5

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Clozapine; Cohort Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Olanzapine; Piperazines; Prospective Studies; Quinolones; Risperidone; Schizophrenia; Weight Loss

2012
[Dysphagia or dysphagias during neuroleptic medication?].
    L'Encephale, 2012, Volume: 38, Issue:4

    Topics: Adult; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Clonazepam; Deglutition Disorders; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Substitution; Drug Therapy, Combination; Homicide; Humans; Ill-Housed Persons; Loxapine; Male; Mental Disorders; Piperazines; Quinolones; Risk Factors; Schizophrenia; Schizophrenic Psychology

2012
Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia.
    Psychiatry and clinical neurosciences, 2012, Volume: 66, Issue:6

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Cytochrome P-450 CYP2D6; Diagnostic and Statistical Manual of Mental Disorders; DNA; Drug Interactions; Female; Genotype; Humans; Japan; Luminescence; Male; Middle Aged; Piperazines; Polymerase Chain Reaction; Polymorphism, Genetic; Postmenopause; Prolactin; Quinolones; Receptors, Dopamine D2; Regression Analysis; Schizophrenia; Sex Characteristics

2012
Daily dose of 105 mg aripiprazole because of delusional origin: a case report.
    Psychiatria Danubina, 2012, Volume: 24, Issue:4

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Delusions; Drug Overdose; Female; Humans; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Self Medication

2012
Aripiprazole augmentation for clozapine-associated tardive torticollis.
    The Journal of neuropsychiatry and clinical neurosciences, 2012,Fall, Volume: 24, Issue:4

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Female; Humans; Piperazines; Quinolones; Schizophrenia; Torticollis; Treatment Outcome

2012
Effects of aripiprazole, risperidone, and olanzapine on 5-HT1A receptors in patients with schizophrenia.
    Journal of clinical psychopharmacology, 2013, Volume: 33, Issue:1

    Topics: Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Case-Control Studies; Cerebral Cortex; Drug Partial Agonism; Female; Humans; Magnetic Resonance Imaging; Male; Olanzapine; Piperazines; Positron-Emission Tomography; Pyridines; Quinolones; Radiopharmaceuticals; Receptor, Serotonin, 5-HT1A; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Young Adult

2013
Effect of aripiprazole on mismatch negativity (MMN) in schizophrenia.
    PloS one, 2013, Volume: 8, Issue:1

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Brain; Cognition; Electroencephalography; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Young Adult

2013
Consensus statement on the use of intramuscular aripiprazole for the rapid control of agitation in bipolar mania and schizophrenia.
    Current medical research and opinion, 2013, Volume: 29, Issue:3

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Haloperidol; Humans; Hypnotics and Sedatives; Olanzapine; Piperazines; Psychomotor Agitation; Quinolones; Schizophrenia; Tranquilizing Agents

2013
Metabolic syndrome and antipsychotic monotherapy treatment among schizophrenia patients in Malaysia.
    Preventive medicine, 2013, Volume: 57 Suppl

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Cross-Sectional Studies; Female; Flupenthixol; Humans; Malaysia; Male; Metabolic Syndrome; Middle Aged; Piperazines; Quinolones; Schizophrenia; Trifluoperazine; Waist Circumference; Young Adult

2013
Mismatch negativity and cognitive performance for the prediction of psychosis in subjects with at-risk mental state.
    PloS one, 2013, Volume: 8, Issue:1

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Electroencephalography; Evoked Potentials; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Piperazines; Psychotic Disorders; Quinolones; Risk Factors; Risperidone; Schizophrenia; Schizophrenic Psychology; Sulpiride; Young Adult

2013
Torsades de pointes after administration of low-dose aripiprazole.
    The Annals of pharmacotherapy, 2013, Volume: 47, Issue:2

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Diabetes Complications; Drug Monitoring; Heart Arrest; Humans; Hypertension; Male; Piperazines; Quinolones; Risk Factors; Schizophrenia; Stroke; Torsades de Pointes; Treatment Outcome

2013
Aripiprazole (Abilify) for schizophrenia.
    The Medical letter on drugs and therapeutics, 2003, Feb-17, Volume: 45, Issue:1150

    Topics: Antipsychotic Agents; Anxiety; Aripiprazole; Dopamine Agonists; Drug Interactions; Fees, Pharmaceutical; Humans; Intestinal Absorption; Nausea; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Therapeutic Equivalency

2003
Aripiprazole. The newest antipsychotic agent for treatment of schizophrenia.
    Journal of psychosocial nursing and mental health services, 2003, Volume: 41, Issue:2

    Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Schizophrenia

2003
Aripiprazole: does partial dopaminergic agonism translate into clinical benefits?
    The Annals of pharmacotherapy, 2003, Volume: 37, Issue:5

    Topics: Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Humans; Piperazines; Quinolones; Schizophrenia

2003
Aripiprazole.
    Nature reviews. Drug discovery, 2003, Volume: 2, Issue:6

    Topics: Animals; Aripiprazole; Clinical Trials as Topic; Humans; Patents as Topic; Piperazines; Quinolones; Schizophrenia

2003
Aripiprazole and extrapyramidal symptoms.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2003, Volume: 42, Issue:11

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Female; Humans; Piperazines; Quinolones; Schizophrenia

2003
Similarities and differences among antipsychotics.
    The Journal of clinical psychiatry, 2003, Volume: 64 Suppl 17

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Haloperidol; Humans; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles

2003
Aripiprazole.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2003, Dec-01, Volume: 60, Issue:23

    Topics: Antipsychotic Agents; Aripiprazole; Biological Availability; Drug Interactions; Humans; Piperazines; Quinolones; Schizophrenia; Treatment Outcome; United States

2003
Medication developments in the treatment of mental illness.
    Behavioral healthcare tomorrow, 2003, Volume: 12, Issue:6

    Topics: Adolescent; Aged; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Blood Glucose; Child; Depressive Disorder; Humans; Mental Disorders; Piperazines; Primary Health Care; Quinolones; Schizophrenia; Selective Serotonin Reuptake Inhibitors

2003
Worsened agitation with aripiprazole: adverse effect of dopamine partial agonism?
    The Journal of clinical psychiatry, 2004, Volume: 65, Issue:1

    Topics: Anger; Antipsychotic Agents; Aripiprazole; Chronic Disease; Humans; Male; Middle Aged; Paranoid Disorders; Piperazines; Psychomotor Agitation; Quinolones; Schizophrenia

2004
Aripirazole-olanzapine combination for treatment of schizophrenia.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2004, Volume: 49, Issue:2

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Drug Therapy, Combination; Female; Humans; Middle Aged; Olanzapine; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Treatment Outcome

2004
European College of Neuropsychopharmacology - 16th Congress. 20-24 September 2003, Prague, Czech Republic.
    IDrugs : the investigational drugs journal, 2003, Volume: 6, Issue:11

    Topics: alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Anxiety; Aripiprazole; Dopamine Antagonists; Humans; Nicotinic Agonists; Piperazines; Psychotropic Drugs; Quinolones; Receptors, Metabotropic Glutamate; Receptors, Nicotinic; Schizophrenia

2003
[Expectations and developments in atypical antipsychotics].
    Praxis, 2004, Aug-25, Volume: 93, Issue:35

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Clozapine; Diabetes Complications; Haloperidol; Humans; Obesity; Olanzapine; Piperazines; Quinolones; Risk Factors; Schizophrenia; Weight Gain

2004
Aripiprazole: novelty, adherence and understatement.
    The international journal of neuropsychopharmacology, 2005, Volume: 8, Issue:1

    Topics: Antipsychotic Agents; Aripiprazole; Haloperidol; Humans; Patient Compliance; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Therapeutic Equivalency

2005
Atypical antipsychotics: matching receptor profile to individual patient's clinical profile.
    CNS spectrums, 2004, Volume: 9, Issue:10 Suppl 1

    Topics: Adult; Affect; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Cognition; Dibenzothiazepines; Dose-Response Relationship, Drug; Histamine; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Receptors, Muscarinic; Receptors, Serotonin; Risperidone; Schizophrenia; Thiazoles

2004
Aripiprazole and neuroleptic malignant syndrome.
    International clinical psychopharmacology, 2004, Volume: 19, Issue:6

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Humans; Lorazepam; Male; Neuroleptic Malignant Syndrome; Piperazines; Quinolones; Schizophrenia

2004
[Expectation and development of atypical antipsychotic drugs].
    Therapeutische Umschau. Revue therapeutique, 2004, Volume: 61, Issue:9

    Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology

2004
Dopamine receptor downregulation: an alternative strategy for schizophrenia treatment.
    Medical hypotheses, 2004, Volume: 63, Issue:6

    Topics: Animals; Antipsychotic Agents; Aripiprazole; Brain; Dopamine Antagonists; Down-Regulation; Humans; Models, Neurological; Piperazines; Quinolones; Receptors, Dopamine; Schizophrenia; Treatment Outcome

2004
Clinical experience with aripiprazole treatment in ten elderly patients with schizophrenia or schizoaffective disorder: retrospective case studies.
    CNS spectrums, 2004, Volume: 9, Issue:11

    Topics: Aged; Antipsychotic Agents; Aripiprazole; Case-Control Studies; Female; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Retrospective Studies; Schizophrenia

2004
Pharmacokinetics of aripiprazole and concomitant lithium and valproate.
    Journal of clinical pharmacology, 2005, Volume: 45, Issue:1

    Topics: Adult; Aripiprazole; Drug Therapy, Combination; Humans; Lithium; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Valproic Acid

2005
Partial agonists in schizophrenia.
    The British journal of psychiatry : the journal of mental science, 2005, Volume: 186

    Topics: Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia; Up-Regulation

2005
Aripiprazole in schizophrenia: consensus guidelines.
    International journal of clinical practice, 2005, Volume: 59, Issue:4

    Topics: Antipsychotic Agents; Aripiprazole; Consensus; Drug Interactions; Heart Diseases; Humans; Hypertension; Mental Disorders; Metabolic Diseases; Patient Compliance; Piperazines; Quinolones; Schizophrenia; Treatment Outcome

2005
Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation.
    Brain research, 2005, May-10, Volume: 1043, Issue:1-2

    Topics: Aminopyridines; Animals; Antipsychotic Agents; Aripiprazole; Clozapine; Corpus Striatum; Disease Models, Animal; Excitatory Amino Acid Agonists; Haloperidol; Kainic Acid; Male; Mice; Mice, Inbred C57BL; Piperazines; Piperidines; Pyridines; Quinolones; Receptor, Serotonin, 5-HT1A; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists; Thiazoles

2005
[Combining effectiveness and tolerance].
    Krankenpflege Journal, 2005, Volume: 43, Issue:1-3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Female; Humans; Long-Term Care; Patient Compliance; Physician-Patient Relations; Piperazines; Prognosis; Quality of Life; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome

2005
An African patient with ziprasidone intolerance.
    The Journal of clinical psychiatry, 2005, Volume: 66, Issue:6

    Topics: Africa; Antipsychotic Agents; Aripiprazole; Dystonia; Ethnicity; Germany; Humans; Male; Middle Aged; Pharmacogenetics; Piperazines; Quinolones; Schizophrenia; Thiazoles; Treatment Outcome

2005
[Aripiprazole in the treatment of schizophrenia].
    Praxis, 2005, Jun-08, Volume: 94, Issue:23

    Topics: Antipsychotic Agents; Aripiprazole; Brain; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia; Schizophrenic Psychology; Treatment Outcome

2005
Aripiprazole: initial clinical experience with 142 hospitalized psychiatric patients.
    Journal of psychiatric practice, 2005, Volume: 11, Issue:4

    Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hospitalization; Humans; Male; Mathematical Computing; Middle Aged; Obesity; Piperazines; Product Surveillance, Postmarketing; Psychotic Disorders; Quinolones; Receptors, Dopamine D2; Schizophrenia; Treatment Outcome

2005
Reversal of symptomatic hyperprolactinemia by aripiprazole.
    The American journal of psychiatry, 2005, Volume: 162, Issue:8

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Injections, Intramuscular; Piperazines; Quinolones; Risperidone; Schizophrenia; Treatment Outcome

2005
8-Substituted 3,4-dihydroquinolinones as a novel scaffold for atypical antipsychotic activity.
    Bioorganic & medicinal chemistry letters, 2005, Oct-15, Volume: 15, Issue:20

    Topics: Antipsychotic Agents; Humans; Quinolones; Schizophrenia

2005
['Awakening': a confusing improvement during treatment with atypical antipsychotic agents].
    Nederlands tijdschrift voor geneeskunde, 2005, Jul-30, Volume: 149, Issue:31

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Cognition; Female; Humans; Piperazines; Quality of Life; Quinolones; Risperidone; Schizophrenia; Treatment Outcome

2005
Therapeutic monitoring of aripiprazole by HPLC with column-switching and spectrophotometric detection.
    Clinical chemistry, 2005, Volume: 51, Issue:9

    Topics: Antipsychotic Agents; Aripiprazole; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Piperazines; Quinolones; Schizophrenia; Spectrophotometry, Ultraviolet

2005
Diabetic ketoacidosis associated with aripiprazole.
    Diabetic medicine : a journal of the British Diabetic Association, 2005, Volume: 22, Issue:10

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Diabetic Ketoacidosis; Female; Humans; Infusions, Intravenous; Insulin; Insulin, Isophane; Piperazines; Quinolones; Schizophrenia; Treatment Outcome

2005
Second generation antipsychotics--aripiprazole revisited.
    The Medical letter on drugs and therapeutics, 2005, Oct-10, Volume: 47, Issue:1219

    Topics: Antipsychotic Agents; Aripiprazole; Costs and Cost Analysis; Economics, Pharmaceutical; Humans; Piperazines; Quinolones; Schizophrenia; Weight Gain

2005
Aripiprazole: new drug. Just another neuroleptic.
    Prescrire international, 2005, Volume: 14, Issue:79

    Topics: Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Drugs, Investigational; Haloperidol; Humans; Piperazines; Quinolones; Schizophrenia; Treatment Outcome

2005
The patient with schizophrenia taking aripiprazole: case report.
    Psychiatria Danubina, 2005, Volume: 17, Issue:3-4

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Approval; Humans; Male; Outcome Assessment, Health Care; Patient Participation; Piperazines; Quality of Life; Quinolones; Schizophrenia

2005
A case of Aripiprazole and extra pyramidal side effects.
    Journal of psychopharmacology (Oxford, England), 2006, Volume: 20, Issue:4

    Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Female; Humans; Middle Aged; Piperazines; Quinolones; Schizophrenia

2006
Aripiprazole as a dopamine partial agonist: positive and negative effects.
    Journal of clinical psychopharmacology, 2006, Volume: 26, Issue:1

    Topics: Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Female; Humans; Male; Middle Aged; Paranoid Disorders; Piperazines; Quinolones; Receptor, Serotonin, 5-HT1A; Schizophrenia; Serotonin 5-HT2 Receptor Antagonists

2006
Improvement or worsening of psychotic symptoms after treatment with low doses of aripiprazole.
    The international journal of neuropsychopharmacology, 2007, Volume: 10, Issue:1

    Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Male; Middle Aged; Piperazines; Psychoses, Substance-Induced; Psychotic Disorders; Quinolones; Schizophrenia; Serotonin Agents; Treatment Outcome

2007
[No rebound psychosis in a case of switching from clozapine to quetiapine].
    Psychiatrische Praxis, 2006, Volume: 33, Issue:2

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Brain; Brief Psychiatric Rating Scale; Clozapine; Dibenzothiazepines; Drug Therapy, Combination; Humans; Male; Piperazines; Quetiapine Fumarate; Quinolones; Receptors, Dopamine D2; Schizophrenia; Secondary Prevention; Substance Withdrawal Syndrome; Treatment Outcome

2006
Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia.
    Pharmacopsychiatry, 2006, Volume: 39 Suppl 1

    Topics: Antipsychotic Agents; Aripiprazole; Cerebral Cortex; Corpus Striatum; Dopamine Agonists; Humans; Limbic System; Mesencephalon; Neural Pathways; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia; Schizophrenic Psychology; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome

2006
Extensive weight loss in a patient with schizophrenia after switching from olanzapine to aripiprazole. A case report.
    Pharmacopsychiatry, 2006, Volume: 39, Issue:2

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Diagnostic and Statistical Manual of Mental Disorders; Drug Therapy, Combination; Female; Humans; Male; Olanzapine; Piperazines; Quinolones; Schizophrenia; Weight Loss

2006
Three cases of risperidone-induced enuresis.
    Schizophrenia research, 2006, Volume: 84, Issue:1

    Topics: Aripiprazole; Enuresis; Female; Humans; Middle Aged; Piperazines; Quinolones; Risperidone; Schizophrenia

2006
Clozapine augmentation with aripiprazole for negative symptoms.
    The Journal of clinical psychiatry, 2006, Volume: 67, Issue:4

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenia, Paranoid; Schizophrenic Psychology; Treatment Outcome

2006
High-dose aripiprazole in treatment-resistant schizophrenia.
    The Journal of clinical psychiatry, 2006, Volume: 67, Issue:4

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Female; Humans; Piperazines; Quinolones; Schizophrenia; Treatment Outcome

2006
Aripiprazole and the neuroleptic malignant syndrome.
    Schizophrenia research, 2006, Volume: 85, Issue:1-3

    Topics: Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Humans; Neuroleptic Malignant Syndrome; Piperazines; Quinolones; Schizophrenia

2006
Elevated lipase and diabetic ketoacidosis associated with aripiprazole.
    JOP : Journal of the pancreas, 2006, May-09, Volume: 7, Issue:3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Diabetic Ketoacidosis; Humans; Lipase; Male; Piperazines; Quinolones; Schizophrenia; Weight Gain

2006
[Pharmacology of antipsychotic drugs]].
    L'Encephale, 2006, Volume: 32 Pt 2

    Topics: Adrenergic alpha-1 Receptor Antagonists; Antipsychotic Agents; Aripiprazole; Brain; Brain Mapping; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Humans; Norepinephrine; Piperazines; Quinolones; Receptors, Adrenergic, alpha-1; Receptors, Dopamine D2; Schizophrenia; Schizophrenic Psychology

2006
Behavioral and biochemical characterization of a mutant mouse strain lacking D-amino acid oxidase activity and its implications for schizophrenia.
    Molecular and cellular neurosciences, 2006, Volume: 32, Issue:4

    Topics: Acoustic Stimulation; Animals; Brain Chemistry; Cyclic GMP; D-Amino-Acid Oxidase; Disease Models, Animal; Dose-Response Relationship, Radiation; Excitatory Amino Acid Antagonists; Extremities; Female; Male; Mice; Mice, Inbred Strains; Mice, Knockout; Motor Activity; Neural Inhibition; Neurologic Examination; Phencyclidine; Psychomotor Performance; Quinolones; Reaction Time; Reflex, Startle; Schizophrenia; Sex Factors; Swimming

2006
Aripiprazole-associated seizure.
    The Journal of clinical psychiatry, 2006, Volume: 67, Issue:6

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Piperazines; Quinolones; Schizophrenia; Seizures

2006
A case of dose-dependent aripiprazole-induced conduction disturbance.
    Journal of clinical psychopharmacology, 2006, Volume: 26, Issue:4

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Bundle-Branch Block; Dose-Response Relationship, Drug; Female; Humans; Piperazines; Quinolones; Schizophrenia

2006
Tolerability of high-dose aripiprazole in treatment-refractory schizophrenic patients.
    The Journal of clinical psychiatry, 2006, Volume: 67, Issue:7

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Hospitalization; Humans; Length of Stay; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Treatment Outcome

2006
Aripiprazole use in individuals with intellectual disability and psychotic or behavioural disorders: a case series.
    Journal of psychopharmacology (Oxford, England), 2006, Volume: 20, Issue:6

    Topics: Adolescent; Aged; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Female; Humans; Intellectual Disability; Male; Mental Disorders; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenia, Paranoid

2006
A model of anticholinergic activity of atypical antipsychotic medications.
    Schizophrenia research, 2006, Volume: 88, Issue:1-3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Binding Sites; Clozapine; Cognition Disorders; Dibenzothiazepines; Dose-Response Relationship, Drug; Female; Humans; Male; Neuropsychological Tests; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Receptors, Cholinergic; Risperidone; Schizophrenia; Thiazoles

2006
A case series: evaluation of the metabolic safety of aripiprazole.
    Schizophrenia bulletin, 2007, Volume: 33, Issue:3

    Topics: Adult; Anthropometry; Antipsychotic Agents; Aripiprazole; Belgium; Cohort Studies; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Follow-Up Studies; Glucose Tolerance Test; Humans; Insulin Resistance; Lipids; Male; Mass Screening; Metabolic Syndrome; Middle Aged; Piperazines; Prospective Studies; Quinolones; Schizophrenia; Sex Factors; Treatment Outcome

2007
Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazole.
    The international journal of neuropsychopharmacology, 2007, Volume: 10, Issue:1

    Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Dopamine Antagonists; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Middle Aged; Piperazines; Quinolones; Schizophrenia; Sulpiride; Treatment Failure

2007
Aripiprazole in chronic schizophrenia: experiences in daily practice.
    Acta psychiatrica Scandinavica, 2006, Volume: 114, Issue:4

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Chronic Disease; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia; Time Factors

2006
Atypical neuroleptic malignant syndrome associated with aripiprazole.
    Journal of clinical psychopharmacology, 2006, Volume: 26, Issue:5

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Neuroleptic Malignant Syndrome; Piperazines; Quinolones; Schizophrenia

2006
Reversibility of antipsychotic treatment-related diabetes in patients with schizophrenia: a case series of switching to aripiprazole.
    Diabetes care, 2006, Volume: 29, Issue:10

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Diabetes Mellitus; Humans; Middle Aged; Piperazines; Quinolones; Schizophrenia

2006
Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia?
    Journal of psychopharmacology (Oxford, England), 2007, Volume: 21, Issue:4

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Weight; Cholesterol; Clozapine; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Quinolones; Retrospective Studies; Schizophrenia; Schizophrenic Psychology

2007
Does antipsychotic polypharmacy increase the risk for metabolic syndrome?
    Schizophrenia research, 2007, Volume: 89, Issue:1-3

    Topics: Adult; Age Factors; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Mass Index; Cholesterol, HDL; Clozapine; Cross-Sectional Studies; Dibenzothiazepines; Drug Therapy, Combination; Female; Humans; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Piperazines; Quetiapine Fumarate; Quinolones; Risk Factors; Schizophrenia; Thiazoles; Triglycerides

2007
[Endocrine side effects among psychiatric patients treated with antipsychotics].
    Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2006, Volume: 8, Issue:2

    Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Breast; Dibenzothiazepines; Endocrine System; Female; Galactorrhea; Gynecomastia; Humans; Male; Olanzapine; Piperazines; Prolactin; Quetiapine Fumarate; Quinolones; Schizophrenia; Sulpiride

2006
In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling.
    Journal of psychopharmacology (Oxford, England), 2007, Volume: 21, Issue:6

    Topics: Animals; Antipsychotic Agents; Aripiprazole; Calcium Signaling; CHO Cells; Cloning, Molecular; Cricetinae; Cricetulus; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Immunoblotting; Lisuride; MAP Kinase Signaling System; Microscopy, Confocal; Mitogen-Activated Protein Kinase 1; Phosphorylation; Piperazines; Piperidines; Quinolones; Raclopride; Receptors, Dopamine D2; Schizophrenia; Time Factors; Transfection

2007
Urinary obstruction with citalopram and aripiprazole combination in an elderly patient.
    Journal of clinical psychopharmacology, 2006, Volume: 26, Issue:6

    Topics: Aged; Antipsychotic Agents; Aripiprazole; Citalopram; Drug Therapy, Combination; Humans; Male; Piperazines; Quinolones; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Urinary Retention

2006
Efficacy with high-dose aripiprazole after olanzapine-related metabolic disturbances.
    The Annals of pharmacotherapy, 2006, Volume: 40, Issue:12

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Humans; Male; Metabolic Diseases; Olanzapine; Piperazines; Quinolones; Schizophrenia; Weight Gain

2006
Aripiprazole augmentation of clozapine in treatment-resistant schizophrenia: a clinical observation.
    Clinical drug investigation, 2006, Volume: 26, Issue:3

    Topics: Adult; Aripiprazole; Clozapine; Dopamine D2 Receptor Antagonists; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia

2006
Aripiprazole in the treatment of schizophrenia: a consensus report produced by schizophrenia experts in Italy.
    Clinical drug investigation, 2007, Volume: 27, Issue:1

    Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Humans; Italy; Piperazines; Quinolones; Schizophrenia; Treatment Outcome

2007
Relapse rates in patients with schizophrenia receiving aripiprazole in comparison with other atypical antipsychotics.
    The Journal of clinical psychiatry, 2006, Volume: 67, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Cohort Studies; Female; Hospitalization; Humans; Male; Middle Aged; Piperazines; Quinolones; Recurrence; Retrospective Studies; Schizophrenia; Treatment Outcome

2006
Diagnostic and therapeutic challenges in narcolepsy-related psychosis.
    The Journal of clinical psychiatry, 2006, Volume: 67, Issue:11

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Diagnosis, Differential; Female; Hallucinations; Humans; Narcolepsy; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia

2006
Safety of aripiprazole: high serum levels in a CYP2D6 mutated patient.
    The American journal of psychiatry, 2007, Volume: 164, Issue:1

    Topics: Antipsychotic Agents; Aripiprazole; Cytochrome P-450 CYP2D6; Drug Monitoring; Female; Humans; Middle Aged; Mutation; Piperazines; Quinolones; Schizophrenia

2007
The atypical antipsychotic, aripiprazole, blocks phencyclidine-induced disruption of prepulse inhibition in mice.
    Psychopharmacology, 2007, Volume: 191, Issue:2

    Topics: Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Haloperidol; Male; Mice; Neural Inhibition; Olanzapine; Phencyclidine; Piperazines; Quinolones; Receptors, Dopamine D2; Reflex, Startle; Schizophrenia

2007
Aripiprazole-associated acute dystonia.
    The Journal of neuropsychiatry and clinical neurosciences, 2007,Winter, Volume: 19, Issue:1

    Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Drug Interactions; Dystonia; Female; Humans; Piperazines; Quinolones; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Sertraline

2007
Indexing of reports on aripiprazole augmentation of clozapine.
    The Journal of clinical psychiatry, 2007, Volume: 68, Issue:2

    Topics: Abstracting and Indexing; Antipsychotic Agents; Aripiprazole; Clozapine; Humans; Information Services; Information Storage and Retrieval; Piperazines; Quinolones; Schizophrenia

2007
Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart review.
    The Journal of clinical psychiatry, 2007, Volume: 68, Issue:3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Male; Middle Aged; Outpatients; Piperazines; Quinolones; Retrospective Studies; Schizophrenia; Weight Loss

2007
Successful monotherapy treatment with aripiprazole in a patient with schizophrenia and prolactinoma.
    Journal of psychiatric practice, 2007, Volume: 13, Issue:2

    Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Cabergoline; Clonazepam; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Follow-Up Studies; Humans; Patient Care Team; Piperazines; Pituitary Neoplasms; Prolactin; Prolactinoma; Quinolones; Schizophrenia

2007
Extrapyramidal side effects associated with aripiprazole administration in a schizophrenic patient.
    Pharmacopsychiatry, 2007, Volume: 40, Issue:2

    Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Humans; Male; Parkinsonian Disorders; Piperazines; Quinolones; Schizophrenia

2007
Concomitant use of lamotrigine and aripiprazole increases risk of Stevens-Johnson syndrome?
    International clinical psychopharmacology, 2007, Volume: 22, Issue:4

    Topics: Adult; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Female; Humans; Lamotrigine; Piperazines; Quinolones; Schizophrenia; Stevens-Johnson Syndrome; Triazines

2007
Intramuscular aripiprazole in the control of agitation.
    Journal of psychiatric practice, 2007, Volume: 13, Issue:3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Arousal; Bipolar Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Haloperidol; Humans; Hypnotics and Sedatives; Injections, Intramuscular; Lorazepam; Male; Middle Aged; Multicenter Studies as Topic; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Treatment Outcome

2007
Practical prescribing with aripiprazole in schizophrenia: consensus recommendations of a UK multidisciplinary panel.
    Current medical research and opinion, 2007, Volume: 23, Issue:7

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Middle Aged; Piperazines; Practice Guidelines as Topic; Quinolones; Schizophrenia; United Kingdom

2007
Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
    Schizophrenia research, 2008, Volume: 98, Issue:1-3

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Female; Follow-Up Studies; Humans; Male; Middle Aged; Patient Readmission; Piperazines; Proportional Hazards Models; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risk Factors; Risperidone; Schizophrenia; Schizophrenia, Paranoid; Schizophrenic Psychology; Sensitivity and Specificity; Substance Withdrawal Syndrome; Survival Rate; Thiazoles

2008
Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study.
    Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:4

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Humans; Insulin Resistance; Lipids; Lipoproteins; Male; Metabolism; Middle Aged; Pilot Projects; Piperazines; Quality of Life; Quinolones; Risk Factors; Schizophrenia; Schizophrenic Psychology; Weight Gain

2007
Acute pancreatitis and diabetic ketoacidosis in a schizophrenic patient taking olanzapine.
    Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:4

    Topics: Acute Disease; Acute Kidney Injury; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cocaine-Related Disorders; Diabetic Ketoacidosis; Humans; Male; Olanzapine; Pancreatitis; Piperazines; Quinolones; Schizophrenia

2007
Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912.
    European journal of pharmacology, 2007, Nov-28, Volume: 574, Issue:2-3

    Topics: Animals; Aripiprazole; Benzoxazoles; CHO Cells; Cricetinae; Cricetulus; Cyclic AMP; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Ergolines; Humans; Piperazines; Quinolones; Radioligand Assay; Receptors, Dopamine D2; Schizophrenia

2007
Aripiprazole: what is the role of dopamine D(2) receptor partial agonism?
    The American journal of psychiatry, 2007, Volume: 164, Issue:9

    Topics: Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Haloperidol; Humans; Hyperprolactinemia; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia; Serotonin 5-HT2 Receptor Antagonists; Synaptic Transmission

2007
Combined use of ECT with aripiprazole.
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2009, Volume: 10, Issue:4 Pt 3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Combined Modality Therapy; Diagnostic and Statistical Manual of Mental Disorders; Dopamine Agonists; Electroconvulsive Therapy; Hospitalization; Humans; Male; Piperazines; Quinolones; Schizophrenia

2009
Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects.
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2008, Volume: 9, Issue:3

    Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia

2008
Aripiprazole improves metabolic adversity in olanzapine-treated schizophrenic patients.
    Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:5

    Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Appetite; Aripiprazole; Benzodiazepines; Drug Therapy, Combination; Female; Humans; Male; Metabolic Diseases; Obesity; Olanzapine; Piperazines; Quinolones; Schizophrenia; Weight Gain

2007
Resolution of tardive dyskinesia after addition of aripiprazole to haloperidol depot.
    Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:5

    Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Haloperidol; Humans; Male; Middle Aged; Piperazines; Quinolones; Remission Induction; Schizophrenia; Substance-Related Disorders

2007
Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo.
    The Journal of clinical psychiatry, 2007, Volume: 68, Issue:10

    Topics: Acute Disease; Adult; Anthropometry; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cholesterol, HDL; Drug Administration Schedule; Female; Humans; Hyperlipidemias; Hypertension; Incidence; Male; Metabolic Syndrome; Olanzapine; Piperazines; Prevalence; Quinolones; Schizophrenia

2007
A prospective 6-month analysis of the naturalistic use of aripiprazole - factors predicting favourable outcome.
    Acta psychiatrica Scandinavica, 2007, Volume: 116, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Quinolones; Retrospective Studies; Schizophrenia; Time Factors

2007
Effectiveness of aripiprazole in treating obsessive compulsive symptoms.
    Progress in neuro-psychopharmacology & biological psychiatry, 2008, Feb-15, Volume: 32, Issue:2

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Comorbidity; Depressive Disorder, Major; Drug Administration Schedule; Female; Humans; Obsessive-Compulsive Disorder; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Treatment Outcome

2008
Aripiprazole and perphenazine: no difference.
    The Journal of clinical psychiatry, 2007, Volume: 68, Issue:11

    Topics: Antipsychotic Agents; Aripiprazole; Humans; Marketing; Perphenazine; Piperazines; Quality of Life; Quinolones; Schizophrenia; Surveys and Questionnaires

2007
A case of aripiprazole-related tardive akathisia and its treatment with ropinirole.
    The Journal of clinical psychiatry, 2007, Volume: 68, Issue:11

    Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Female; Humans; Indoles; Middle Aged; Piperazines; Quinolones; Schizophrenia

2007
Tardive dystonic symptoms associated with aripiprazole treatment.
    Progress in neuro-psychopharmacology & biological psychiatry, 2008, Feb-15, Volume: 32, Issue:2

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Comorbidity; Dyskinesia, Drug-Induced; Dystonia; Humans; Intellectual Disability; Male; Ocular Motility Disorders; Piperazines; Quinolones; Schizophrenia

2008
Worsened agitation and confusion in schizophrenia subsequent to high-dose aripiprazole.
    The Journal of neuropsychiatry and clinical neurosciences, 2007,Fall, Volume: 19, Issue:4

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Drug Therapy, Combination; Humans; Male; Olanzapine; Piperazines; Psychomotor Agitation; Quinolones; Schizophrenia; Schizophrenic Psychology

2007
Aripiprazole resolves symptomatic hyperprolactinemia in a male schizophrenic patient.
    Progress in neuro-psychopharmacology & biological psychiatry, 2008, Apr-01, Volume: 32, Issue:3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Hyperprolactinemia; Male; Piperazines; Quinolones; Schizophrenia; Sulpiride

2008
Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis.
    The Journal of clinical psychiatry, 2007, Volume: 68, Issue:12

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Incidence; Male; Middle Aged; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Retrospective Studies; Schizophrenia; Severity of Illness Index

2007
Aripiprazole treatment for risperidone-associated tic movement: a case report.
    Progress in neuro-psychopharmacology & biological psychiatry, 2008, Apr-01, Volume: 32, Issue:3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Piperazines; Quinolones; Risperidone; Schizophrenia; Tic Disorders

2008
Aripiprazole-induced rabbit syndrome in a drug-naive schizophrenic patient.
    Schizophrenia research, 2008, Volume: 103, Issue:1-3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Movement Disorders; Piperazines; Quinolones; Schizophrenia

2008
Aripiprazole diminishes cannabis use in schizophrenia.
    The Journal of neuropsychiatry and clinical neurosciences, 2008,Winter, Volume: 20, Issue:1

    Topics: Antipsychotic Agents; Aripiprazole; Humans; Marijuana Abuse; Piperazines; Quinolones; Schizophrenia

2008
Partial agonists and suicide: the role of the mental health nurse.
    Journal of psychiatric and mental health nursing, 2008, Volume: 15, Issue:3

    Topics: Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Humans; Nurse's Role; Piperazines; Quinolones; Schizophrenia; Suicide Prevention

2008
Combined low-dose clozapine with low-dose aripiprazole in a schizophrenic patient.
    Journal of psychopharmacology (Oxford, England), 2009, Volume: 23, Issue:1

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Clozapine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Guidelines as Topic; Humans; Male; Piperazines; Quinolones; Risk Assessment; Risperidone; Schizophrenia

2009
Who responds to aripiprazole in clinical practice? An observational study of combination versus monotherapy.
    Journal of psychopharmacology (Oxford, England), 2008, Volume: 22, Issue:7

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Resistance; Drug Therapy, Combination; Female; Hospitalization; Humans; Male; Middle Aged; Patient Compliance; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Treatment Outcome

2008
Use of Aripiprazole in treatment resistant schizophrenia.
    Journal of psychopharmacology (Oxford, England), 2008, Volume: 22, Issue:8

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Resistance; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia

2008
Adjunctive versus monotherapeutic treatment for schizophrenia: addressing antipsychotic side effects.
    The American journal of psychiatry, 2008, Volume: 165, Issue:3

    Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Drug Costs; Drug Therapy, Combination; Haloperidol; Humans; Hyperprolactinemia; Piperazines; Polypharmacy; Quinolones; Schizophrenia

2008
Aripiprazole's receptor pharmacology and extrapyramidal side effects.
    The American journal of psychiatry, 2008, Volume: 165, Issue:3

    Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Humans; Piperazines; Piperidines; Positron-Emission Tomography; Psychomotor Agitation; Quinolones; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Urea

2008
The prescribing pattern of a new antipsychotic: a descriptive study of aripiprazole for psychiatric in-patients.
    Basic & clinical pharmacology & toxicology, 2008, Volume: 103, Issue:1

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Drug Prescriptions; Drug Therapy, Combination; Female; Hospital Bed Capacity, 300 to 499; Hospitals, Psychiatric; Hospitals, University; Humans; Inpatients; Male; Middle Aged; Piperazines; Polypharmacy; Practice Patterns, Physicians'; Quinolones; Retrospective Studies; Schizophrenia

2008
Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder.
    The Journal of clinical psychiatry, 2008, Volume: 69, Issue:3

    Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Body Mass Index; Clozapine; Diabetes Mellitus, Type 2; Dibenzothiazepines; Fasting; Feeding Behavior; Female; Glucose; Glucose Tolerance Test; Humans; Incidence; Insulin; Male; Middle Aged; Olanzapine; Piperazines; Prevalence; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risk Factors; Schizophrenia; Time Factors

2008
Asymptomatic QTc prolongation during coadministration of aripiprazole and haloperidol.
    The Journal of clinical psychiatry, 2008, Volume: 69, Issue:2

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Electrocardiography; Female; Haloperidol; Heart Conduction System; Humans; Long QT Syndrome; Piperazines; Quinolones; Schizophrenia

2008
Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study.
    The American journal of psychiatry, 2008, Volume: 165, Issue:8

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzamides; Binding Sites; Brain; Female; Fluorine Radioisotopes; Humans; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Pyrrolidines; Quinolones; Receptors, Dopamine D2; Receptors, Dopamine D3; Schizophrenia

2008
Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2008, Volume: 33, Issue:13

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzamides; Binding, Competitive; Brain; Brain Chemistry; Cerebral Cortex; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Piperazines; Pituitary Gland; Positron-Emission Tomography; Pyrrolidines; Quinolones; Receptors, Dopamine D2; Schizophrenia; Young Adult

2008
Severe hyperglycemic hyperosmolar nonketotic coma in a nondiabetic patient receiving aripiprazole.
    Annals of emergency medicine, 2009, Volume: 53, Issue:2

    Topics: Antipsychotic Agents; Aripiprazole; Humans; Hyperglycemic Hyperosmolar Nonketotic Coma; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia

2009
Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking atypical antipsychotics: an open-label switch study.
    Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:3

    Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Comorbidity; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Sulpiride; Treatment Outcome

2008
Aripiprazole treatment causes extrapyramidal side effects but not prolactin elevation: a disconnect of the striatal D2 occupancy story: case report.
    Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:3

    Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Benztropine; Corpus Striatum; Dose-Response Relationship, Drug; Humans; Male; Piperazines; Prolactin; Quinolones; Receptors, Dopamine D2; Schizophrenia

2008
Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action.
    The Journal of clinical psychiatry, 2001, Volume: 62, Issue:12

    Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia; Treatment Outcome

2001
Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2002, Volume: 27, Issue:2

    Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Binding, Competitive; Brain; Cerebellum; Corpus Striatum; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Neurons; Piperazines; Quinolones; Raclopride; Radioligand Assay; Receptors, Dopamine D2; Receptors, Dopamine D3; Schizophrenia; Tomography, Emission-Computed

2002
The effect of OPC-4392, a partial dopamine receptor agonist on negative symptoms: results of an open study.
    Pharmacopsychiatry, 1988, Volume: 21, Issue:6

    Topics: Adult; Dopamine Agents; Hallucinations; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology

1988